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R A T IO N A L  A N T I-M A L A R IA L  D RU G  D ESIGN
A B STR A C T
M alaria is a mosquito-borne disease caused by several species o f plcismodium 
protozoa. It is one o f  the major killer diseases o f  the world, causing 2 million deaths 
annually. The most dangerous form is caused by Plasmodium falciparum  with infections 
often ending terminally. Attempts to eradicate malaria have failed due to the emergence 
o f drug resistant strains and thus there is a need for novel anti-malarial drugs.
Recently an identical aminopeptidase has been isolated from the both the human 
malarial parasite P. falciparum  and the rodent malarial parasites P. berghi and P. 
chabaudi. It is significantly different in both size and structure to mammalian 
aminopeptidases and thus provides a prime target for chemotherapeutic intervention. 
Investigations were directed towards the design and synthesis o f novel selective 
inhibitors o f  this enzyme.
Initially over forty amino acid and dipeptide derivatives with N- and C-terminal 
modifications w ere prepared. These included 7V-cinnamoyl, A ^S-dinitrobenzoyl, N- 
toluene-/?-sulphonyl, N-2-nitrophthaloyl, vV-phenylureido and 7V-chloroacetyl amino 
acids, amino esters, amino amides and amino alcohols. The design rationale and synthesis 
o f /V-2-hydroxy-2-phenylacetyl, AL2-hydroxy-3-phenylpropionyl, 7V-3-hydroxy-3 - 
phenylpropionyl and 2-thio-2-phenylacetyl amino acid derivatives are also presented, 
along with accompanying structure-activity analysis. The compounds were characterized 
by I.R. and N.M .R. spectroscopy, as well as high resolution M.S. X-ray crystallography 
was used to  elucidate the crystal structures and hydrogen bonding interactions o f two of 
the compounds.
All o f  the compounds were tested for inhibitory potency in a novel bioassay 
based on the liberation o f  fluorescent 7-amino-4-methyl-coumarin from L-leucine-7- 
amido-4-methyl-coumarin upon enzymatic hydrolysis o f the amide bond. Many o f the 
compounds possessed modest enzyme inhibitory potency in the micromolar range [3- 
nitrocinnamoyl glycine ethyl ester (3c); I C 5 o= 6 . 6 | j M ] .  Some o f the compounds also 
acted as potent activators o f  the aminopeptidase [3-nitrophthaloyl-L-leucine methyl ester 
(10c); activation at concentration o f  10(iM=132.8%], The most effective inhibitor was 
./V-2-thio-2-phenylacetyl phenethylamide (30) (IC5o~5.2(_iM).
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C H A P T E R  O NE 
M A LA R IA  - T H E  D ISEA SE
Malaria is a mosquito-borne disease which is caused by several species of 
plasmodium  p rotozoa.1,2 It is probably older than mankind, it's symptoms o f intermittant 
fevers with enlargement o f the spleen having been described in medical writings from the 
earliest times. The name malaria comes from the Italian “mal-aria” , meaning bad air, which 
refers to the association o f the disease with the foul-smelling air o f  the Tiberian marshes. 
The four plasmodial species that are pathogenic to man are Plasmodium falciparum, P. 
vivax, P. malariae and P. Ovale. These organisms produce respectively, malignant tertian 
malaria, benign tertian malaria, quartan malaria and a milder form o f benign tertian 
malaria.3'5 P. falciparum  and P. vivax are the most common, accounting for 93% of 
malarial infections in the world.2 P. falciparum  is the most dangerous o f the plasmodial 
species, with infections often ending terminally. This is because o f the tendancy of the 
erythrocytic parasite to clump together, adhering to capillary walls, and restricting blood 
flow in the vessels o f  the heart, intestine, brain or bone marrow. Malaria is one o f the major 
killer diseases o f  the world, causing over 2 million deaths annually.6
During the 1950's and 1960's the W orld Health Organisation attempted to 
eradicate malaria from most parts o f the world where it was prevalent. By the end of the 
1950's, the incidence o f  the disease had dropped dramatically from the originally estimated 
250 million cases per year. However for various reasons not only more virulent strains but 
also economic and administrative problems, during the 1970's it became obvious that the 
eradication attem pt had failed. The 1988 estimate o f the number o f  new malaria infections 
globally w as 210-220 million per year.'' About 85% o f these cases were malignant malaria, 
caused by the most dangerous of the malaria parasites Plasmodium falciparum.
At present about 46% o f mankind is at risk from malaria because they live in 
malarious areas3 (fig 1.1). Some cases are even seen in the western world due to the ease o f 
modern air travel. It is clear that the design o f novel and potent anti-malarial drugs is of the 
utmost im portance in controlling the disease, especially with the emergence o f new drug- 
resistant strains.6
In tro d u c tio n
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Fig. 1.2 The lifecycle of th e  m alaria l parasite .
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1.1 The life-cycle o f the  m alaria l parasite
The life cycle o f the malarial parasite consists o f a sexual stage which takes 
place in the female Anopheles mosquito and an asexual stage which takes place in humans 
(fig 1.2).1 W hen a female mosquito bites a human, sporozoites are injected into the blood 
stream with some anticoagulant saliva. Within an hour they disappear from the blood into 
the parenchymal cells o f the liver where during the next 10-14 days they develop and 
multiply. The liver cells then rupture releasing merozoites which enter the red blood cells 
and form motile intracellular parasites called trophozoites.
Following mitotic replication, the parasite in the blood cell is called a 
schizont and it's grow th and division schizogony which results in the release of further 
merozoites when the blood cell ruptures. It is at this stage that the symptoms o f malaria 
appear as the parasite degrades the hosts haemoglobin in order to replicate itself and it is 
also at this stage that clinical cure malarial drugs act. In certain forms o f malaria some 
sporozoites form resting forms of the parasite called hypnozoites on entering the liver cells 
which can be reactivated at a later stage. Some merozoites on entering red blood cells 
differentiate into male and female gametocytes which can only complete their life cycle when 
taken up by the mosquito when it sucks the blood o f the infected host.
Malaria parasites can multiply in the body rapidly, for example a single 
parasite o f Plasmodium vivax can give rise to 250 million merozoites in two weeks. In 
chemotherapeutic terms this means that if a drug destroys 94% of the parasites every 48hrs 
it will only maintain equilibrium and will not reduce their number or their ability to 
multiply.’
1.2 The pa th w ay  of haem oglobin d eg rada tion  in m alaria l parasites
During intra-erythrocytic development the malaria parasite degrades the 
haemoglobin o f  the host and uses the peptide fragments to replicate itse lf7 Haemoglobin 
appears to  be the main source o f most amino acids as parasite growth in semi-defined media 
requires few exogeneous amino acids.8 It has been estimated that 25-75% of the 
haemoglobin in an infected erythrocyte is degraded by the parasite.9,10 An ordered pathway
9
exists that efficiently breaks down haemoglobin to yield amino acids which the parasite uses 
as a nutrient source. The enzymes involved are specific and present prime targets for 
chem otherapeutic intervention.11,12
Haemoglobin is ingested by the intra-erythrocytic parasite via a mouth-like 
structure called a cytosome. Vesicles form around the blood cell cytosol and carry it off to 
the acidic (pH  5.0-5.5) digestive vacuole.13, 14 The vesicle is then lysed and the globin 
broken dow n to  amino acids. In plasmodia there are many proteases many of which can 
degrade haem oglobin in vitro.
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Fig. 1.3 T he  p a th w ay  of haem oglobin d eg rad a tio n  by the m alaria l parasite.
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Physiologically initial cleavage o f the haemoglobin into large fragments is 
found to proceed in the presence o f a group o f  aspartic, serine, cysteine, and 
metalloproteases.15-19 When pepstatin a specific aspartic protease inhibitor was added to 
parasites growing in culture proteolysis was prevented. Further proteolysis to small peptides 
could be partially inhibited by specific cysteine protease inhibitors. This suggests that the 
initial action is by an aspartic protease followed by a cysteine protease and perhaps others 
(fig 1.3). This is complicated by the presence o f an enzyme called heme polymerase which 
converts the heme moiety o f haemoglobin to  insoluble hemozoin, or malarial pigm ent8 If 
this did not occur, the ferrous form would be converted to the toxic ferric form which can 
cause damage to  biological membranes and inhibit enzymes such as proteases.
A recent study has shown the presence o f only a single aminopeptidase in 
cell-free extracts o f Plasmodium falciparum , Plasmodium berghi, and Plasmodium 
chabaudi20 A  comparative study o f the aminopeptidase activity in each extract revealed 
that the enzymes have similar substrate specificity and kinetics. The three enzymes were 
selectively inhibited by o-phenanthroline and are thus metallo-aminopeptidases. However in 
contrast to other aminopeptidases the metal co-factor did not appear to be Zn2+. Since 
recent research has shown that only a single aminopeptidase is present in all plasmodia 
species this seems to be the perfect target for a chemotherapeutic agent. In addition the fact 
that it is different to mammalian aminopeptidases in both size and structure, may improve 
the chances o f  designing a drug which selectively inhibits the malarial enzyme.
1.3 A n ti-m ala ria l d rugs
Anti-malarial drugs are classified depending on the stage of the parasite's 
life-cycle in which they are active. Clinical cure anti-malarial drugs are blood schizonticidal 
agents which which are effective against the erythrocytic forms o f the plasmodium  organism. 
This classification includes quinoline methanols [e.g. quinine (fig. 1.4) and mefloquine (fig 
1.5)], the 4-aminoquinolines [e.g. chloroquine (fig. 1.7)], and agents that interfere with the 
synthesis o f  folate [e.g. sulphadoxine (fig. 1.12)] or with its action [e.g. pyrimethamine (fig.
11
1.9)]. Combinations o f these drugs are often used, sometimes with antibiotics such as 
tetracycline (fig. 1.15) and clindamycin (fig. 1.16).
Radical cure anti-malarial drugs are tissue schizonticidal agents which are 
effective against the parasites in the liver. Only the 8-aminoquinolines [e.g. primaquine (fig. 
1.8)] have this action. These drugs also destroy gametocytes and thus reduce the spread o f 
infection.
Drugs used for suppressive prophylaxis are drugs which prevent the 
development o f  malarial attacks True causal prophylaxis (the prevention o f infection by 
destroying the sporozoites on entry into the host) is not feasible with the drugs in present 
use. Prevention o f  the development o f clinical attacks can however be effected by drugs 
which kill the parasites when they emerge from the liver. The drugs used for this purpose are 
mainly those listed as clinical cure anti-malarial drugs
1.3.1 Q uino line m ethanols 
Q uin ine
Quinine3'5,21 (fig. 1.4) is the chief alkaloid obtained from the bark of various 
species o f  Cinchona trees which are indigenous to certain regions o f South America. It was 
first isolated in 1820 by two French chemists, Pierre Joseph Pelletier and Joseph Bienaime 
Caventou. Synthetic quinine was first prepared by W oodw ard22 and is now principally used 
for the oral treatm ent o f chloroquine-resistant P. falciparum  malaria. The drug is 
formulated as quinine sulphate for oral use and as quinine dihydrochloride for parenteral use.
12
Fig. 1.4 Q uin ine.
Anti-malarial action
Quinine is a rapidly acting highly effective blood schizonticide against the 
four malaria parasites. Quinine has no effect on sporozoites o f the liver stages of any o f the 
parasites. The mechanism o f action is unclear, however it is known to depress many enzyme 
systems. It also forms a hydrogen complex with double-stranded D NA that inhibits the 
strand separation, transcription, and protein synthesis. The secondary alcohol group is 
essential for activity.
Clinical uses
Quinine dihydrochloride is given slowly intravenously for the parenteral 
treatm ent o f severe P. falciparum  malaria. It is administered orally as quinine sulphate for 
the treatm ent o f attacks o f P. falciparum  malaria resistant to  chloroquine, however it must 
be used in combination with other drugs as quinine alone fails to completely eliminate the 
infection. Because o f  its potential toxicity quinine is generally not used in prophylaxis 
except in cases o f  resistance to chloroquine and pyrimethamine-sulphadoxine.
Adverse effects
W hen taken orally quinine commonly causes gastric irritation. Therapeutic 
doses can sometimes cause hypoglycaemia through stimulation o f the pancreatic B cell 
release o f  insulin, particularly in severe infections and pregnant patients. However recently 
the role o f  quinine in causing hypoglycaemia has been called into question.23’24 Cinchonism 
is the toxic state that usually develops when plasma levels o f  quinine exceed 7-10pg/ml.
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Symptoms o f  mild to  moderate cinchonism include headache, nausea, slight visual 
disturbances and dizziness. Severe toxicity is rare and is associated with fever, skin 
eruptions, deafness, visual abnormalities and central nervous system effects.
M efloqu ine
General
Mefloquine3"5 (fig. 1.5) is a schizonticidal agent with a long plasma half-life 
(>30 days), which may be due to  active metabolites. It is related to quinine, but unlike 
quinine, it does not intercalate DNA. It may be a valuable drug for the treatment o f multi- 
resistant P. falciparum  malaria particularly if combined with sulphadoxine and 
pyrimethamine. Because o f  its long half-life it can be given every two weeks for suppressive 
prophylaxis.
H 
CHOH
Fig. 1.5 M efloquine.
Anti-malarial action
Mefloquine has a strong blood schizonticidal activity against P. falciparum  
and P. vivax but is not active against P. falciparum  gametocytes or the hepatic stages of P. 
vivax. The mechanism o f action is not known and resistance can occur rapidly. Resistant 
strains have been found in areas where the drug has never been used.
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M efloquine is effective in prophylaxis against most strains o f chloroquine- 
resistant or pyrimethamine-sulphadoxine-resistant P. falciparum  malaria, and is curative 
when taken weekly for four weeks after leaving an endemic area. W hen used for this 
purpose the drug also provides prophylaxis against P. vivax, and probably against P. ovale 
and P. malariae.
Adverse effects
In prophylactic doses minor effects include gastrointestinal disturbances, 
headaches and dizziness. Opthalmological lesions were seen in rats given daily doses, and 
daily doses o f  160mg/kg was found to be embryotoxic in rabbits
Clinical uses
1.3.2 P h e n a n th re n e  m ethanols 
H alo fan trine
General
Halofantrine3 (fig 1.6) is a blood schizonticidal drug. It was discovered 
during the Second W orld W ar but was not developed when chloroquine was found to be 
successful. H ow ever since the development o f chloroquine resistance in plasmodia there 
has been renewed interest in the use o f halofantrine. Its mode o f action however is 
unknown.
H O - C - H
Fig. 1.6 H alofan trine .
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It is active against strains o f  P. falciparum  that are resistant to chloroquine, 
pyrimethamine and quinine and is also effective against erythrocytic forms o f P. vivax but 
not the hypnozoites. Cross-resistance with mefloquine has been reported. The half-life o f 
the parent drug is 1-2 days and that o f  the active metabolite is 3-5 days.
Adverse effects
Common unwanted effects include abdominal pain, gastrointestinal tract 
disturbances and headache. Serious cardiac problems can sometimes occur.
1.3.3 4-A m inoquinolines 
C h lo roqu ine
Clinical uses
Anti-malarial action
Chloroquine3'5-21 (fig. 1.7) is a highly effective blood schizonticide and the 
4-aminoquinoline most widely used to prevent or terminate attacks o f P. vivax, P. ovale, P. 
malariae or sensitive P. falciparum  malaria. It is also moderately effective against
Fig. 1.7 C hloroquine.
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gametocytes o f  P. vivctx, P. ovale and P. malariae, but not those o f  P. falciparum. It was 
developed because o f  a need for synthetic quinine substitutes during both World Wars.25 
The exact mechanism o f anti-malarial action has not been determined but it may function by 
blocking the enzymatic synthesis o f  DNA and RNA to both mammalian and protozoal cells 
and forming a complex with DNA that prevents replication or transcription to RNA It may
O '!  O Q
also bind to  heme forming a complex which is toxic to the parasite. ’ ’ Within the parasite 
the drug concentrates in vacuoles and raises the pH o f those organelles,13’14 interfering with 
the parasite's ability to  metabolize and utilize erythrocyte haemoglobin.29 Interference with 
the phospholipid metabolism has also been proposed as a mechanism.30'31 
Clinical uses
Chloroquine is the preferred drug for prophylaxis against all forms of 
malaria except in regions where P. falciparum  is resistant to  4-aminoquinolines. It usually 
terminates the fever o f  acute malarial attacks in 24-48 hours and for P. falciparum  and P. 
malariae infections a complete cure can be obtained. H ow ever the drug has no effect on 
secondary tissue schizonts o f relapsing malarias and thus cannot effect a radical cure of 
infections caused by P. vivax or P. ovale.
Adverse effects
Gastrointestinal symptoms, mild headaches and anorexia may result. Taking 
the drug after meals may reduce some adverse effects. Rare reactions observed include 
haemolysis in glucose-6-phosphate deficient patients, impaired hearing, confusion, 
psychosis, convulsions and hypertension.
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1.3.4 8-Aminoquinolines
P rim aqu ine
Fig. 1.8 P rim aquine.
Anti-malarial action
Primaquine3'5’32 (fig. 1.8) is the most commonly used and least toxic of the 
8-aminoquinoline anti-malarial drugs. The 8-aminoquinolines differ from the previously 
discussed anti-malarials in that they have no activity against erythrocytic schizonts. They are 
thus usually used in conjunction with another anti-malarial drug such as chloroquine. They 
kill sexual forms in the blood and are active against the pre-erythrocytic and para- 
erythrocytic forms in the liver and spleen. They bind to  D N A  and their anti-plasmodial 
activity is probably due to this. They also cause the mitochondria o f cultured 
exoerythrocytic forms to  swell and become vacuolated, but it is not known whether a 
mitochondrial site o f action contributes to anti-malarial activity in vivo.
Clinical uses
Primaquine is always given orally usually as the phosphate. Unlike the 4- 
aminoquinolines it does not bind to tissues and due to its rapid metabolism daily doses are 
necessary. It is mainly used for the radical cure o f relapsing malarias.
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M ost patients tolerate primaquine well but occasionally mild gastrointestinal 
upsets are produced. Haemolytic anaemia is caused in patients who are glucose-6- 
phosphate sensitive.
1.3.5 D rugs effecting th e  synthesis an d  utilisation  of fo late
General
This group include both folate antagonists and agents which inhibit the 
synthesis o f folate. The former act by inhibiting dihydrofolate reductase and includes 
pyrimethamine (fig. 1.9), proguanil (fig. 1,10) and trimethoprim (fig. 1.11), the latter by 
competing with />aminobenzoic acid and includes sulphadoxine (fig. 1.12) and dapsone (fig. 
1.13).
P y rim e th am in e  an d  P roguan il
Pyrimethamine3'5 (fig. 1.9) in fixed combination with sulphadoxine is used in 
a single dose treatm ent o f  chloroquine-resistant P. falciparum  malaria, however because o f 
the toxicity o f  the combined drug it is no longer used in prophylaxis. Proguanil3'5 (fig. 1.10) 
is used in some regions o f  the world for malaria prophylaxis particularly when used in 
combination w ith chloroquine.
A dverse effects
Fig. 1.9 P yrim etham ine.
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Fig. 1.11 T rim etoprim .
Anti-malarial action/Clinical uses
Pyrimethamine and proguanil are blood schizonticides active against 
susceptible plasmodia, however because they act more slowly then chloroquine or quinine 
they can only be used in prophylaxis not in treatment. Neither drug is adequately 
gametocidal nor effective against the persistant liver strains o f P. vivax. Resistant strains of 
P. falciparum  have appeared world-wide wherever pyrimethamine and proguanil have been 
extensively used. Resistant strains o f P. vivax have appeared less frequently. Therefore 
prophylaxis against P. falciparum  malaria with either drug alone is no longer recommended. 
Adverse effects
M ost patients tolerate pyrimethamine and proguanil well. Gastrointestinal 
and allergic reactions are rare. Formerly pyrimethamine was not recommended during
20
pregnancy because the drug is teratogenic in large doses in some animals. However it has 
been widely used in humans for over 20 years and such effects have not been reported.
S u lphadoxine an d  D apsone
Fig. 1.12 Sulphadoxine.
h 2 n  -<  ; n h 2
Fig. 1.13 Dapsone.
Sulphadoxine'“' (fig. 1.12) and dapsone30 (fig. 1.13) compete with p- 
aminobenzoic acid in the synthesis o f folic acid Since this is an essential step in plasmodia 
they may be expected to display anti-malarial activity. They are not as potent as other anti- 
malarials but are therapeutically useful when used in conjunction with inhibitors o f 
dihydrofolate reductase especially in chloroquine-resistant infection by P. falciparum.
21
1.3.6 O th e r  d rugs w ith  an ti-m ala ria l activity  
A rtem isin in  (Q inghaosu)
Artemisinin3,5,33 (fig. 1.14) is an unusual heterocyclic compound which has 
been isolated from the Chinese herb Quinghao (Artemisia annua). It is believed to be a 
prodrug, its activity being due to  the metabolite dihydroartemisinin. Several derivatives of 
dihydro artemisin, namely arthemether, artheether and artesunate are currently undergoing 
clinical trials.34 The most unusual feature o f its chemical structure is the 1,2,4-trioxane ring, 
the only example found in nature.
Fig. 1.14 A rtem isin in .
It has rapid blood schizonticidal activity against all types o f human 
malarias35 and its m ode o f action is thought to  involve an oxidative mechanism affecting 
changes both to red blood cells and the membranes o f the malarial parasite.36 It may also 
involve damage to the parasite membranes by free radicals.37 The peroxide bridge is 
essential for activity. It has no effect on hepatic stages and therefore cannot cure the 
relapsing malarias. It is effective against chloroquine resistant P. falciparum  malaria and has 
been especially useful in cerebral malaria.38,39 It's major disadvantage is the high rate of 
recurrence o f malaria and thus it is recommended that it be used in conjunction with an 
antifolate. Research has shown that /V-alkylazaartemisinin derivatives have greater activity 
than the parent compound 40,41 Some structurally simple tricyclic trioxanes have been 
synthesized with extraordinary antimalarial activity.42,43 Alkylamino and benzylamino ether
22
derivatives o f  artemisinin have also shown enhanced a c tiv ity "  The weakly basic side chains 
probably assist accumulation o f the molecules in the acidic food vacuole
T etracycline  an d  clindam ycin
Fig. 1.15 T etracycline.
Fig. 1,16 C lindam ycin.
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Tetracycline3'5 (fig. 1.15) was originally thought to have little value other 
than as an antibacterial drug. However the emergence o f  chloroquine-resistant drugs has led 
to a re-exam ination o f previously discarded remedies. I t acts by binding to  both the mRNA 
and the 3 OS subunit o f  ribosomes, the latter being the binding site o f  importance in its ability 
to inhibit protein synthesis. Tetracycline has been shown to  have a useful role when used in 
combination with standard anti-malarial drugs. Tetracycline can Clear asexual forms o f the 
parasite in 7 days, but has no effect against the gametocytes.
Clindamycin3'5 (fig. 1.16) is another antibiotic which has been shown to 
have a useful role in the treatment o f  malarial infection. I t probably acts by binding to the 
5OS ribosomal subunit, thus inhibiting the correct attachm ent o f  the amino acid end o f the 
aminoacyl tRN A  to this subunit.
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P R O T E A S E  IN H IB IT O R S AS PO T E N T IA L  A N T I-M A L A R IA L  DRUGS
CHAPTER TWO
In tro d u c tio n
As we have seen the dream o f eradicating malaria totally from most parts of the 
world has gradually faded before the grim realities o f drug resistant-malarial strains 
and insecticide-resistant mosquitoes which have led to  malaria making a comeback 
w ith renewed vigour sometimes surpassing earlier recorded levels. In truth there are 
fewer tools with which to combat malaria today than there were 20 years ago and 
few believe that global eradication o f malaria will be possible in the foreseeable 
future. Although the production o f an anti-malarial vaccine is an exceptionally 
attractive strategy for preventing and controlling malaria,45'47 many obstacles prevent 
its development and even if a safe vaccine was developed this would not negate the 
neccessity o f developing new anti-malarial dings such is the enormity o f the problem. 
Because at the moment, malaria is predominantly seen as a Third World problem (in 
the future this may not be the case) pharmaceutical companies are unwilling to spend 
research funds on something they view as being economically unfavorable. To 
western governments this is a false economy because not only is the global advance 
o f malaria expensive in terms o f foreign aid, it also threatens to invade temperate 
countries which have been malaria-free for centuries. The onus thus rests mostly on 
small research groups to carry out studies both into the malarial parasite itself and to 
develop novel drugs to control its proliferation. The proteases which plasmodia 
employ to degrade haemoglobin provide excellent targets for chemotherapy.
2.1 P ro teases
Proteases are enzymes which cleave peptide bonds (fig 2.1). Four major classes 
o f proteases are known and are designated by the principal functional group in their 
active site namely serine, cysteine, aspartyl and m etalloproteases.48'51 Proteases do 
not rely simply on binding interactions to catalyze cleavage o f peptide bonds but also
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use caicial polar groups with functional roles. These groups have distinct roles to 
play in the four classes, and four ways o f catalyzing the same chemical reaction (i.e. 
the hydrolysis o f  the amide bond) exist.
Fig. 2.1 H ydrolysis o f th e  am ide bond.
In spite o f  the differences in catalytic mechanisms, the enzymes o f the four 
classes share a common property o f  going through an intermediate in which the 
normally trigonal carbonyl carbon becomes tetrahedral due to the temporary addition 
o f  a nucleophile (fig 2.2). In the case o f  the serine and cysteine proteases the 
nucleophile is the serine hydroxyl or the cysteine thiol, whereas in the aspartyl and 
metalloproteases, it is a water molecule which hydrolyses the peptide bond. The 
reaction proceeds more directly in the latter tw o classes because the acyl-enzyme 
intermediate that occurs with the serine and cysteine proteases must be hydrolysed by 
w ater in a second step.
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Fig. 2.2 M echanism  of action o f th e  fo u r classes of p ro teases.49
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2.2 A m inopeptidases
Aminopeptidases are a class o f  metalloproteses which cleave peptide bonds 
sequentially from the ^-term inus o f the peptide chain.50 They generally require a free 
a-am ino or a-im ino group and release free amino acids from the jV-terminus o f the 
peptide substrate. The metal ions bound to the enzymes act as electrophilic centres in 
catalytic reactions. This is important because the side chains o f the amino acid 
residues in the enzyme may only act as acids, bases, or nucleophiles and cannot 
provide this function. The transition metals Fe2+, Co2+, Cu2+, Mg2 and Zn2+ are 
among the metal ions found at the active sites o f  metalloenzymes. The catalytic 
function o f the metal ion often depends on polarization o f the substrate through the 
formation o f a complex between the substrate and the metal ion. In aminopeptidases 
the metal co-factor is usually Zn2', but as has already been stated this does not seem 
to be true for the aminopeptidase isolated from the malarial parasite. Studies have 
shown that when the active site metal o f  the malarial aminopeptidase was removed 
with o-phenanthroline, the activity o f the enzymes could be restored to 30-50% of the 
control value with 10pM concentrations o f M n2+, Ca2' and M g2", whereas a 
concentration o f  even lOOOpM o fZ n 2+ did not restore activity.20
A mechanism for the action o f leucine aminopeptidase has been reported.52 The 
metal ion mediated the binding o f  the substrate to the enzyme and secondary 
interactions between the substrate and enzyme have been shown to exist. The 
substrate binds to the metal ion via the free amino group and the amide or ester 
carbonyl oxygen (fig 2.3a). The formation o f this ternary substrate-metal ion-enzyme 
complex would not enhance the rate o f hydrolysis and so a w ater binding site is 
needed to allow addition o f w ater to the susceptible carbonyl bond. This results in a 
tetrahedral adduct as opposed to the planar peptide group o f the substrate. The 
second stage o f  the reaction is the decomposition o f  the adduct (fig 2.3b). This may 
be assisted by the interaction o f the peptide nitrogen or ester oxygen with an acid 
group. An interaction o f this sort would not be expected for the substrate because of 
the resonance o f  the peptide bond which makes the lone pair unavailable. However
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no such resonance exists in the adduct, and interaction with an acid group should 
occur much more readily.
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Fig. 2.3 T he  m echanism  of action o f leucine am inopeptidase. ‘
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2.3 P ro tease inh ib ito rs as poten tial an ti-m alaria l d rugs
As has already been stated, the specificity o f the protease enzymes that malarial 
parasites employ to degrade haemoglobin provide an attractive target for the design 
o f  novel anti-malarial drugs. The aspartic protease inhibitor pepstatin53 (fig. 2.4) 
prevents the degradation o f haemoglobin by plasmodia  species.11
Pepstatin is a low molecular weight transition state analogue inhibitor, which contains 
the novel amino acid statine ((3lS',4iT)-4-amino-3-hydroxy-6-methylheptanoic acid). A 
convenient synthesis o f statine starting from from L-leucine has been described.54,55
It is known that leupeptin (an inhibitor o f  cysteine and serine proteases), blocks 
haemoglobin degradation in the trophozoite food vacuole18 and supresses the 
symptoms o f malaria.56 Leupeptin (fig. 2.5) is a naturally occuring protease inhibitor 
isolated from various species o f  actinomyces 57
Fig.2.5 Leupeptin.
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Leupeptin is a transition state analogue inhibitor which exists in three covalent forms 
in aqueous solution.58 Its mode o f action involves firstly binding non-covalently to 
the active site, and then in a second step it reacts with the active site nucleophile to 
form a hemiacetal or hemithioacetal. Leupeptin is not selective among enzymes of 
similar substrate specificities and it's use as a therapeutic agent is thus limited, 
how ever derivatives of leupeptin might show selectivity. Early w ork by Ito and co­
w orkers59 showed that the specificity o f leupeptin analogues is determined by the 
side-chain structure o f the C-terminal aldehyde and the composition and sequence of 
the peptide as a whole. Several C-terminal aromatic aminoaldehydes were 
synthesized by DIBAL (diisobutylaluminium hydride) reduction o f  the corresponding 
Z-protected amino acid esters60 followed by deprotection and coupling ^-terminally 
modified analogues synthesized by Saino et a t 1 containing a C-terminal arginal 
functionality showed dramatic increases in the inhibition o f certain enzymes in 
comparison to  leupeptin. The synthesis o f these inhibitors involved a semisynthetic 
route via the enzymatic cleavage o f arginal dibutyl acetal from protected leupeptin.62 
M ore recent studies describe the synthesis o f several tripeptide analogues o f leupeptin 
containing C-terminal arginal, lysinal or ornithinal units.63,64 The three amino aldehyde 
derivatives w ere synthesised via DIBAL reduction o f the corresponding Z-protected 
amino acids. The aldehydes were converted to the semicarbazones, deprotected, and 
then coupled to  a series o f Z-protected dipeptide acids. The synthetic analogues 
w ere tested as inhibitors o f trypsin, plasmin, and kallikrein and showed significant 
variation in selectivity.
E-64 (L-ir<ms-epoxysuccinyl-leucylamido-4-guandino-butane)65,66 (fig. 2.6), is 
another cysteine protease inhibitor which blocks haemoglobin degradation by the 
malaria parasite.18 It acts by alkylating the cataltytic cysteine thiol67 and it has been 
proposed that the free carboxylate a  to the epoxide both positions and activates the 
epoxide for alkylation by the cysteine thiol.68
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Fig. 2.6 E-64.
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The inhibitory effects o f E-64 and its analogues have been described69,70 It was found 
that E-64 inhibited all of the cysteine proteases tested but none o f  the other classes of 
enzymes. It is not however a general cysteine protease, but shows selectivity for 
papain, other plant enzymes and the lysosomal cysteine proteases.
Rosenthal and co-workers71,72 showed that the trophozoite cysteine protease 
had a similar biochemistry to the lysosomal enzymes cathepsin B and cathepsin L 
with a similar pH  optimum for activity. It was efficiently inhibited by highly specific 
peptidyl fluoromethylketone inhibitors (general structure shown in fig. 2.7) o f 
cathepsin B and L. Micromolar concentrations o f the fluoromethylketone inhibitor 
Z-Phe-A la-CH 2F blocked the degradation o f haemoglobin in the trophozoite and 
much larger concentrations were found not to be toxic in mice due to the low 
reactivity o f  these enzymes outside the inhibitor-enzyme complex. This suggests that 
these inhibitors may have potential as anti-malarial drugs.
H 0  R ’
Z - N  C H  F
hN T
Ft 0
Fig. 2.7 A peptidylfluoromethylketone.
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Their mode o f  action involves the alkylation o f  the active site nucleophile. The 
synthesis o f  these compounds has been described.73"76
Azapeptides are also inhibitors o f serine proteases77’78 and thus may have uses as 
anti-malarial drugs. Aza-amino acids, whose general structure is shown in fig. 2.8, 
are amino acids in which the a-carbon has been replaced by a nitrogen atom. They 
are presumed to  act by alkylating the active site nucleophile, forming a stable 
carbazate.
O  
H N A  
2 N OH
l
R
Fig. 2.8 A n aza-am ino acid.
Considerable specifity can be obtained by altering the side chain o f  the aza-amino acid 
residue.79’80 Aza-peptides with good leaving groups (eg. /?-nitrophenolate) are 
required for inhibition o f serine proteases81 and this neccessarily results in a high rate 
o f  undesirable side reactions in solution thus reducing the half life o f the inhibitor.82 
M ore recently it has been shown that the more stable simple alkyl esters of 
azapeptides can act as cysteine protease inhibitors due to the increased nucleophilicity 
o f  the cysteine thiol.83 The synthesis o f azapeptides has been described.84
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2.4 A m inopep tidase  inhibitors
W e have previously seen how the malarial parasite employs a single 
aminopeptidase in the role o f haemoglobin degradation. The goal o f this research is 
the design and synthesis o f a compound which would efficiently and selectively inhibit 
this enzyme. This would provide a suitable starting point for the development of 
novel anti-malarial drugs.
The aminopeptidases are a group o f  metal-containing exopeptidases with a 
specificity for cleavage at the amino terminus o f  the polypeptide chain. There is 
much evidence for the catalytic role o f  the metal ion and inhibitors o f these enzymes 
usually contain functional groups which coordinate to the metal ion. Fournie-Zaluski 
and co-w orkers85 studied the effect o f aminopeptidase N  inhibitors. Aminopeptidase 
N  (APN) is a zinc metalloprotease which degrades opiate peptides in the brain. APN 
removes A'-terminal hydrophobic acids o f substrates preferentially. It also binds with 
higher affinity to  compounds possessing aromatic or highly hydrophobic residues. It 
appears that there are four essential residues in the active site, one arginine and a 
carboxylic acid (glutamic or aspartic), as well as a histidine and tyrosine residue.86 A 
large number o f amino acid derivatives with zinc-coordinating moieties e.g. SH, 
COOH, CONHOH, and P 0 3H 2, were studied to test their inhibitory effects. The 
results showed that p-amino thiols were the most efficient APN inhibitors. The 
general structure o f these compounds is shown in fig. 2.9. It is known that simple 
amino thiols such as L-leucinethiol [fig. 2.10(a)],87 L-phenylalaninethiol [fig.
no m # 89
2.10(b)] and L-lysinethiol [fig. 2.10(c)] are the m ost potent inhibitors of 
aminopeptidases with a thiol-metal ion interaction again responsible for inhibitory 
potency. A synthetic phenyalanine-P-mercaptoketone90 has also been shown to be a 
potent inhibitor, probably forming a bidentate ligand with the active site zinc via the 
carbonyl and thiol functionalities (fig. 2.11)
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H N CH SH2 2
Fig. 2.9 P-A m inothiol.
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(a) L -L eucineth io l. (b) L -Phenylalan ineth io l. (c) L-Lysinethiol.
Fig. 2.10 A m inothiols.
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Fig. 2.11 P -M ercap toketone bound  to  active site zinc.
Aminophosphonates91'93 are believed to  be tetrahedral analogue inhibitors of 
aminopeptidases. Giannousis and Bartlett94 synthesized a variety o f phosphorous 
amino acid and dipeptide analogues and evaluated them as inhibitors o f leucine 
aminopeptidase. Some o f these compounds showed modest activity with the most 
active inhibitors being the phosphonic acid analogues o f L-leucine [fig. 2.12(a)] and
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L-phenylalanine [fig. 2.12(b)], Several aminophosphonates were synthesized by 
Lejczak and co-workers9'1 and tested as inhibitors o f  leucine and microsomal 
aminopeptidases in order to observe the effect o f  structural changes on the activity o f 
the aminophosphonic acids The most effective inhibitor studied was [l-amino-2-(A- 
cyclohexylamino)ethyl]phosphonic acid [fig, 2.12(c)],
0
(a) L -L eucine- (b) L -Phenylalan ine- (c) [l-A m ino-2-
phosphonic acid phosphonic acid (jV-cyclohexylamino)
ethyl] phosphonic acid 
Fig. 2.12 A m inophosphonates.
Hydroxamates o f amino acids are also effective inhibitors of 
aminopeptidases.90,96'99 Their mode o f action results from the formation o f a 
bidentate ligand with the active site zinc (fig. 2.13).
H N
3
R
,ZnX» \
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N 
H
Fig. 2.13 Am ino acid  hydroxam ate  b o u n d  to active site zinc.
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L-leucinal (fig. 2.14) has been shown to  be an inhibitor o f leucine 
aminopeptidase100 and is believed to act as a transition state analogue inhibitor.
0
Fig. 2.14 L-leucinal.
Bestatin (fig. 2.15a) is a potent aminopeptidase inhibitor, isolated from species 
o f  actinomycesm  which has attracted much attention due to  its many biological 
activities. This activity is due to the presence o f the novel amino acid 2(S)-hydroxy- 
3 (R)-amino-4-phenylbutanoic acid (AHPB) moiety in its structure.102,103 Many 
methods for the synthesis o f AHPB have been described, including, the 
iodocyclocarbamation o f chiral allylamines,104 the aldol condensation o f a -  
am inoacetophenone with glyoxylic acid,105 the stereospecific hydroxamination of an 
alkene,106 the chain extension o f D-phenylalanine,107 the opening o f  an epoxy alcohol 
with an azide ion,108 from (3-lactams109 and from the aldol condensation o f a chiral 
glycolate enolate.110 Amastatin (fig.2.16) is a similar aminopeptidase inhibitor.111 
The synthesis o f amastatin via a chain extension o f  D-leucine has been described in 
the literature.112 Bestatin and amastatin generally act as slow-binding inhibitors of 
am inopeptidases113 and are selective for different aminopeptidases 114
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(a) R=(3Æ)-NH2, R ’=(2^)-O H  (B estatin)
(b) R=(3Æ)-NH2, R ’=(2i?)-OH (epi-B estatin)
(c) R=(3J?)-NH2, R ’=(25)-N H 2 (A m inodeoxybestatin)
(d) R=(3Æ)-NH2, R ’=(2i?)-NH2 (e/n-A m inodeoxybestatin)
Fig. 2.15 B esta tin  and  b esta tin  analogues.
O
Fig. 2.16 A m astatin .
Structure-modification studies o f bestatin, have shown that the presence o f  the 
2(S)-hydroxyl group is necessary for tight binding to aminopeptidases. The structural 
relationship between bestatins critical 2(S)-hydroxyl group and a probable 
intermediate for amide bond hydrolysis led to  the idea that bestatin may be a 
transition state analogue inhibitor o f aminopeptidases,115 in which the sp3 geometry of 
the 2(S)-hydroxyl o f the inhibitor mimics the tetrahedral intermediate formed during 
substrate hydrolysis. Nishizawa et a ln6 proposed that the essential active site zinc is 
chelated by the 2(S)-hydroxyl group and the 3-amino group when the bestatin is 
bound to  the aminopeptidase (fig2.17(a)). Nishino and Powers117 proposed a
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different mechanism in which the 2(S)-hydroxyl and the amide carbonyl bind to the 
active site zinc (fig 2.17(b)). Both models place the aromatic side chain o f the A H P B  
moeity at P i for binding to the Si enzyme site. The binding site terminology o f 
B erger and Schechter148 is used in which the carboxyl side o f  the scissile bond is 
term ed the P i residue and that on the amino side the P i residue with the 
corresponding subsites to which they bind being labelled Si and S i respectively. 
M any analogues o f bestatin have been synthesized in order both to test these 
hypotheses and to increase activity.
Z n
/ i
E n z y m e
* • 118Fig. 2.17(a) M echanism  o f b ind ing  of besta tin  as proposed  by N ishisawa et aL
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E n z y m e
Fig. 2 .17(b) M echanism  of b ind ing  of b esta tin  as proposed by 
N ishino and  Pow ers.118
N ishizaw a et a /116 showed that although a free amino group was necessary for 
inhibition, the stereochemical configuration at the amino group, was not as important 
as the configuration at the hydroxyl group. Replacement o f the benzyl group with an 
alkyl or phenyl group resulted in a marked decrease in activity. When the L-leucine 
residue o f  bestatin was replaced by other amino acids, only the analogue containing 
L-isoleucine showed greater activity. /?-Methyl-, ¿»-chloro- and p-nitrobestatins 
showed greater activity than bestatin.
Sulphur replacement analogues o f bestatin have been synthesized118 in which the 
2(S)-hydroxyl w as replaced by a thiol functionality. Since thiols bind well to zinc it 
w as expected that this would increase activity due to the strengthened interaction 
betw een this group and the active site zinc. H ow ever the inhibitory potency of the 
thiolbestatin w as similar to the the corresponding alcohol. This would seem to
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suggest that the 2(S)-hydroxyl group o f  bestatin is not involved in binding to the 
active site zinc. An alternative mechanism is presented in which the hydroxyl acts as 
a transition state analogue o f the incoming nucleophile i.e. the oxygen o f the 
tetrahedral intermediate which is not bound to the zinc. In this model only the
analogues showed no significant increase in activity over bestatin. The thioamide 
analogues were modest inhibitors o f  aminopeptidases. The expected increase in 
activity due to  the affinity o f sulphur for the active site zinc was not observed. By 
studying leucinethiol derivatives with substituents a  to the thiol it was observed that 
alkyl and carboxyl substituents decreased activity by destabilizing the interaction 
between the thiol inhibitor and the aminopeptidases. This could account for the 
absence o f the expected increased activity for the thiolbestatin. However it was 
observed that a carboxamide substituent favoured binding to the enzyme relative to 
the methyl carboxylate perhaps due to increased stabilizing interactions o f the amide 
proton or the side chain. When viewed together these results seem to suggest that 
substituents a  to the thiol funtionality disfavours binding to the active site zinc, but 
that this may be overcome by increased substituent size as in thiolbestatin.
oxygen o f  the amide carbonyl is bound to  the active site zinc. Ocain and Rich119 also 
synthesized thiol and thioamide analogues o f  bestatin and found that the thiol
SH O
R R
fig. 2.18 - Pep tidy l d iam ino  thiol.
The novel peptidyl diamino thiols which were synthesized by Gordon et alm  
have no carbonyl a  to the thiol functionality (fig. 2.18), and show inhibition in the
nanomolar range. Further evidence for the im portance o f the C2-hydroxyl group 
emerges from studies by Herranz and co-w orkersI2<’ who synthesized 
aminodeoxybestatin (fig. 2.15(c)) and ep/'-aininodeoxybestatin (fig. 2.15(d)) These 
compounds are bestatin (fig. 2.15(a)) and <?p/-bestatin (fig. 2.15(b)) analogues 
respectively, in which the hydroxy group has been replaced by an amino functionality. 
It was observed that the substitution o f an amino group for the hydroxyl group 
resulted in a decrease in inhibitory potency.
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C H A P T E R  T H R E E  
1N IT IA L STU D IES O F A M IN O  A C ID  D E R IV A T IV ES AS IN H IB ITO R S
In tro d u c tio n
The synthetic strategy employed in this study involved the synthesis o f various amino 
acid and dipeptide derivatives and testing their inhibitory potency in a novel biological assay. 
Aminopeptidases cleave peptide bonds between amino acids in a peptide chain and thus 
amino acid and peptide derivatives provide a favourable starting point for the design of 
novel aminopeptidase inhibitors.
Initially a large number o f  derivatives with A^-terminal modifications were 
synthesized. These derivatives will be discussed in more detail in the relevant sections. 
These compounds all contained either amide carbonyl or sulphonamide sulphonyl moieties 
which could form a monodentate ligand with the metal ion at the active site, and would give 
us an indication o f  the size and hydrophobicity /  hydrophilicity o f the active site. The 
malarial aminopeptidase is known to have an affinity for amino acids with aliphatic 
hydrophobic side chains20 and so several derivatives o f amino acids possessing hydrophobic 
side chains, as well as derivatives o f glycine in which the side chain is simply a hydrogen 
atom, were synthesized. Derivatives o f  both the L and D isomers o f leucine were prepared 
in order to observe the effect of the stereochemistry o f the a-carbon o f the amino acid on 
the activity o f  the aminopeptidase. The dipeptide derivatives were synthesized to ascertain 
whether or not the aminopeptidase had an extended binding site with several sub-sites which 
could interact with an inhibitor with a longer peptide chain. Further modifications o f the N- 
terminal derivatives which showed activity could lead to a very potent inhibitor o f the anti- 
malarial aminopeptidase. To this end it was decided to modify the C-terminus of the 
inhibitors showing the highest activity to increase the potency o f the inhibitor Methyl and 
ethyl ester, amide and alcohol derivatives o f  the most potent TV-terminal modified amino acid 
inhibitors w ere prepared and their synthesis will be discussed.
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3.1 A'-fty/w.v-Cmnamoyl and related derivatives.
l a  - R=H, R ’= C 0 2H 
lb  - R=H, R ’= C 0 2C H 3 
lc  - R=H, R ’= C 0 2C H 2C H 3 
Id  - R =(5)-C H 3, R ’= C 0 2H 
le  - R=(.V)-CH(CH3)2, R ’= C 0 2H 
I f  - R=(.S>CH2C H (C H 3); , R ’= C 0 2H 
lg  - R={S)-CH2C H (C H 3)2, R ’= C 0 2C H 3 
lh  - R=(,S)-CH2C H (C H 3)2, R ’= C 0 2C H 2C H 3 
l i  - R=GS>CH2C H (C H 3)2, R ’=C O N H 2 
l j  - R =(S)-C H 2C H (C H 3)2, R ’=C H 2OH
2
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3a - R =H , R ’=H  
3b - R =H , R ’=C H 3 
3c - R =H , R ’=C H 2C H 3
TV-Terminal modifications
A^/ram-Cinnamoyl derivatives were synthesized via a Schotten-Bauman procedure, 
by treating the amino acid with cinnamoyl chloride121,122 in aqueous alkaline conditions. N- 
/ram -Cinnam oyl-am ino acids are simple, inexpensive derivatives bearing a degree of 
structural similarity to  bestatin (fig. 2.15a). The phenyl group may interact with the same 
site in the active site o f  the ami no peptidase as the phenyl group o f  bestatin. The presence of 
the a , (3-unsaturated carbonyl system could lead to nucleophilic attack via Michael type 
addition by a nucleophilic centre in the active site (fig 3.1).
Nu O R 
E N Z Y M E
E N Z Y M E
fig. 3.1 Possible M ichael type  ad d itio n  by nucleophilic cen tre  in  th e  active site of an 
enzym e.
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The N-trans-cmnamoy\ derivatives o f glycine ( la ) , L-alanine (Id ), L-valine (le), and L- 
leucine (If) were synthesized to test the affinity o f the aminopeptidase for different amino 
acid side chains. The purification o f compound (If) was found to be difficult with the 
procedure used for the other amino acids. The preparation o f (If) by careful base catalyzed 
hydrolysis o f //-/m m -cinnainoyl-L-leucine methyl ester ( lg )  or ethyl ester ( lh )  gave 
superior results. Hydrolysis with sodium hydroxide solution123,124 was found to be too 
harsh, resulting in hydrolysis o f the amide bond. Satisfactory results were obtained using 
sodium carbonate solution.125 Ar-/ra«.s'-Cinnamoyl glycylglycine (2) was synthesized in order 
to observe the effect o f  lengthening the peptide chain on aminopeptidase inhibition.
The i.r. spectra o f  these compounds all display the characteristic sharp NH  peaks 
superimposed on a broad OH peak in the high frequency region at 3400cm '1, the carboxylic 
acid C = 0  peak at 1720cm'1 and the amide C = 0  peak at 1650cm'1. Absorptions in the 
aromatic region w ere also noted. The ^ -n .m .r . spectra contain signals at 8 8.2 which 
integrate as one proton, due to the amide NH. The signal at 5 13-1.6  integrates as six 
protons and is due to the five phenyl protons and one o f the vinylic protons. The signal at 5
6.8 which integates as one proton are due to the second vinylic proton. The signal for the a  
-proton o f  the amino acid residue is seen as a multiplet at 8 4 3. The 13C-n.m.r. spectra 
show characteristic carbonyl signals at 8 165 and 8172 corresponding to the amide and acid 
carbonyls respectively. There are six signals in the region 8 120-140 corresponding to four 
non equivalent aromatic carbons, and the two vinylic carbons.
N-trans-3-Nitrocinnamoyl glycine (3a) was synthesized using similar method to that 
used for the iV-irara'-cinnamoyl derivatives to  test the effect o f an electron-withdrawing 
group on the phenyl ring. This would deactivate the aromatic ring, and this may affect its 
binding to  the enzyme. It may also increase the polarization o f the amide carbonyl, by 
withdrawing electron density from the carbonyl carbon. It was found that tram-3- 
nitrocinnamoyl chloride could not be obtained by the treatment o f  irara-3-nitrocinnamic acid 
with thionyl chloride even with the addition o f a catalytic amount o f D M F126 to form a 
Vilsmeier type reagent127 because o f the electron withdrawing effect o f the nitro group. 
H owever treatm ent o f  3-nitrocinnamic acid with PC15 in a variation o f the method used for 
the synthesis o f  3,5-dinitrobenzoyl chloride121 furnished the corresponding acid chloride.
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The i.r. spectra o f these compounds are similar to the i.r. spectra o f the 7V-/rans-cinnamoyl 
derivatives except that peaks due to the NO 2 group are observed at 1530 and 1350cm 1. 
The ^I-n.m .r. spectra are also similar to the ’H-n.m.r. spectra o f the 7V-/ram-cinnamoyl 
derivatives except for the aromatic region where a separate signal is observed for each 
phenyl proton and the signals are shifted downfield to 5 7.5-8.2 by the deshielding effect of 
the N 0 2 group. The 13C-n.m.r. spectra are again similar to the spectra o f the N-trans- 
cinnamoyl derivatives, however the carbon attached to the nitro substituent is shifted to 5 
150 due to  its deshielding effect.
It should be noted that there is a disparity in the carbon backbone chain lengths 
between bestatin (fig. 2.14a) and the Af-ira«.v-cinnamoyl derivatives, o f one carbon atom 
which may affect the interaction between the phenyl group and the active site. To overcome 
this possible problem, Ar-4-phenylbut-2-enoyl-L-leucine methyl ester (5) was also 
synthesized, to  increase the structural similarity to bestatin. 4-phenylbut-2-enoic acid (4) 
could not be obtained by a Perkin type reaction procedure but was prepared via a Doebner 
reaction procedure in a variation o f the method used for furylacrylic acid.121 After formation 
o f the acid chloride by treating with thionyl chloride, it was coupled to  L-leucine methyl 
ester (scheme I).
47
Scheme I
0 )
OH
CH
(")
(iii)
(i) - H 2C (C O O H )2, C 5H 5N
(ii) - SO C l2, D C M
(iii) -L -leucine inethyl ester hydroch loride, EÎ3N, D C M
The i.r spectrum o f this compound shows the characteristic N H  peak at 3294cm'1, 
the ester carbonyl peak at 1743cm"1, and an amide carbonyl peak at 1641cm'1. Absorptions 
in the aromatic region are also observed. The ^ -n .m .r . spectrum has a multiplet at <5 7.75- 
7.91 which integrates as five protons due to the aromatic protons. A  multiplet at 8 5.2 which 
integrates as one proton is due to the a-proton. The singlet at 8 4.2 which integrates as 
three protons is due to the methyl ester protons. The doublet at 8 3.75 integrates as two 
protons and is due to the benzylic protons. The signals between 8 1.47 and 8 2.19 integrate 
as nine protons and are due to the protons on the side-chain o f  the L-leucine residue. The 
13C-n.m.r. spectrum is similar to  that o f iV-ira«s-cinnarnoyl-L-leucine methyl ester (lg), with 
an extra signal at 8 40 due to the methylene carbon o f the benzyl group.
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M odifications o f the C-terminus
In order to observe the effect o f altering the C-terminus o f  the aminopeptidase inhibitors, N- 
/ram ’-cinnamoyl glycine methyl ester ( lb ) , /'/-¿ram'-cinnamoyl glycine ethyl ester (lc), N- 
ira/M-cinnamoyl-L-leucine methyl ester (lg ), A/’-/ram ,-cinnamoyl-L-leucine ethyl ester (lh ), 
N-trans-3 -nitrocinnamoyl glycine methyl ester (3b) and N-trans-3-nitrocinnamoyl glycine 
ethyl ester (3c) w ere synthesized, by either treating the vV-/nmv-cinnamoyl derivatives and 
N-trans-3 -nitrocinnamoyl derivatives with thionyl chloride and the corresponding alcohol or 
by treating the amino acid methyl ester hydrochloride with triethylamine and the required 
carboxylic acid chloride. The i.r. spectra o f the esters are similar to the i.r. spectra o f the 
corresponding carboxylic acid derivatives except that as expected the carboxylic acid OH 
peak is not observed. The ^ -n .m .r . spectra o f the esters are also similar to the ^ -n .m .r. 
spectra o f the corresponding carboxylic acid derivatives. A singlet at 5 3.4-4.2 which 
integrates as three protons is due to methyl ester protons and signals at 8 3.6-4.2 and 8 1.2-
1.3 which integate as tw o and three protons respectively are due to ethyl ester protons. The 
13C-n.m.r. spectra show an extra signal at 8 52 due to the methyl carbon o f the methyl ester 
group, and those o f  the ethyl esters show tw o extra signals at 8 61 and 8 14 corresponding 
to the methylene and methyl carbons o f the ethyl ester group respectively.
A -/ram ’-Cinnamoyl-L-leucinamide ( l i)  was synthesized via an ammonolysis121,123’ 124 
o f Ar-/ram-cinnarnoyl-L-leucine methyl ester (lg ). Reduction o f /'/-¿ram-cinnamoyl-L- 
leucine methyl ester ( lg )  with lithium borohydride128 furnished A-/ram ’-cinnamoyl-L-leucinol
( l j )
The i.r. spectrum of Ar-iraw-Cinnamoyl-L-leucinamide ( li)  is similar to the i.r. 
spectrum o f  the starting compound (If) except that three N H  peaks are observed in the high 
frequncy region at 3400cm '1. The ^ -n .m .r . spectrum is also similar to that of the starting 
material except that that no ethyl ester protons are observed. The signal due to the primary 
amide protons are obscured by the signals for the aromatic protons. The 13C-n.m.r, has only 
five signals due to  CH, CH2 and CH3 groups, as compared to seven signals in the starting 
product. This clearly shows the loss o f  the ethyl ester funtionality.
The i.r. spectrum  of iV-im/i^-cinnamoyl-L-leucinol ( l j )  is again similar to the i.r. 
spectrum o f Af-iraws'-cinnarnoyl-L-leucine methyl ester ( lg ), except that there is only one
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carbonyl peak at 1650cm'1 due to the amide carbonyl. A  broad peak due to the hydroxyl 
group is observed in the high frequency region at 3400cm '1. The ^ -n .m .r . spectra o f N- 
frYm?-cinnamoyl-L-leucinol ( l j )  is also similar to the ^ -n .m .r . spectra of N-trcms- 
cinnamoyl-L-leucine methyl ester (lg ). However there are tw o signals at 5 3.6 and 5 3.74 
both o f which integrate as one proton, due to the tw o methylene protons adjacent to the 
hydroxyl group. Only one carbonyl peak is observed in the 13C-n.m.r. spectrum due to the 
reduction o f  the ester functionality to  an alcohol. The loss o f the methyl ester methyl carbon 
signal at 5 52 is observed as well as an extra signal at 5 66 due to the methylene to which the 
hydroxyl group is attached.
Attempts to prepare Ar-/ram-cinnamoyl-L-leucine hydroxamate, by treating the 
corresponding ester ( lg )  with hydroxylamine hydrochloride,117’129 w ere unsuccessful. The 
preparation o f A^ram -cinnam oyl-L-leucinal by treatm ent o f the corresponding methyl ester 
(lg ) with diisobutylaluminium hydride54 was not successful. The preparation o f N-trans- 
cinnamoyl-L-leucinthiol was also unsuccessful, because the first step in the attempted 
synthesis i.e. the formation o f  the O-tosylate o f  Ar-/ram ,-cinnamoyl-L-leucinol ( l j )  did not 
proceed.
0
O R '
R
6a - R =H , R ’=C H 2C H 3
6b - R=OS)-CH2C H (C H 3)2, R ’=C H 3
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Modifications o f the -C=C- bond
The presence o f  the -C=C- bond in the N-trans-c\nmmoy\ derivatives opens up the 
possibility o f  addition o f  substituents in the correct positioning for interactions with the 
active site metal ion o f  the aminopeptidase. To this end it was desired to brominate, and 
epoxidise the -C=C- bond to examine the feasibility o f  this process. Treatment o f N-trans- 
cinnamoyl glycine ethyl ester (lc ) and Af-ira/7s-cinnamoyl-L-leucine methyl ester (lg ) with 
bromine in carbon tetrachloride121 yielded a mixture o f the two enantiomers [(25,3R) and 
2P,35)] o f 7V-(3-phenyl-2,3-dibromopropionyl)-glycine ethyl ester (6a) and TV-(3-phenyl-2,3- 
dibromopropionyl)-L-leucine methyl ester (6b) respectively. The i.r. spectra o f both of 
these brominated compounds are similar to the corresponding unbrominated vinylic starting 
compounds. The ^ -n .m .r .  spectra o f the brominated compounds are also similar to the 1H- 
n.m.r. spectra o f  the unbrominated starting compounds, except that the signals due to the 
vinylic protons are replaced by two doublets at 5 5.4 and 8 5.5 both o f which integrate as 
tw o protons due to the protons on the two brominated carbons. Only four signals are 
observed in the region 8 120-140 o f the 13C-n.m.r. spectrum. This is concurrent with the 
loss o f the vinylic carbon signals.
The epoxidation o f  Ar-iram ,-cinnamoyl-L-leucine methyl ester ( lg )  was unsuccessful 
using m-CPBA. It has been shown that the rate o f epoxidation is increased by the presence 
o f  electron-donating substituents on the alkene, and very low reactivity is observed for 
alkenes with strongly electron-withdrawing substituents.130 The presence o f the phenyl 
group conjugated to the -C=C- bond in the cinnamoyl derivatives, as well as the electron- 
withdrawing effect o f  the amide carbonyl, may be reducing the electron density around the - 
C=C- bond thus making electrophilic addition by the peroxy acid less favourable. To 
overcom e this, the epoxidation was also attempted using i-butyl hydroperoxide in alkaline 
conditions, which has a different mechanism involving conjugate nucleophilic addition.131 
This reagent is often used to epoxidise electron-poor alkenes, however in this case the 
desired product was not formed. The epoxidation o f Ar-phenylbut-2-enoyl-L-leucine methyl 
ester (5) with ra-CPBA was then attempted. In this compound, the phenyl group is not 
conjugated to the vinylic group, and it was hoped that the epoxidation would proceed more
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readily. However in this case the epoxide derivative o f  3-phenylbut-2-enoic acid was 
obtained. Thus the formation o f the epoxide causes the hydrolysis o f the amide bond.
3.2 iV -3,5-D initrobenzovl derivatives
NO
7a R=0S)-CH3 
7b R =(£)-C H 2C H (C H 3)2 
7c R = (5)-C H (C H 3)C H 2C H 3 
7d R=(/?)-CH 2C H (C H 3)2
//-Term inal modifications
Synthesis o f Af-3,5-dinitrobenzoyl derivatives was achieved by a Schotten-Baumcinn 
reaction procedure using 3,5-dinitrobenzoyl chloride.121 It was decided to prepare these 
compounds for tw o reasons. Firstly in order to observe w hether the phenyl would still 
interact with the binding site if the distance between it and the amide bond was shortened. 
M ore importantly the effect o f  strongly electron-withdrawing substituents on the phenyl 
group was investigated. The 3,5-dinitrobenzoyl derivatives o f  L-alanine (7a), L-leucine 
(7b), L-isoleucine (7c) and D-leucine (7d) were prepared because the aminopeptidase is 
known to have specificity for amino acids with hydrophobic side chains.
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The i.r. spectra o f the iV-3,5-dinitrobenzoyl derivatives all show the characteristic 
N H  peak superimposed on a broad OH peak at 3400cm"1. Peaks at 1720cm'1 and 1650cm'1 
are due to the carboxylic acid and amide carbonyls respectively. Peaks at 1530cm'1 and 
1350cm'1 are characteristic o f the N 0 2 groups. Absorptions in the aromatic region are also 
seen. The ^ -n .m .r . spectra all show a doublet in the region 5 8.4-9.4 which integrates as 
one proton due to the N H  proton. The signals at 6 9.1 and 5 8.9 which integrate as two 
protons and one proton respectively are due to the aromatic protons. The signal due to the 
a-p ro ton  occurs as a multiplet in the region 5 4.4-4.6. The 13C-n.m.r. spectrum has two 
carbonyl peaks at 5 162 and 5 174 as well as four aromatic signals in the region 5 120-150. 
The signal for the aromatic carbon containing the nitro group is shifted downfield to 5 148 
due to its deshielding effect.
It was observed from x-ray crystallographic data that A-3,5-dinitrobenzoyl-L-leucine 
(7c) crystallizes as tw o separate molecules A and B which differ in conformation about the 
N1-C2 bond (fig 3.2). The largest angle difference is N1-C2-C4, 115.9(5)°, 110.0(5)° and 
the torsional angle C1-N1-C2-C3 is 56.1(7)° and -81.5(7)° in A,B respectively. 
Intermolecular hydrogen bonding arises between the amide and carboxylic acid groups as N- 
H  • • -0 = C  forming one-dimensional chains and C = 0  • • H -0  forming a two dimensional 
netw ork by linking neighbouring chains.
Dipeptide derivatives
To test the effect o f  increased chain length o f  the derivative on the activity of the 
am inopeptidase Ar-3,5-dinitrobenzoyl-L-leucine-L-alanine methyl ester (8) was also
Fig. 3.2 The two conformations of crystalline 3,5-dinitrobenzoyI-L-leucine (7b).
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synthesized by coupling jV-3,5-dinitrobenzoyl-L-leucine and L-alanine methyl ester by 
treatment with D C C D 132 and TV-hyroxybenzotriazole.133'134 The i.r spectrum of this 
compound is similar to  the i.r. spectra o f the other /</-3,5-dinitrobenzoyl derivatives 
described above. The ^ -n .m .r . spectrum is also similar to  the ‘H-n.m.r. spectra o f the other 
7V-3,5-dinitrobenzoyl derivatives described above. Doublets at 5 8.4 and 5 6.4 which 
integrate as one proton each, are due to the L-leucyl and L-alanyl NH protons respectively. 
A  singlet at 5 3.6 which integrates as three protons is due to methyl ester protons. The 
signals at 5 0.88-0.93 and 8 1.57 and S 1.69 which integrate as six and three protons 
respectively are due to the L-leucyl side chain. The doublet at 5 1.3 which integrates as 
three protons is due to the L-alanyl side chain. Three carbonyl signals are observed in the 
13C-n.m.r. spectrum at § 162, 5 172, and 8 173.
3.3 A^-Toluene-p-sulphonyl derivatives
9a R =H , R ’=H  
9b R=(,S)-CH3, R ’=H 
9c R =(S)-C H (C H 3)2, R ’=H  
9d R =(S)-C H 2C H (C H 3)2, R ’=H  
9e R=(.S)-CH(CH3)C H 2C H 3, R ’=H  
9 f R=(iS)-C H (C H 3)C H 2C H 3, R ’= C H 3 
9g R=(.V)-CH(CH3)C H 2C H 3, R ’=C H 2CH 3 
9h R=(/?)-CH 2C H (C H 3)2, R ’=H
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//-Term inal modifications
The synthesis o f sulphonamide derivatives was acheived by treating the amino acids with p- 
toluenesulphonyl chloride in aqueous alkaline conditions.121 The 7V-toluene-p-sulphonyl 
derivatives o f glycine (9a), L-alanine (9b), L-valine (9c) L-leucine (9d), L-isoleucine (9e) 
and D-leucine (9h) were prepared in this manner. In this class o f compounds the usual 
peptide bond is replaced by a sulphonamide functionality which can interact with the active- 
site metal. The sulphonyl functionality is tetrahedral as compared with the trigonal carbonyl 
group and this may affect both binding and activity.
The i.r. spectra o f the //-toluene-p-sulphonyl derivatives show characteristic NH 
peaks at 3300cm '1 and carboxlyic acid carbonyl peaks at 1720cm"1. Several peaks are seen 
in the region 1350-1450cm '1 due to the sulphonamide moiety. Absorbtions in the aromatic 
region are also noted. The ^ -n .m .r . spectra show a signal at 8 7.9-8 8.1 which integrates as 
one proton due to the sulphonamide NH proton. Two doublets at 8 7.6 and 8 7.3, both of 
which integrate as tw o protons are due to the aromatic protons. The a-protons give a signal 
at 8 3.5-3.7. The protons o f the toluyl methyl are present as a singlet at 8 2.35 which 
integrates as three protons. The 13C-n.m.r. spectra contain one carbonyl signal at 8 170 and 
four aromatic carbon peaks in the region 8 125-143. The toluyl methyl carbon gives a signal 
at 8 21.
C-Terminal derivatives
7V-toluene-p-sulphonyl-L-isoleucine methyl ester (9f) and TV-p-toluenesulphonyl-L- 
isoleucine ethyl ester (9g) were synthesized to observe the effect o f the esterification on the 
potency o f  derivatives as inhibitors.
The i.r. and ^ -n .m .r . spectra are similar to the spectra o f the iV-terminal derivatives 
described above. The methyl ester protons give a singlet at 8 3.3 which integrates as three 
protons in the ^ -n .m .r .  spectrum while the ethyl ester protons give a quartet and a triplet at 
8 3.73 and 8 0.97 which integrate as two and three protons respectively. The 13C-n.m r 
spectrum o f compound (9f) has an extra signal at 8 62 due to the methyl ester carbons, and 
that o f compound (9g) has two extra signals at 8 62 and 8 14 due to the ethyl ester carbons.
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3.4 3 -N itroph thaIoy l derivatives
O
10a R=0S)-CH3, R ’- H  
10b R =(S)-C H 2C H (C H 3)2, R ' II 
10c R=OS)-CH2C H (C H 3)2, R ’= C H 3 
lOd R=(1S)-CH2C H (C H 3)2, R ’= C H 2C H 3 
lOe R =(S)-C H (C H 3)C H 2C H 3, R ’=H  
lO f R=(iy)-C H (C H 3)C H 2C H 3, R ’=C H 3 
lOg R = (£)-C H (C H 3)C H 2C H 3, R ’= C H 2C H 3
//-Term inal derivatives
The synthesis o f  //-3-nitrophthalimides was achieved by condensing 3-nitrophthalic 
anhydride with the appropriate amino acid at high tem peratures.121 The 3-nitrophthaloyl 
derivatives o f  L-alanine (10a), L-leucine (10b) and L-isoleucine (lOe) were prepared. These 
compounds are notable in that they do not have a normal peptide bond which the 
aminopeptidase could cleave. Assuming that the compounds still are recognized by and fit 
into the enzyme's active site, they may have an inhibitory effect on the enzyme. The 
presence o f  the electron-withdrawing nitro group on the phenyl ring could also increase the 
polarization o f  the imide carbonyl bonds. This may increase hydrogen bonding interactions 
in the active site.
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The i.r. spectra o f the iV-3-nitrophthaloyl derivatives have a peak at 1720cm'1, due to 
the carboxylic carbonyl. Characteristic peaks at 1530cm'1 and 1350cm'1, are due to the N 0 2 
group. The ^ -n .m .r. spectra show three signals between 5 7.9 and 5 8.3 which integrate as 
three protons due to the aromatic protons. The a-protons give a signal at 5 4.5-4.9. Three 
peaks are seen in the 13C-n.m.r spectra at 5 170, 5 165 and 5 162, due to the carboxylic acid 
and phthaloyl carbonyls. Six signals are observed in the region 5 122-145 corresponding to 
the six non-equivalent aromatic carbons. The aromatic carbon with the nitro substituent is 
shifted downfield to 5 145.
C-Terminal modifications
Synthesis o f methyl and ethyl ester derivatives o f the 7V-3-nitrophthaloyl amino acids was 
achieved by treatment with thionyl chloride and the corresponding alcohol. N-3- 
Nitrophthaloyl-L-leucine methyl ester (10c), vV-3-nitrophthaloyl-L-leucine ethyl ester (lOd), 
7V'-3-nitrophthaloyl-L-isoleucine methyl ester (10f) and iV-3-nitrophthaloyl-L-isoleucine 
(lOg) were synthesized in this manner. The i.r. and ’H-n.m.r. spectra of the ester compounds 
are similar to the 7V-3-nitrophthaloyl amino acid derivatives described above. In the 1H- 
n.m.r. spectra, a singlet at 5 1.5 is due to the methyl ester protons, while signals at 5 4.1 and 
5 1.2 which integrate as two and three protons are due to the ethyl ester protons. The 13C- 
n.m.r spectra are similar to the parent compounds with the extra signals for the methyl and 
ethyl ester carbons occuring at 5 55 for the methyl ester carbons and 8 62 and 5 14 for the 
ethyl ester carbons.
3.5 ./V-Phenvlureido derivatives
11a R-(5)-CH3
lib  R=(S)-CH2CH(CH3)2
11c R=(5)-CH(CH3)CH2CH3
TV-Terminal modifications
The synthesis o f /v'-phenylureido amino acids was achieved by treating the amino 
acids with phenyl isocyanate in alkaline aqueous solution.121 vV-Phenylureido-L-alanine 
(11a), yV-phenylureido-L-leucine (lib), and JV-phenylureido-L-isoleucine (11c) were 
furnished in this manner. Again these compounds are unusual in that they possess a urea 
functionality rather than a normal peptide bond which could affect recognition and binding at 
the active site.
The i.r. spectra o f these compounds show two NH peaks at 3400cm'1 and 
3350cm'1. The carboxylic acid carbonyl gives a peak at 1720cm"1 and an amide carbonyl 
peak appears at 1650cm'1. Absorptions in the aromatic region are also observed. The ’H- 
n.m.r. gives two NH signals which appear at 8 8.5 and 8 6.4. Three peaks between 8 6.9
13and 6 7.4 which integrate as five protons are due to the aromatic protons. The C-n.m.r 
spectra shows a carboxylic acid carbonyl signal at 8 175 and a peak due to the urea carbonyl 
at 8 155 which is shifted upfield because of the shielding effect of the two NH substituents.
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3.6 iV-Chloroacetvl derivatives
0  R
12a R=H, R’=H
12b R=(lS)-CH2CH(CH3)2, R’=H 
12c R=(„V)-CH2CH(CH3)2, R’=CH3 
12d R=(S)-CH2CH(CH3)2, R’=CH2CH3 
12e R=(/?)-CH2CH(CH3)2, R’=H
H 3 C 
H C 
3
+
N
CH O 
3
O
OH
CH
CH
Cl
13
yV-Terminal modifications
iV-Chloroacetyl amino acid derivatives were synthesized by a direct method of 
acétylation in the absence of any added base, by refluxing the amino acid with chloroacetyl 
chloride in anhydrous ethyl acetate.135’136 This method of acétylation furnished N- 
chloroacetyl glycine (12a), 7V-chloroacetyl-L-leucine (12b) and vV-chloroacetyl-D-leucine
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(12c). The presence of the alkyl halide bond could lead to nucleophilic displacement by a 
nucleophilic group present in the active site. Also the compounds may be further derivatised 
by nucleophilic displacement with functional groups to chelate the active site metal ion.
The i.r spectra o f the TV-chloroacetyl amino acid derivatives show characteristic 
peaks at 3400cm'1 due to the NH group, at 1720cm'1 due to the carboxylic acid carbonyl, 
and at 1650cm"1 due to the amide carbonyl. A singlet at 5 4.0 which integrates as two 
protons in the ^ -n .m .r. spectra is due to the chloroacetyl methylene protons. The 13C- 
n.m.r. spectra show two carbonyl signals at 5 171 and 5 166 which correspond to the 
carboxylic acid and chloroacetyl carbonyls respectively. A peak observed at 5 42 is due to 
the chloroacetyl methylene carbons.
Af-Trimethylammoniumacetyl-L-leucine chloride (13), was synthesized by treating N- 
chloroacetyl-L-leucine (12b) with a solution of trimethylamine137 in order to observe the 
effect of a charged group incorporated into the inhibitor on aminopeptidase activity.
The ^ -n .m .r. spectrum has a signal at 5 3.33 which integrates as nine protons due to 
the trimethylammonium protons. The CH2 o f the acetyl group gives a singlet at 5 4.18, 
which integrates as two protons. A signal at 5 64 in the ljC-n.m.r. spectrum is due to the 
trimethylammonium methyl carbons.
C-terminal modifications
JV-Chloroacetyl-L-leucine methyl ester (12c) and iV-chloroacetyl-L-leucine ethyl ester 
(12d), were synthesized by treating ,/V-chloroacetyl-L-leucine (12b), with thionyl chloride 
and methanol or ethanol respectively. The i.r and ^ -n .m .r. spectra are similar to that of N- 
chloroacetyl-L-leucine (12b), described above. The ^ -n .m .r. spectrum of the methyl ester 
has a singlet at 8 3.68 which integrates as three protons due to the methyl ester protons 
while that of the ethyl ester has a quartet at 5 4.09 and a triplet at 5 1.18 which integrate as 
two and three protons respectively due to the ethyl ester protons. The 13C-n.m.r. spectra 
show characteristic signals at 5 52 for the methyl ester carbons and at 5 61 and 5 14 for the 
ethyl ester carbons.
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3.7 Experimental 
Experimental note
All melting point determinations were carried out on a Griffin melting point 
apparatus and are uncorrected. All infra-red spectra were recorded on either a Nicolet 205 
FTIR or a Perkin Elmer System 2000 FTIR spectrometer. 'H-n.m.r spectra were recorded 
on a Bruker AC 400 spectrometer, operating at 400MHz in Aldrich deuterated solvents 
with tetramethylsilane as an internal standard. 13C-n.m.r spectra were also recorded on a 
Bruker AC 400 spectrometer, operating at 100MHz in Aldrich deuterated solvents with 
tetramethylsilane as an internal standard. Electron impact mass spectra were recorded on a 
VG 7070E mass spectrometer (electron energy=70ev, source temperature=200°C, 
resolution=10,000). Fast atom bombardment mass spectra were run on a Jeol SX 102 mass 
spectrometer (resolution=5,000) with thioglycerol or nitrobenzyl alcohol as the matrix. 
Riedel-de H aen silica gel 60 F254 TLC plates and Riedel-de H aen silica gel S were used for 
thin layer and column / flash chromatography respectively. The t.l.c. plates were examined 
with u.v. illumination at A, 254nm, by staining with iodine or vanillin or by spraying with 
ninhydrin solution. All chemicals were purchased from the Sigma/Aldrich Company. Amino 
acid ester hydrochlorides were prepared by the method o f Brenner138 by treating the amino 
acid with thionyl chloride and the corresponding alcohol.
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N-ftyms-Cinnamoyl glycine (la)
/ra/zs-Cinnamoyl chloride (6.7g, 0.04mol) in diethyl ether (50ml) was added cautiously to a 
solution o f glycine (1.5g, 0.02mol) in 10% sodium hydrogen carbonate (30ml). The 
resulting solution was stirred at room temperature for 4hr. The solution was acidified with 
10% hydrochloric acid and the resulting precipitate filtered. Recrystallisation of the solid 
from ethanol/water gave vV-/ram-cinnamoyl glycine as fine white needles (1.4g, 34.2%). 
m.p. 190-192°C (uncorrected). Lit 197°C (193-4°C).136’139
Spectroscopic analysis
i.r vmax(KBr): 3300 (NH), 1740 (carboxylic acid C=0), 1650 (amide C=0), 1600, 
1 2 0 0 cm •
1H-n.m.r.(400MHz)8(DMSO): 3.9 (2H, d, J=5.9Hz -NHCH2C 0 2H), 6.7 (1H, d, J=15.8Hz 
PhCH=CHCO-), 7.37-7.47 (4H, m, PhCH=CHCO- and ArH 3,4&5), 7.6 (2H, d, J=6.4Hz, 
ArH 2&6), 8.45 (1H, t, J=5.9Hz -NH).
13C-n.m.r.(100MHz)5(DMSO): 171.41 (-NHCH2C 0 2H), 163.34 (PhOCH CO -), 139.26, 
134.82, 129.61, 128.50, 127.63, 121.68 (aromatic and vinylic carbons), 40.87 
(-NHCH2C 0 2H).
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N -trans-C innsim oy\ glycine methyl ester (lb)
Thionyl chloride (1.2g, O.Olmol) was added dropwise to methanol (20ml) at 0°C. N-trcins- 
cinnamoyl glycine (2g, O.Olmol) was added in portions and the temperature was slowly 
increased to 40°C. The reaction mixture was stirred at 40°C for 4hr and the excess methanol 
removed in vacuo. The resulting white solid was washed with 5% sodium hydrogen 
carbonate, water and dried. The white solid crystallised from ethyl acetate/petroleum ether 
(40-60°C) furnishing A^-iram-cinnamoyl glycine methyl ester140 as fine white needles (1.23g, 
56.1%).
m.p. 60-62°C (uncorrected).
Spectroscopic analysis
i.r. vmax(KBr): 3325 (NH), 1750 (ester C=0), 1650 (amide C=0), 1600, 1550, 1200cm' 1
1H-n.m.r.(400MHz)5(DMSO): 3.37 (3H, s, -NHCH2C 0 2CH3, 3.9 (2H, d, J=6 Hz, 
-NHCH2CO2CH3), 6.7 ( 1H, d, J=15.8Hz, PhCH=CHCO-), 7.4-7.48 (4H, m,
PhCH=CHCO- and ArH 3,4&5), 7.6 (2H, d, J=6.4Hz, ArH 2&6), 8.58 (1H, t, J=6Hz, 
-NH).
13C-n.m.r.(100MHz)5(DMSO): 170.46 (-NHCH2C 0 2CH3), 165.46 (PhCH=CHCO-),
139.48, 134.73, 129.66, 128.50, 127.66, 121.40 (aromatic and vinylic carbons), 51.78 
(-NHCH2C 0 2CH3), 40.80 (-NHCH2C 0 2CH3).
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jV-frflns-Cinnamoyl glycine ethyl ester (lc)
iV-/ra?w-Cinnamoyl glycine ethyl ester was synthesized by the procedure used for the 
synthesis of TV-fra^-cinnamoyl glycine methyl ester. Thionyl chloride (1.2g, O.Olmol), was 
added to ethanol (20ml) at 0°C. ,AA-ir<my-cinnamoyl glycine (2g, O.Olmol.) was added in 
portions. Recrystallisation from ethyl acetate/petroleum ether 40-60 yielded N-trans- 
cinnamoyl glycine ethyl ester as fine white needles (890mg, 38.2%). 
m.p. 102-104°C (uncorrected). Lit 108°C.139
Spectroscopic analysis
i.r vmax(KBr): 3400 (NH), 1725 (ester C=0), 1675 (amide C=0)), 1625, 1525, 1200cm'1-
H-n.m.r.(400MHz)8(DMSO): 1.2 (3H, t, J=6.9Hz, -NHCH2C 0 2CH2CH3), 3.95 (2H, d, 
J=5.9Hz, -N(H)CH2C 0 2CH2CH3), 4.1 (2H, q, J=6.9Hz, NHCH2C 0 2CH2CH3), 6.7 (1H, d, 
J=15.7Hz, PhCH=CHCO-), 7.39-7.47 (4H, m, PhCH=CHCO and ArH 3,4&5), 7.6 (2H, d, 
J=6.4Hz, ArH 2&6), 8.55 (1H, t, J=5.9Hz, -NH).
13C-n.m.r.(100MHz)5(DMSO): 169.95 (-NHCH2C 0 2CH2CH3), 165.43 (PhCH=CHCO-), 
139.44, 134.73, 129.64, 128.50, 127.66, 121.42 (aromatic and vinylic carbons), 60.50 
(-NHCH2C 0 2CH2CH3), 40,89 (-NHCH2C 0 2CH2CH3), 14.11 (-NHCH2C 0 2CH2CH3),
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AT-fmws-Cinnamovl-L-alanine (Id)
ira/w-Cinnamoyl chloride (6.7g, 0.04mol) in diethyl ether (50ml) was added to a solution of 
L-alanine (1.8g, 0.02mol) in 1M sodium hydroxide (40ml). The reaction mixture was stirred 
for 4hr at room temperature and the ether removed in vacuo. The reaction mixture was 
acidified with 10% hydrochloric acid and the precipitate filtered. Purification using column 
chromatography on silica gel [chloroform-ethyl acetate ( 1 :1) to which a small amount of 
acetic acid was added] yielded Af-irafts-cinnamoyl-L-alanine (1.16g, 26.4%) as a white solid, 
m.p. 184-186°C (uncorrected). Lit 191°C.136
Spectroscopic analysis
i r. vmax(KBr): 3400 (NH), 1725 (carboxylic acid C=0), 1650 (amide C=0), 1550,
1 2 0 0 cm'1.
H-n.m.r.(400MHz)5(DMSO): 1.32 (3H, d, J=7Hz, -NHCH(CH3)C 0 2H), 4.32-4.33 (1H, 
m, -NHCH(CH3)C 0 2H), 6.71 (1H, d, J=16.2Hz, PhCH=CHCO-), 7.37-7.46 (4H, m, 
P hC H C H C O - and ArH 3,4&5), 7.56 (2H, d, J=6.4Hz, ArH 2&6) 8.43 (1H, d, J=7Hz, 
-NH).
13C-n.m.r.(100MHz)5(DMSO): 173.68 (-NHCH(CH3)C 0 2H), 164.14 (PhCH=CHCO-), 
138.61, 134.31, 128.46, 127.03, 121.22 (aromatic and vinylic carbons), 47.14 
(-NHCH(CH3)C 0 2H, 16.81 (-NHCH(CH3)C 0 2H).
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A'-fra/is-Cinnamovl-L-valine (le)
The synthesis o f A^/ranj-cinnamoyl-L-valine was achieved using the procedure described for 
7V-/raft5,-cinnamoyl-L-alanine. iram'-Cinnamoyl chloride (6.7g, 0.04mol) in diethyl ether 
(50ml) was added to a solution of L-valine (2.34g, 0.02mol) in 1M sodium hydroxide 
(40ml). Purification by column chromatography on silica gel [chloroform-ethyl acetate (1:1) 
to which a small amount of acetic acid was added] furnished iV-iram'-cinnamoyl-L-valine as 
a white solid (845mg, 17.1%) 
m.p. 176-178°C (uncorrected). Lit 188°C.136
Spectroscopic analysis
i r vmix(KBr): 3350 (NH), 1700 (carboxylic acid C=0), 1650 (amide C=0), 1550, 1200cm"1
H-n.m.r.(400MHz)5(DMSO): 0.92 (6H, d, J=6Hz, -NHCH(CH(CH3)2)C0 2H), 2.1 (1H, m, 
-NHCH(CH(CH3)2)C 0 2H), 4.29 (1H, dd, JA=8.4Hz, JB=6Hz, -NHCH(CH(CH3)2C0 2H), 
6.87 (1H, d, J=15.8Hz, PhCH=CHCO-), 7.36-7.46 (4H, m, PhCH=CHCO- and ArH
3,4&5), 7.57 (2H, d, J=6.4Hz, ArH, 2&6), 8.23 (1H, d, J=8.4Hz, -NH).
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13C-n.m.r.(100MHz)5(DMSO): 173.09 (-NHCH(CH(CH3)2)Ç 0 2H), 163.14 
(PhCH=CHÇO-), 139.14 , 134.93, 129.51, 128.97, 127.53, 121.91 (aromatic and vinylic 
carbons), 57.30 (-NHÇH(CH(CH3)2)C 0 2H), 29.95 (-NHCH(CH(CH3)2C 0 2H), 19.20, 18.01 
(-NHCH(CH(CH3)2C 0 2H ).
Af-fm»,v-Ciniiamovl-L-leucinc (If)
Potassium carbonate solution (1M, 20ml) was added slowly to a solution of N-trcins- 
cinnamoyl-L-leucine methyl ester (lg ) (2.75, O.Olmol) in methanol (20ml). The resulting 
solution was stirred at room temperature for 48hr, acidified with hydrochloric acid (1M) and 
the methanol removed in vacuo. After cooling the precipitate was filtered and dried. 
Purification of the product by flash chromatography [petroleum ether 40-60/ethyl acetate 
(6:4)] yielded the title compound141 as a waxy solid (1.74g, 67%).
Spectroscopic analysis
i.r vmax(CHCl3): 3312 (OH), 1714 (carboxylic acid C=0), 1663 (amide C=0)), 1620, 1542, 
1353, 1216, 975cm'1.
1H-n.m.r.(400MHz)5(CDCl3): 0.92 (6 H, d, J=5.9Hz, -NHCH(CH2CH(CH3)2)C 0 2H), 1.61- 
1.77 (3H, m, -NHCH(CH2CH(CH3)2C 0 2H and -NHCH(CH2CH(CH3)2)C 0 2H), 4.71-4.77 
(1H, m, -NHCH(CH2CH(CH3)2)C 0 2H), 6.46 (1H, d, J=15.7Hz, PhCH=CHCO-), 6.58 (1H, 
d, J=8Hz, NH), 7.24-7.44 (5H, m, ArH), 7.60 (1H, d, J=15.7Hz, PhCH=CHCO-).
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13C-n.m.r.(100MHz)8(CDCl3): 176.46 (-NHCH(CH2CH(CH3)2)C 0 2H), 166.75
(PhCH=CHCO-), 142.36, 134.42, 129.87, 128.73, 127.94, 119.58 (aromatic and vinylic 
carbons), 51.23 (-NHCH(CH2CH(CH3)2)C 0 2H), 41.07 (-NHCH(CH2CH(CH3)2)C 0 2H),
24.88 (-NHCH(CH2CH(CH3)2)C 0 2H), 22.81, 21.77 (-NHCH(CH2CH(CH3)2)C 0 2H).
Ai-frans-Cinnamoyl-L-leucine methyl ester (lg)
A solution o f frvms-cinnamoyl chloride (3.35g, 0.02mol) in chloroform (50ml) was added 
dropwise to a solution of L-leucine methyl ester hydrochloride (1.8g, O.Olmol) and 
triethylamine (1.4ml, O.Olmol) in chloroform (50ml) at 0°C. After 30min the reaction 
temperature was increased to room temperature and the reaction allowed to proceed for 6 hr. 
The solution was then washed with 10% sodium hydrogen carbonate solution, water and 
dried. The solvent was removed in vacuo and recrystallization o f the resulting oil from ethyl 
acetate/pet ether yielded the title product141 as a white crystalline solid (1.15g, 42%). 
m.p. 70-72°C (uncorrected). Lit. 80-82°C.142
CH
3
Spectroscopic analysis
i.r. vmax(KBr): 3257 (NH), 3075, 2951, 2879, 1736 (ester C =0), 1663 (amide C=0), 1620, 
1554, 1445, 1343, 1205, 1154cm-i.
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1H-n.m.r.(400MHz)5(CDCl3): 0.97 (6H, m, -NHCH(CH2CH(CH3)2)C 0 2CH3, 1.58-1 73 
(3H, m, -NHCH(CH2CH(CH3)2)C 0 2CH3 and -NHCH(CH2CH(CH3)2)C 0 2CH3), 3.76 (3H, 
s, -NHCH(CH2CH(CH3)2C 0 2CH3), 4.80 (1H, m, -NHCH(CH2CH(CH3)2)C 0 2CH3), 6.29 
(1H, d, J=8.4Hz, -NH), 6.45 (1H, d, J=15.8Hz, PhCH=CHCO-), 7.32-7.36 (3H, m, ArH 
2,4&6), 7.45-7.48 (2H, m, ArH3&5), 7.62 (1H, d, J=15.8Hz, PhCH=CHCO-).
13C-n.m.r.(100MHz)5(CDCl3): 173.80 (-NHCH(CH2CH(CH3)2)C 0 2CH3), 165.58
(PhCH=CHCO-), 141.71, 134.63, 129.71, 128.73, 127.81, 119.99 (aromatic and vinylic 
carbons), 52.31 (-NHCH(CH2CH(CH3)2)C 0 2CH3), 50.80 (-NHCH(CH2CH(CH3)2C 02CH3), 
41.78 (-NHCH(CH2CH(CH3)2C 0 2CH3), 24.86 (-NHCH(CH2CH(CH3)2C 0 2CH3), 22.79,
21.95 (-NHCH(CH2CH(CH3)2)C 0 2CH3),
Ar-frfl«5-Cinnamoyl-L-leucine ethyl ester (lh)
A^-iram’-Cinnamoyl-L-leucine ethyl ester was synthesized using the same method as outlined 
for A^ram'-cinnamoyl-L-leucine methyl ester. A solution o f /ram’-cinnamoyl chloride 
(3.35g, 0.02mol) in chloroform (50ml) was added dropwise to a solution o f L-leucine ethyl 
ester hydrochloride (1.95g, O.Olmol) and triethylamine (1.4ml, O.Olmol) in chloroform 
(50ml) at 0°C. Recrystallization from ethyl acetate/pet ether yielded /V-/ram'-cinnamoyl-L- 
leucine ethyl ester as a white crystalline solid (1.05g, 38%). 
m.p. 88-90°C (uncorrected).
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Spectroscopic analysis
i.r. v max(KBr): 3274, 2968, 1744 (ester C=0), 1629 (amide C=0), 1558, 1452, 1353, 1203, 
1152, 1082cm'1.
1H-n.m.r.(400MHz)5(CDCl3): 0.95-0.99 (6 H, d, J=5.9Hz,-NHCH(CH2CH(CH3)2C 0 2CH2 
CH3), 1.3 (3H, t, J=7.1Hz, -NHCH(CH2CH(CH3)2)C 0 2CH2CH3), 1.58-1.75 (3H, m, 
-NHCH(CH2CH(CH3)2)C 0 2CH2CH3 and -NHCH(CH2CH(CH3)2C 0 2CH2CH3), 4.2 (2H, q, 
J=7.2Hz, -NHCH(CH2CH(CH3)2C 0 2CH2CH3), 4.77-4.83 (1H, m,
-NHCH(CH2CH(CH3)2)C 0 2CH3) 6.36 (1H, d, J=8.4Hz, -NH), 6 45 (1H, d, J=15.7Hz, 
PhCH=CHCO-), 7.26-7.48 (5H, m, ArH), 7.62 (1H, d, J=15.7Hz, PhCH=CHCO-).
13C-n.m.r.(100MHz)8(CDCl3): 173.46 (-NHCH(CH2CH(CH3)2)C 0 2CH2CH3), 165.60 
(PhCH=CHCO-), 141.64, 134.64, 129.69, 128.72, 127.81, 120.04 (aromatic and vinylic 
carbons), 61.43 (-NHCH(CH2CH(CH3)2)C 0 2CH2CH3), 50.86
(-NHCH(CH2CH(CH3)2)C 0 2CH2CH3), 41.85 (-NHCH(CH2CH(CH3)2)C 0 2CH2CH3),
24.87, (-NHCH(CH2CH(CH3)2)C 0 2CH2CH3), 22.81, 21.96
(-NHCH(CH2CH(CH3)2)C 0 2CH2CH3), 14.12 (-NHCH(CH2CH(CH3)2)C 0 2CH2CH3) .
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Ai-frflMS-Cinnamoyl-L-Ieucinamide (li)
A vigorous stream of ammonia gas was introduced to a solution of Ar-iram-cinnamoyl-L- 
leucine methyl ester (2.75g,0.01mol) in methanol (75ml) at 0°C. After lhr the introduction 
of ammonia was discontinued, the reaction vessel sealed and allowed to warm to room 
temperature. The reaction was left to stand for 12hr and the solvent removed in vacuo. The 
resulting dry residue was triturated with ethyl acetate, filtered, washed with ethyl acetate and 
dried to yield A ^ram ’-cinnamoyl-L-leucinamide as a white solid (1.87g, 72%). 
m.p. 178-180°C (uncorrected).
Spectroscopic analysis
i.r. vmax(KBr): 3388, 3295, 3189 (NH and NH2), 3189, 2968, 1651 (amide C=0), 1609, 
1545, 1452, 1346, 1217cm'1.
H-n.m.r.(400MHz)5(DMSO): 0.85-0.90 (6H, d, J=6.4Hz, -NHCH(CH2CH(CH3)2)CO 
NH2), 1.47-1.51 (2H, m, -NHCH(CH2CH(CH3)2)CONH2), 1.56-1.64 (1H, m, 
-NHCH(CH2CH(CH3)2CONH2), 4.36-4.42 (1H, m-NHCH(CH2CH(CH3)2)CONH2), 6.75 
(1H, d, J=15.7Hz, PhCH=CHCO-), 7.33-7.55 (8 H, m, ArH, PhCH=CHCO- and -NH2), 
8.16 (1H, d, J=8.4Hz, -NH).
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13C-n.m.r.(100MHz)8(DMSO): 174.17, 164.68 (PhC H C H C O - and 
-NHCH(CH2CH(CH3)2CONH2), 138.74, 134.95, 129.39, 128.91, 127.46, 122.25 (aromatic 
and vinylic carbons), 50.90 (-NHCH(CH2CH(CH3)2)CONH2), 41.24 
(-NHCH(CH2CH(CH3)2)CONH2), 24.36, (-NHCH(CH2CH(CH3)2)CONH2), 23.02, 21.60 
(-NHCH(CH2CH(CH3)2)CONH2).
Mass spectrum: [M+H]+found: 261.1046 CisH2iN20 2 requires 261.16016
iV-fmo.v-Cinnamovl -L-lcucinol (li)
Lithium chloride (1.83g, 0.04mol) and sodium borohydride (1.64g, 0.04mol), were added to 
a solution o f  N-^ms'-cinnamoyl-L-leucine methyl ester (2.75g, O.Olmol) in tetrahydrofuran 
(50ml) and ethanol (50ml) at 0°C. The reaction was allowed to proceed under nitrogen at 
room temperature for 18hr and then quenched with 1M HC1. The reaction mixture was 
extracted with ethyl acetate and the organic fraction washed with water, HC1 (1M), 
N aH C 03 (1M) and brine. After drying the solvent was removed under reduced pressure 
Recrystallization o f the residue from ethyl acetate/pet ether yielded the title product as fine 
white crystals (1.93g, 73%). m.p. 110-114°C (uncorrected). Lit. 115-116°C.143
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Spectroscopic analysis
i.r. vmax(KBr): 3466, 3301 (OH), 2960, 1659 (amide C=0)), 1630, 1552, 1346, 1210, 
1068cm'1.
1H-n.m.r.(400MHz)5(CDCl3): 0.94 (6H, d, J=6.9Hz, -NHCH(CH2CH(CH3)2)CH2OH), 
1.36-1.51 (2H, m, -NHCH(CH2CH(CH3)2)CH20H), 1.63-1.73 (1H, m, 
-NHCH(CH2CH(CH3)2)CH20H), 3.58-3.62 (1H, dd, Ja=11Hz, JB=3.5Hz, 
-NHCH(CH2CH(CH3)2)CH20H), 3.72-3.76 (1H, dd, Ja=11Hz, JB=3.5Hz, 
-NHCH(CH2CH(CH3)2)CH2OH), 4.17-4.22 (1H, m, -NHCH(CH2CH(CH3)2)CH20H), 6.15 
(1H, d, J=8.4Hz, -NH), 6.44 (1H, d, J=15.8Hz, PhCH=CHCO-), 7.30-7.33 (3H, m, ArH
3,4&5), 7.44-7.47 (2H, m, ArH2&6). 7.61 (1H, d, J=15.8Hz, PhCH=CHCO-).
13C-n.m.r.(100MHz)5(CDCl3): 166.71 (PhCH=CHCO-), 141.38, 134.67, 129.69, 128.75, 
127.78, 120.51 (aromatic and vinylic carbons), 66.11 (-NHCH(CH2CH(CH3)2)CH2OH),
50.24 (-NHCH(CH2CH(CH3)2)CH20H ), 40.33 (-NHCH(CH2CH(CH3)2)CH20H), 24.93, 
(-NHCH(CH2CH(CH3)2)CH20H ), 23.02, 22.18 (-NHCH(CH2CH(CH3)2)CH2OH).
Attempted preparation of A^-ftvms-cinnamovl-L-leucine liydroxamate
Triethylamine (2ml, 0.014mol) was added to a stirring solution of hydroxylamine 
hydrochloride (lg , 0.014mol) in DMF (10ml) and the precipitated triethylamine 
hydrochloride filtered. The filtrate was added to a solution of A^/raas-cinnamoyl-L-leucine 
ethyl ester (4g, 0.014mol) in DMF (20ml) and stirred gently at room temperature for 5 days. 
The DMF was evaporated under reduced pressure to yield a red solid. Recrystallization 
from ethyl acetate/petroleum ether did not yield the desired product and the reaction was not 
investigated further.
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m-CPBA (3.45g, 0.02mol) was added to solution of 7'/-/ram-cinnamoyl-L-leucine methyl 
ester (2.75g, O.Olmol) in dichloromethane (50ml) at 0°C. The reaction was stirred at room 
temperature for 40hr, washed with 2.5% sodium hydrogen carbonate solution, water and 
dried. The solvent was removed by evaporation. Recrystallization from ethyl 
acetate/petroleum ether yielded only the starting material and the reaction was not 
investigated further.
Attempted preparation of Ar-cinnamovl-L-leucinol-0-tosylate
Toluene-p-sulphonyl chloride (3.8lg, 0.02mol) in dry pyridine (25ml) was added to N- 
cinnamoyl-L-leucinol (2.47g, O.Olmol) in dry pyridine (25ml) at 0°C. The reaction mixture 
was warmed to room temperature and stirred at this temperature for 24hr. Dichloromethane 
(100ml) was then added and the reaction mixture washed with cold hydrochloric acid (1M, 
3x25ml), sodium bicarbonate solution (10%, 2x25ml) and water (3x25ml). The organic 
fraction was dried and the solvent evaporated. Attempted purification o f the resultant oil by 
flash chromatography did not yield the desired product and the reaction was not investigated 
further.
Ai-fm/ts-Cinnamoyl glycylglycine (2)
¿rafts-Cinnamoyl chloride (6.7g, 0.04mol), in diethyl ether (50ml) was added cautiously to a 
solution of glycylglycine (2.64g, 0.02mol) in sodium hydrogen carbonate (10%, 50ml). The 
solution was stirred at room temperature for 4hr, acidified with 10% hydrochloric acid and 
the precipitate filtered. Recrystallisation of the solid from ethanol/water furnished N-trcins- 
cinnamoyl glycylglycine as very fine white needles (1.4g, 26.5%). 
m.p. 212-216°C (uncorrected).
Attempted preparation of yV-(phenvl-2,3-epoxypropionvO-L-leucine methyl ester
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i.r. vmax(KBr): 3350 , 3300 (OH), 1720 (carboxylic acid C=0), 1650 (amide C=0), 1600, 
1550, 1200cm'1.
1H-n.m.r.(400MHz)5(DMSO): 3.77 (2H, d, J=5.9Hz, -NHCH2C0NHCH2C 0 2H), 3.87 (2H, 
d, J=5.9Hz, -NHCH2C0NHCH2C 0 2H), 6.74 (1H, d, J=15.8Hz, PhCH=CHCO-), 7.38-7.46 
(4H, m, PhCH=CHCO-, ArH 3,4&5), 7.57 (2H, d, J=6.4Hz, ArH 2&6), 8.26 (1H, t, 
J=5.9Hz, -NHCH2C0NHCH 2C 0 2H), 8.41 (1H, t, J=5.9Hz, NHCH2C0NHCH2C 0 2H)
Note: The peaks at 3.77 and 3.87 may be interchangeable. The peaks at 8.26 and 8.41 may 
also be interchangeable.
l3C-n.m.r.(100MHz)5(DMSO): 172.34, (-NHCH2C0NHCH 2C 0 2H), 165.25, 163.12
(PhCH=CHCO- and -NHCH2C0NHCH2C 0 2H), 139.02, 134.88, 129.58, 129.02, 127.60,
121.96 (aromatic and vinylic carbons), 41.96, 40.65 (-NHCH2C0NHCH2C 0 2H and 
-NHCH2C0NHCH 2C 0 2H ).
Note: The signals at 165.25 and 163.12 may be interchangeable. The signals at 41.96 and 
40.65 may also be interchangeable.
Mass spectrum: [M+H]+ found: 263.0610 Ci3H i5N20 4  requires 263.10304
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■/V-frfl«s-3-Nitrocinnamovl glycine (3a)
Finely powdered iram-3-nitrocinnamoyl chloride (8.46g, 0.04mol) was added cautiously to 
a solution o f glycine (1.5g, 0.02mol) in 10% sodium hydrogen carbonate (30ml). The 
reaction mixture was stirred vigorously for 4hr at room temperature, acidified with 10% 
hydrochloric acid and the precipitate filtered. Recrystallisation o f the solid from 
ethanol/water afforded A-/ram’-3-nitrocinnamoyl glycine as an off-white precipitate (980mg, 
19.6%).
m.p. 168-170°C (uncorrected).
Spectroscopic analysis
i r vmax(KBr): 3500 (OH), 3400 (NH), 1725 (carboxylic acid C=0), 1650 (amide C=0), 
1600, 1525, 1350, 1225cm'1.
1H-n.m.r.(400MHz)5(DMSO): 3.90 (2H, d, J=5.9Hz, -NHCH2C 0 2H), 6.92 (1H, d, 
J=15.7Hz, 0 2NPhCH=CHC0-), 7.57 (1H, d, J=15.8Hz, 0 2NPhCH=CHC0-), 7.70 (1H, t, 
J=7Hz, ArH 5), 8.02 (1H, d, J=7Hz, ArH 6 ), 8.20 (1H, d, J=7Hz ArH 4), 8.4 (1H, s, Aril 
2), 8.47 (1H, t, J=5.4Hz, -NH).
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13C-n.m.r.(100MHz)8(DMSO): 171.18 (-NHCH2C 0 2H), 164.72 ( 0 2NPhCH=CHC0-), 
148.30, 136.91, 136.69, 133.89, 130.49, 124.54, 123.81, 121.70 (aromatic and vinylic 
carbons), 41.50 (-NHCH2C 0 2H).
■/V-frv»ts-3-NitrocinnamovI glycine methyl ester (3b)
Af-ira/rv-3-Nitrocinnamoyl glycine methyl ester was synthesized by the method described for 
AL/ra«s-cinnamoyl glycine methyl ester. Thionyl chloride (1.2g, O.Olmol) was added 
dropwise to methanol (20ml) at 0°C. 7V-iram--3-nitrocinnamoyl glycine (2.5g, O.Olmol), was 
added in portions. Purification by column chromatography yielded N-trans-3- 
nitrocinnamoyl glycine methyl ester (1.22g, 46.2%). m.p 154-156°C (uncorrected).
Spectroscopic analysis
i.r. vmnx(KBr): 3371 (NH), 1727 (ester C=0), 1674 (amide C=0), 1636, 1537, 1348, 
1 2 1 1 cm'1.
1H-n.m.r.(400MHz)8(CDCl3): 3.81 (3H, s, -NHCH2C 0 2CH3), 4.22 (2H, d, J=5.4Hz, 
-NHCH2C 0 2CH3), 6.3 (1H, bs, -NH), 6.61 (1H, d, J=15.8Hz, 0 2NPhCH=CHC0-), 7.57 
(1H, t, J=7Hz, ArH 5), 7.71 (1H, d, J=15.7Hz, 0 2NPhCH=CHC0-), 7.8 (1H, d, J=7Hz, 
ArH 6 ), 8.20 (1H, m, ArH 4), 8.38 (1H, s, ArH 2).
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13C-n.m.r.(100MHz)8(CDC13) : 170.27 (-NHCH2C 0 2CH3), 164.85 (0 2NPhCH=CHC0-), 
148.60, 139.30, 136.36, 133.87, 129.93, 124.18, 122.71, 121.93 (aromatic and vinylic 
carbons), 52.57 (-NHCH2C 0 2CH3), 41.52 (-NHCH2C 0 2CH3).
Mass spectrum: [M+H]+ found: 265.0658 Ci2Hi3N20 5  requires 265.0823 
iV-frfltt.s-3-Nitrocinnainovl glycine ethyl ester (3c)
N-trans-3 -Nitrocinnamoy 1 glycine ethyl ester was furnished by the method outlined for N- 
trarn-cinnamoyl glycine ethyl ester. Thionyl chloride (1.2g, 0.01 mol) was added to ethanol 
(20ml) at 0°C. N-trans-3-Nitrocinnamoyl glycine (2.5g, O.Olmol.) was added portionwise. 
Purification by column chromatography yielded N-trans-3 -nitrocinnamoyl glycine ethyl ester 
(1.15g, 41.4%)
m.p. 120-124°C (uncorrected).
O
2
Spectroscopic analysis
i.r. vmax(KBr): 3356 (NH), 3311, 1727 (ester C=0), 1674 (amide C=0), 1621, 1537, 1348, 
1 2 1 1cm '1.
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1H-n.m.r.(400MHz)5(CDCl3): 1.31 (3H, t, J=7Hz, -NHCH2C 0 2CH2CH3), 4.20 (2H, d, 
J=4.9Hz, -NHCH2C 0 2CH2CH3), 4.26 (2H, q, J=7Hz, -NHCH2C 0 2CH2CH3), 6.4 (1H, bs, 
-NH), 6.63 (1H, d, J=15.8Hz, 0 2NPhCH=CHC0-), 7.57 (1H, t, J=7Hz, ArH 5), 7.70 (1H, 
d, J=15.7Hz, 0 2NPhCH=CHC0-), 7.8 (1H, d, J=7Hz, ArH 6 ), 8.20 (1H, d, J=7Hz, ArH 4),
8.38 (1H, s, ArH 2).
13C-n.m.r.(l00MHz)5(CDC13): 169.85 (-NHCH2C 0 2CH2CH3), 164.85 
(0 2NPhCH=CHC0-), 148.60, 139.17, 136.37, 133.86, 129.91, 124.14, 122.79, 121.91 
(aromatic and vinylic carbons), 61.77 (-NHCH2C 0 2CH2CH3), 41.66 
(-NHCH2C 0 2CH2CH3), 14.13 (-NHCH2C 0 2CH2CH3),
Mass spectrum: [M+H]+ found 279.0565 Ci3H i5N20 5  requires 279.09749, [M+Na] found 
300.9804 C 13H i4N 20 5Na requires 301.07944
A/-fr,fl«5-(4-Phenvlbut-2-enoyl')-L-leucine methyl ester (5)
Thionyl chloride (lml, 0.01 mol) was added to a solution o f 4-phenylbut-2-enoic acid. (2g,
0.01 mol) in dichloromethane (20ml). The mixture was heated under reflux for lhr, allowed 
to cool and the dichloromethane and unreacted thionyl chloride removed in vacuo. The 
resulting brown oil was dissolved in chloroform (2 0 ml) and added dropwise to a soluion of 
L-leucine methyl ester hydrochloride (1.8g, 0.01 mol) and triethylamine (lml, 0.01 mol) at 
0°C. The reaction mixture was stirred at room temperature for 4hr, washed with 10% 
sodium hydrogen carbonate (2x20ml), water and dried. Purification by column 
chromatography on silica gel [ethyl acetate:pet ether ( 1 :1)] furnished the title compound as a 
yellow oil.
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Spectroscopic analysis
i.r. vmax(CHCl3): 3294 (NH), 2959, 1743 (ester C=0), 1641 (amide 0 0 ) ,  1532, 1437, 
1365, 1205, 1169cm'1.
lH-n.m.r.(400MHz)8(CDCl3): 1.47 (6H, d, J=6 Hz, -NHCH(CH2CH(CH3)2)C 0 2CH3), 2.06-
2.19 (3H, m, -NHCH(CH2CH(CH3)2)C 0 2CH3 and -NHCH(CH2CH(CH3)2)C 0 2CH3), 3.73 
(2H, d, J=7.4Hz, PhCH2CH=CHCO-), 4.25 (3H, s, -NHCH(CH2CH(CH3)2)C 0 2CH3), 5.20 
(1H, m, -NHCH(CH2CH(CH3)2)C 0 2CH3), 6.80-6.88 (1H, m, PhCH2CH=CHCO-), 6.95 
(1H, d, J=7.9Hz NH), 7.07 (1H, d, J=15.8Hz, PhCH2CH=CHCO-), 7.75-7.91 (5H, m, 
ArH).
13C-n.m.r.(100MHz)5(CDCl3): 173.47 (-NHCH(CH2CH(CH3)2)C 0 2CH3), 170.70
PhCH2CH=CHCO-), 136.53, 134.32, 128.40, 127.40, 126.13, 121.90 (aromatic and vinylic 
carbons), 52.13 (-NHCH(CH2CH(CH3)2)C 0 2CH3), 50.65
(-NHCH(CH2CH(CH3)2)C 0 2CH3), 41.26, 40.24 (-NHCH(CH2CH(CH3)2)C 0 2CH3 and 
PhCH2CH-CHCO-), 24.73, (-NHCH(CH2CH(CH3)2)C 0 2CH3), 22.62, 21.79 
(-NHCH(CH2CH(CH3)2)C 0 2CH3).
Note: The signals at 41.26 and 40,24 may be interchangeable.
Mass spectrum: [M+H]+ found: 290.0768 CnH 24N 0 3 requires 290.17545
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Attempted preparation of N-(4-phenyl-2,3-epoxvbutanovl)-L-leucine methyl ester 
m-CPBA (3.45g, 0.02mol) was added to solution of JV-fr'ims-cinnamoyl-L-leucine methyl 
ester (2.75g, 0.01 mol) in dichloromethane (50ml) at 0°C. The reaction was stirred at room 
temperature for 40hr, washed with 2.5% sodium hydrogen carbonate solution, water and 
dried. The solvent was removed by evaporation. Recrystallization from ethyl 
acetate/petroleum ether did not afford the expected product and the reaction was not 
investigated further.
Af-(3-Phenvl-2,3-dibromopropionyl)-glvcine ethvl ester (6a)
A solution of bromine in carbon tetrachloride (20ml) was added dropwise at 0°C to a stirring 
suspension o f N-trans-cmmmoyl glycine ethyl ester ( l .lg , 0.005mol) in carbon 
tetrachloride. The temperature of the reaction was slowly raised to 40°C and stirred at this 
temperature for a further 4hr. The excess solvent and unreacted bromine were removed in 
vacuo and the resulting oil was recrystallized from ethanol/water to furnish a mixture of 
isomers o f the title compound as a white crystalline solid (412mg, 28.9%). m.p. 122-124°C 
(uncorrected).
Spectroscopic analysis
i.r. vmax(KBr): 3309 (NH), 1763 (ester C=0), 1667 (amide O O ) , 1578, 1377, 1214cm'1.
Br O
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1H-n.m.r.(400MHz)5(DMSO): 1.2 (6H, t, J=7Hz, -NHCH2C 0 2CH2CH3), 3.99 (4H, d, 
J=5.9Hz, -NHCH2C 0 2CH2CH3), 4.09-4.14 (4H, q, J=7Hz, -NHCH2C 0 2CH2CH3), 5.36 
(2H, d, J= 11.8Hz, PhCH(Br)CH(Br)CO-), 5.52 (2H, d, J=11.8Hz, PhCH(Br)CH(Br)CO-),
7.33-7.51 (10H, m, ArH), 8.94 (2H, t, J=5.9Hz, -NH).
13C-n.m.r.(100MHz)5(DMSO): 169.18, 167.13 (-NHCH2C 0 2CH2CH3 and
PhCH(Br)CH(Br)CO-), 138.80, 129.03, 128.83, 128.08 (aromatic protons), 60.64 
(-NHCH2C 0 2CH2CH3), 51.44, 48.23 (PhCH(Br)CH(Br)CO- and PhCH(Br)CH(Br)CO-), 
41.09 (-NHCH2C 0 2CH2CH3), 14.11 (-NHCH2C 0 2CH2CH3).
Note: The signals at 169.18 and 167.13 may be interchangeable. The signals at 51.44 and 
48.23 may also be interchangeable.
Mass spectrum: [M+H]+ found: 391.9231 Ci3Hi6N03Br2 requires 391.94967. 
jV-(3-Phenvl-2,3-dibromoi)roDionvD-L-leucine methyl ester (6b)
N-(3-Phenyl-2,3-dibromopropionyl)-L-leucine methyl ester was furnished by the method 
described for the synthesis of compound (6 a). A solution o f bromine in carbon tetrachloride 
(20ml) was added dropwise at 0°C to a stirring solution o f Ar-/ram'-cinnamoyl-L-leucine 
methyl ester (2.75g, O.Olmol) in carbon tetrachloride. Recrystallization from ethyl 
acetate/petroleum afforded a mixture of isomers of iV-(3-phenyl-2,3-dibromopropionyl)-L- 
leucine methyl ester as an off-white crystalline solid (2.52g, 58%). 
m.p. 136-140°C (uncorrected).
8 3
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Spectroscopic analysis
i.r. vmax(KBr): 3281 (NH), 2968, 1744 (ester C=0), 1666 (amide C=0), 1559, 1445, 1388, 
1346, 1274, 1202, 1153cm'1
1H-n.m.r.(400MHz)5(CDCl3): 0.93-1.00 (12H, m, -NHCH(CH2CH(CH3)2)C 0 2CH3) 1.61- 
1.84 (6H, m, -NHCH(CH2CH(CH3)2)C 0 2CH3) and -NHCH(CH2CH(CH3)2)C 0 2CH3), 3.78 
(6H, s, -NHCH(CH2CH(CH3)2)C 0 2CH3), 4.73-4.84 (4H, m, PhCH(Br)CH(Br)CO- and 
-NHCH(CH2CH(CH3)2)C 0 2CH3), 5.44-5.48 (2H, d, J= llH z , PhCH(Br)CH(Br)CO-), 6.59 
(2H, t, J=9.1Hz, -NH), 7.31-7.42 (10H, m, ArH).
13C-n.m.r.(100MHz)8(CDCl3): 172.98, 172.94 (-NHCH(CH2CH(CH3)2C0 2 CH3), 166.51 
(PhCH(Br)CH(Br)CO-), 138.04, 138.03, 129.21, 129.18, 128.78, 128.74, 128.21, 128.17 
(aromatic carbons), 51.40, 51.20 (-NHCH(CH2CH(CH3)2C0 2CH3), 51.14, 50.80 49.92, 
49.44 (PhCH(Br)CH(Br)CO- and PhCH(Br)CH(Br)CO-), 41.67 
(-NHCH(CH2CH(CH3)2)C 0 2CH3), 24.80 (-NHCH(CH2CH(CH3)2)C 0 2CH3), 22.78 
(-NHCH(CH2CH(CH3)2)C 0 2CH3), 22.01, 21.94 (-NHCH(CH2CH(CH3)2)C 0 2CH3)
Mass spectrum: [M+H]+ found: 434.1722 Ci6H22N 0 3Br2 requires 433.99659
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Ai-3.,5-Dinitrobenzovl-L-alanine (7a)
Finely powdered 3,5-dinitrobenzoyl chloride (2.32g, O.Olmol) was added to a solution of L- 
alanine (0.89g, O.Olmol) in 1M sodium hydroxide (20ml). The mixture was shaken 
vigorously for 5min in a stoppered flask, filtered and the filtrate acidified with 10% 
hydrochloric acid. The resulting precipitate was filtered and recrystallized from 
ethanol/water to yield A^S-dinitrobenzoyl-L-alanine as white needles (917mg, 32.4%). 
m.p. 170-172°C (uncorrected). Lit. 177°C.121
Spectroscopic analysis
ir . vmax(KBr): 3300 (OH), 1725 (carboxylic acid C=0), 1650 (amide C=0), 1600,1350cm'1.
1H-n.m.r.(400MHz)5(DMSO): 1.43 (3H, d, J=7.4Hz, -NHCH(CH3)C 0 2FI) 4.44-4.51 (1H, 
m, -NHCH(CH3)C 0 2H), 8.96 (1H, t, J=2Hz, ArH 4), 9.09 (2H, d, J=2Hz, ArH 2&6), 9.47 
(1H, d, J=6.9Hz -NH).
13C-n.m.r.(l OOMHz)S(DMSO): 173.73 (-NHCH(CH3)C 0 2H), 162.11 ((0 2N)2PhC0-),
148.29, 136.31, 127.73, 121.14 (aromatic carbons), 48.74 (-NHCH(CH3)C 0 2H), 16.77 
(-NHCH(CH3)C 0 2H).
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A^-3,5-Dinitrobenzoyl-L-leucine (7b)
A^S-Dinitrobenzoyl-L-leucine was afforded by the method used for iV-3,5-dinitrobenzoyl- 
L-alanine. Finely powdered 3,5-dinitrobenzoyl chloride (2.32g, O.Olmol) was added to a 
solution o f L-leucine (1.3lg, O.Olmol) in sodium hydroxide (1M, 20ml). Recrystallization 
from ethanol/water furnished 7V-3,5-dinitrobenzoyl-L-leucine as yellow needles (993mg, 
28.7%). m.p. 178-180°C (uncorrected) Lit 186-188°C.121
O
Spectroscopic analysis
i r. vmax(KBr): 3400 (OH), 1725 (carboxylic acid C=0), 1650 (amide C=0), 1550,
1350cm'1.
1H-n.m.r.(400MHz)5(DMSO): 0.87-0,94 (6H, d, J=6.4Hz, -NHCH(CH2CH(CH3)2)C 0 2H), 
1.59-1.82 (3H, m, -NHCH(CH2CH(CH3)2)C 0 2H and -NHCH(CH2CH(CH3)2)C 0 2H), 4.47-
4.53 (1H, m, -NHCH(CH2CH(CH3)2C 0 2H), 8.38 (1H, d, J=7.9Hz, -NH), 8.96 (1H, t, 
J=2Flz, ArH 4), 9.10 (2H, d, J=2Hz, ArH 2&6).
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13C-n.m.r.(l OOMHz)5(DMSO): 173.72 (-NHCH(CH2CH(CH3)2)C 0 2H), 162.45
((0 2N )2PhC0), 148.31, 136.27, 127.76, 121.16 (aromatic carbons), 51.43 
(-NHCH(CH2CH(CH3)2)C 0 2H), 41.02 (-NHCH(CH2CH(CH3)2)C 0 2H), 24.52 
(-NHCH(CH2CH(CH3)2)C02H), 22.99, 21.12 (-NHCH(CH2CH(CH3)2)C 0 2H).
./V-3,5-Dinitrobenzovl-L-isoleucine (7c)
A^S-Dinitrobenzoyl-L-isoleucine was furnished by the method used for N-2,5- 
dinitrobenzoyl-L-alanine. Finely powdered 3,5-dinitrobenzoyl chloride (2.32g, O.Olmol) 
was added to a solution of L-isoleucine (1.3 lg, O.Olmol) in sodium hydroxide (1M, 20ml), 
Recrystallization from ethanol/water yielded Af-3,5-dinitrobenzoyl-L-isoleucine121 as pale 
yellow needles (729mg, 22.4%). 
m.p. 160-166°C (uncorrected).
i r. vmax(KBr): 3350 (OH), 1720 (carboxylic acid C=0), 1650 (amide C=0), 1600, 
1350cm'1.
O N
3
Spectroscopic analysis
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I
H-n.m.r.(400MHz)5(DMSC)): 0.85-0.95 (6 H, m, -NHCH(CH(CH3)CH2CH3)C 0 2H and 
-NHCH(CH(CH3)CH2CH3)C 0 2H) 1.23-1.34 (1H, m, -NHCH(CH(CH3)CH2CH3)C 02H),
1.46-1.56 (1H, m, -NHCH(CH(CH3)CH2CH3)C 0 2H), 1.94-2.02 (1H, m, 
-NHCH(CH(CH3)CH2CH3)C 0 2H), 4.39-4.42 (1H, m, -NHCH(CH(CH3)CH2CH3)C 0 2H),
8.96 (1H, t, J=2Hz, ArH 4), 9.09 (1H, d, J=2Hz, ArH 2&6), 9.31 (1H, d, J=7.9Hz, -NH),
13C-n.m.r.(100MHz)5(DMSO): 172.71 (-NHCH(CH(CH3)CH2CH3)C 0 2H); 162.81
((0 2N )2PhC0-), 148.16, 136.46, 128.03, 121.08 (aromatic protons), 57.80 
(-NHCH(CH(CH3)CH2CH3)C 0 2H), 35.88 (-NHCH(CH(CH3)CH2CH3)C 0 2H), 25.15 
(-NHCH(CH(CH3)CH2CH3)C 0 2H), 15.67, 11.13 (-NHCH(CH(CH3)CH2CH3)C 02H and 
-NHCH(CH(CH3)CH2CH3)C 0 2H),
Note: The signals at 15.67 and 11.13 may be interchangeable. 
7V-3,5-Dinitrobenzoyl-D-leucine (7d)
The synthesis o f /V-3,5-dinitrobenzoyl-D-leucine was achieved by the method used for 
compound iV-3,5-dinitrobenzoyl-L-alanine. Finely powdered 3,5-dinitrobenzoyl chloride 
(2.32g, O.Olmol) was added to a solution of D-leucine (1.3 lg, O.Olmol) in sodium 
hydroxide (1M, 20ml). Recrystallization from ethanol/water gave A^S-dinitrobenzoyl-D- 
leucine as yellow needles (856mg, 26.3%). m.p. 180-184UC (uncorrected). Lit. 187°C.121
Spectroscopic analysis
i.r. vmax(KBr): 3400 (OH), 1725 (carboxylic acid C =0), 1650 (amide C=0), 1550,
1350cm'1.
1H-n.m.r.(400MHz)5(DMSO): 0.88-0.95 (6H, d, J=6.4Hz, -NHCH(CH2CH(CH3)2)C 0 2H), 
1.61-1.83 (3H, m, -NHCH(CH2CH(CH3)2)C 0 2H and -NHCH(CH2CH(CH3)2C 0 2H), 4.48-
4.54 (1H, m, NHCH(CH2CH(CH3)2)C 0 2H), 8.97 (1H, t, J=2.2Hz, ArH 4), 9.11 (2H, d, 
J=2Hz, ArH 2&6), 9.41 (1H, d, J=7.9Hz, -NH).
13C-n.m.r.(100MHz)8(DMSO): 173.69 (-NHCH(CH2CH(CH3)2)C 0 2H), 162.42
((0 2N)2PhC0-), 148.30, 136.23, 127.73, 121.14 (aromatic carbons), 51.40 
(-NHCH(CH2CH(CH3)2C 0 2H), 24.50 (-NHCH(CH2CH(CH3)2C 0 2H), 22.97 
(-NHCH(CH2CH(CH3)2C 0 2H), 21.10 (-NHCH(CH(CH3)2)C 0 2H).
A^-S^-Dinitrobenzoyl-L-leucine-L-alanine methyl ester (8)
Ar-3,5-Dinitrobenzoyl-L-leucine (3g, O.Olmol) was dissolved in dichloromethane (50ml) with 
L-alanine methyl ester hydrochloride (1.4g, O.Olmol), A^-hydroxybenzotriazole (1.35g,
O.Olmol) and triethylamine (1.4ml, O.Olmol). The mixture was cooled to 0°C and DCCD 
(2g, O.Olmol) added. After 30min the reaction temperature was raised to room temperature 
and the reaction allowed to proceed for 4hr. The precipitated DCU was removed by 
filtration and the filtrate washed with 5% sodium hydrogen carbonate solution, water, and 
dried. The solvent was evaporated in vacuo and the resulting oil was recrystallized from 
ethyl acetate/«-hexane, to yield the title product144,145 as an off-white solid (780mg, 19%). 
m.p. 180-184°C (dec) (uncorrected).
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Spectroscopic analysis
i.r. vmax(KBr): 3279, 3122 (NH), 2959, 1743 (ester O O ), 1649 (amide C=0), 1532, 1452, 
1343, 1219cm'1.
1H-n.m.r.(400MHz)5(DMSO): 0.88-0.93 (6H, d, J=6.9Hz, -NHCH(CH2CH(CH3)2CO-), 1.3 
(3H, d, J=7.4Hz, -NHCH(CH3)C 0 2CH3), 1.57-1.69 (3H, m, -NHCH(CH2CH(CH3)2)CO- 
and -NHCH(CH2CH(CH3)2)CO-), 3.6 (3H, s, -NHCH(CH3)C 0 2CH3), 4.25-4.29 ( 1H, m, 
-NHCH(CH3)C 0 2CH3), 4.60-4.65 (1H, m, -NHCH(CH2CH(CH3)2)CO-), 8.58 (1H, d, 
J=6.4Hz, -NHCH(CH3)C 0 2CH3), 8.95 (1H, t, J=2.22Hz, ArH 4), 9.1 (2H, d, J=1.96Hz, 
ArH 2&6), 9.3 (1H, d, J=8.4Hz, -NHCH(CH2CH(CH3)CO-).
13C-n.m.r.(1 OOMHz)5(DMSO): 172.93, 171.70, 162.18 ((0 2N)PhC0-, 
-NHCH(CH2CH(CH3)2)CO- and -NHCH(CH3)C 0 2CH3), 148.16, 136.55, 127.81, 120.95 
(aromatic carbons), 51.84 (-NHCH(CH3)C 0 2CH3), 47.63, 40.19 
(-NHCH(CH2CH(CH3)2)CO- and -NHCH(CH3)C 0 2CH3), 33.35 
(-NHCH(CH2CH(CH3)2CO-) 24.46, (-NHCH(CH2CH(CH3)2CO-), 23.07, 21.33 
(-NHCH(CH2CH(CH3)2)CO-), 17.05, 16.73 (-NHCH(CH3)C 0 2CH3).
Note: The signals at 172.93, 171.70 and 162.18 may be interchangeable. The signals at
47.63 and 40.19 may also be interchangeable.
iV-Toluene-p-sulphonyl glycine (9a)
Toluene-p-sulphonyl chloride (2g, O.Olmol) in diethyl ether (25ml) was added to a solution 
of glycine (0.75g, O.Olmol) in 1M sodium hydroxide (20ml). The reaction mixture was 
stirred vigorously for 4hr at room temperature and the ether layer separated. The aqueous 
layer was acidified with 10% hydrochloric acid and the precipitate filtered. Recrystallization 
from ethanol/water gave iV-toluene-p-sulphonyl glycine as white crystals (558mg 24.3%). 
m.p. 140-142°C (uncorrected) Lit 150°C.121
Spectroscopic analysis
i.r. vmax(KBr): 3300 (OH), 1725 (C=0), 1600, 1400, 1325, 1150cm'1.
lH-n.m.r.(400MHz)8(DMSO): 2.36 (3H, s, H3CPhS02-), 3.53 (2H, d, J=6Hz, 
-NHCH2C 0 2H), 7.35 (2H, d, J=8.4Hz, ArH 3&5), 7.66 (2H, d, J=8.4Hz, ArH 2&6), 7.96 
(1H, t, J=6.1Hz, -NH).
13C-n.m.r.(100MHz)5(DMSO): 170.33 (-NHCH2C 0 2H), 142.69, 137.82, 129.58, 126.60 
(aromatic carbons), 43.81 (-NHCH2C 0 2H), 21.03 (H3CPhS02-).
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iV-ToIuene-p-sulphonyl-L-alanine (9b)
7V-Toluene-p-sulphonyl-L-alanine was furnished by the method described for A^-toluene-p- 
sulphonyl glycine. Toluene-p-sulphonyl chloride (2g, 0.01 mol) in diethyl ether (25ml) was 
added to a solution o f L-alanine (0.89g, O.Olmol) in 1M sodium hydroxide (20ml). 
Recrystallization from ethanol/water yielded AMxiluene-p-sulphonyl-L-alanine as white 
needles (649mg, 26.7%). 
m.p. 130-132°C (uncorrected) Lit 139°C.121
Spectroscopic analysis
i.r. vmax(KBr): 3300 (OH), 1725 ( O O ), 1400, 1350, 1225, 1150cm'1.
1H-n.m.r.(400MHz)5(DMSO): 1.11 (3H, d, J=7.4Hz, -NHCH(CH3)C 0 2H), 2.35 (3H, s, 
H 3C PhS02-), 3.71 (1H, m, -NHCH(CH3)C 0 2H), 7.34 (2H, d, J=8.4Hz, ArH 3&5), 7.66 
(2H, d, J=8.4Hz, ArH 2&6), 8.06 (1H, d, J=8.4Hz,-NH).
13C-n.m.r.(100MHz)5(DMSO): 173.37 (-NHCH(CH3)C 0 2H), 142.63, 138.51, 129.56, 
126.57 (aromatic carbons), 51.18 (-NHCH(CH3)C 0 2H), 21.05 (H3CPhS02-), 18.50 
(-NHCH(CH3)C 0 2H).
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A^-Tolueiie-zj-sulphonvl-L-valinc (9c)
TV-Toluene-p-sulphonyl-L-valine was synthesized using the method described for N-toluene- 
p-sulphonyl glycine. Toluene-/7-sulphonyl chloride (2g, O.Olmol) in diethyl ether (25ml) was 
added to a solution o f L-valine (1.17g, O.Olmol) in 1M sodium hydroxide (20ml) 
Recrystallization from ethanol/water furnished TV-toluene-p-sulphonyl-L-valine as a white 
crystalline solid (998mg, 36.8%). 
m.p. 100-102°C (uncorrected). Lit 110°C.m
Spectroscopic analysis
i.r. vmax(KBr): 3293 (OH), 2930, 1708 (C=0), 1475, 1425, 1350, 1150, 1100cm'1.
1H-n.m.r.(400MHz)5(DMSO): 0.75-0.80 (6H, d, J=6Hz, -NHCH((CH(CH3)2)C 0 2H), 1.87-
1.92 (1H, m, -NHCH(CH(CH3)2)C 0 2H), 2.35 (3H, s, H3C PhS02-), 3.44-3.48 (1H, dd, 
Ja=9Hz, Jb= 6 Hz -HNCH(CH(CH3)2)C 0 2H), 7.32 (2H, d, J=8.4Hz, ArH 3&5), 7.63 (2H, d, 
J=8.4Hz, ArH 2&6), 7.89 (1H, d, J=9ilz, -NH).
13C-n.m.r.(100MHz)5(DMSO): 172.18 (-NHCH(CH(CH3)2)C 0 2H), 142.33, 138.34,
129.28, 126.55 (aromatic carbons), 61.17 (-NHCH(CH(CH3)2)C 0 2H), 30.38 
(-NHCH(CH(CH3)2)C 0 2H), 20.95 (H3CPhS02-), 19.00, 17.85 (-NHCH(CH(CH3)2)C 0 2H).
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TV-ToIuene-p-sulphonyl-L-leucine (9d)
The synthesis o f iV-toluene-p-sulphonyl-L-leucine was achieved using the procedure 
described for A^-toluene-p-sulphonyl glycine. Toluene-p-sulphonyl chloride (2g, O.Olmol) in 
diethyl ether (25ml) was added to a solution of L-leucine (1.31g, O.Olmol) in 1M sodium 
hydroxide (20ml). Recrystallization from ethanol/water yielded JV-toluene-/?-sulphonyl-L- 
leucine as white crystals (680mg, 23.8%). 
m.p. 116-118°C (uncorrected). Lit. 124°C.121
Spectroscopic analysis
i.r. vmax(KBr): 3300, 1725, 1350, 1150cm'1.
1H-n.m.r.(400MHz)5(DMSO): 0.65-0.79 (6H, d, J=6 Hz, -NHCH(CH2CH(CH3)2)C 0 2H), 
1.29-1.41 (2H, m, -NHCH(CH2CH(CH3)2)C 0 2H), 1.49-1.59 (1H, m, 
-NHCH(CH2CH(CH3)2)C 0 2H), 3.58-3.64 (1H, m, -NHCH(CH2CH(CH3)2)C 0 2H), 7.33 
(2H, d, J=8.5Hz, ArH 3&5), 7.63 (2H, d, J=8.5Hz, ArH2&6), 8.05 (1H, d, J=8 .8Hz, -NH).
13C-n.m.r.(100MHz)5(DMSO): 173.33 (-NHCH(CH2CH(CH3)2)C 0 2H), 142.49, 138.31,
129.41, 126.57 (aromatic carbons), 53.94 (-NHCH(CH2CH(CH3)2)C 0 2H),
40.95 (-NHCH(CH2CH(CH3)2)C 0 2H), 23.89 (-NHCH(CH2CH(CH3)2)C 0 2H),
22.64 (H3CPhS02-), 21.03, 21.01 (-NHCH(CH2CH(CH3)2)C 0 2H).
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jV-Toluene-p-sulphonyl-L-isoleucine (9e)
Af-Toluene-p-sulphonyl-L-isoleucine was by the method described for A-toluene-/> 
sulphonyl glycine. Toluene-/?-sulphonyl chloride (2g, 0.01 mol) in diethyl ether (25ml) was 
added to a solution of L-isoleucine (1.3lg, O.Olmol) in 1M sodium hydroxide (20ml). 
Recrystallization from ethanol/water gave Ar-toluene-p-sulphonyl-L-isoleucine (676mg, 
26.7%), as white needles, 
m.p. 130-132°C (uncorrected) Lit 141°C.121
Spectroscopic analysis
i.r.vmax(KBr): 3400 (OH), 1700 (C=0), 1325, 1150, 1075cm’1.
1H-n.m .r .(400MHz)S(DMSO): 0.71-0.78 (6H, m, -NHCH(CH(CH3)CH2CH3)C 0 2H, and 
-NH(CH(CH(CH3)CH2CH3) 1.01-1.12 (1H, m, -NHCH(CH(CH3)CH2CH3), 1.27-1.38 (1H, 
m, -NHCH(CH(CH3)CH2CH3), 1.59-1.66 (1H, m, -NHCH(CH(CH3)CH2CH3)C 0 2H), 2.35 
(3H, s, H3CPhS02-), 3.48-3.51 (1H, m, -M iCH(CH(CH 3)CH2CH3)C 0 2H), 7.33 (2H, d, 
J=8.36Hz, ArH 3&5), 7.63 (2H, d, J=8.36Hz, ArH 2&6), 7.95 (1H, d, J=9.32 Hz, -NH).
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3C-n.m.r.(100MHz)8(DMSO): 172.21 (-NHCH(CH(CH3)CH2CH3)C 0 2H), 142.42, 138.30, 
129.35, 126.60 (aromatic carbons), 60.00 (-NHCH(CH(CH3)CH2CH3)C 0 2H), 36.93 
(-NHCH(CH(CH3)CH2CH3)C 0 2H), 24.39 (-NHCH(CH(CH3)CH2CH3)C 0 2H), 21.01 
(H3C PhS02-), 15.41, 10.94 (-NHCH(CH(CH3)CH2CH3)C 0 2H  and 
-NHCH(CH(CH3)CH2CH3)C 0 2H).
Note: The signals at 15.41 and 10.94 may be interchangeable. 
iV-Toluene-p-sulphonvl-L-isoIeucine methyl ester (9f)
The synthesis o f //-toluene-p-sulphonyl-L-isoleucine methyl ester was achieved by the 
procedure described for N-trans-c\nnamoy\ glycine methyl ester. Thionyl chloride (6.7g,
0.005mol), was added to methanol (20ml), at 0°C. TV-Toluene-jD-sulphonyl-L-isoleucine 
(1.43g, 0.005mol.), was added portionwise, and the temperature was slowly raised to 40°C. 
Recrystallization from ethyl acetate/petroleum ether furnished 7V-toluene-p-sulphonyl-L- 
isoleucine methyl ester as white needles (584mg, 39%). 
m.p.76-78°C (uncorrected).
Spectroscopic analysis
i.r. vmax(KBr): 3281 (NH), 2975, 1744 (C=0), 1602, 1438, 1353, 1324, 1253, 
1203cm'1.
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1H-n.m.r.(400MHz)5(DMSO): 0.70-0.74 (6H, m, -NHCH(CH(CH3)CH2CH3)C 0 2CH3 and 
-NHCH(CH(CH3)CH2CH3)C 0 2CH3) 1.02-1.14 (1H, m, 
-NHCH(CH(CH3)CH2CH3)C 0 2CH3), 1.31-1.41 (1H, m, 
-NHCH(CH(CH3)CH2CH3)C 0 2CH3), 1.58-1.67 (1H, m, 
-NHCH(CH(CH3)CH2CH3)C 0 2CH3), 2.36 (3H, s, H3C PhS02-), 3.3 (3H, s, 
-NHCH(CH(CH3)CH2CH3)C 0 2CH3), 3.53 (1H, m, -NHCH(CH(CH3)CH2CH3)C 0 2CH3),
7.35 (2H, d, J=7.8Hz, ArH 3&5),7.59-7.61 (2H, d, J=7.8Hz, ArH 2&6), 8.21 (1H, s, -NH).
13C-n.m.r.(100MHz)5(DMSO). 171.21 (-NHCH(CH(CH3)CH2CH3)C 0 2CH3), 142.63,
137.86, 129.37, 126.57 (aromatic carbons), 62.73 (-NHCH(CH(CH3)CH2CH3)C 0 2CH3),
59.96 (-NHCH(CH(CH3)CH2CH3)C 0 2CH3), 36.63 (-NHCH(CH(CH3)CH2CH3)C 0 2CH3), 
24.46 (-NHCH(CH(CH3)CH2CH3)C 0 2CH3), 20.98 (H3CPhS02-), 15.11, 10.52 
(-NHCH(CH(CH3)CH2CH3)C 0 2CH3) and-NHCH(CH(CH3)CH2CH3)C 0 2CH3) .
Note: The signals at 15.11 and 10.52 may be interchangeable.
A'-Toluene-p-sulphonyl-L-isoleucine ethyl ester (9g)
A^Toluene-p-sulphonyl-L-isoleucine ethyl ester was afforded by the procedure for the 
synthesis o f A-fra^-cinnamoyl glycine ethyl ester. Thionyl chloride (6.7g, 0.005mol) was 
added to ethanol (20ml) at -4°C. 7V-Toluene-/?-sulphonyl-L-isoleucine (1.43g, 0.005mol.) 
was added portionwise and the temperature was slowly raised to 40°C. Recrystallization 
from ethyl acetate/petroleum ether yielded iV-toluene-/?-sulphonyl-L-isoleucine ethyl ester as 
white needles (658mg, 42%). 
m.p. 48-50°C (uncorrected).
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Spectroscopic analysis
i.r. vmax(KBr): 3267 (NH), 2975, 1730 (C=0), 1452, 1338, 1203cm*1.
1H-n.m.r.(400MHz)5(DMSO):0.71-0.75 (6 H, -NHCH(CH(CH3)CH2CH3)C0 2CH2CH3 and 
-NHCH(CH(CH3)CH2CH3)C 0 2CH2CH3), 0.95-0.99 (3H, t, J=7.1Hz, 
-NHCH(CH(CH3)CH2CH3)C 0 2CH2CH3), 1.03-1.14 (1H, m, 
-NHCH(CH(CH3)CH2CH3)C 0 2CH2CH3), 1.32-1.42 (1H, m, 
-NHCH(CH(CH3)CH2CH3)C 0 2CH2CH3), 1.59-1.66 (1H, m, 
-NH(CH(CH(CH3)CH2CH3)C 0 2CH3), 2.35 (3H, s, H3CPhS02-), 3.49-3.53 (1H, m, 
-NHCH(CH(CH3)CH2CH3)C 0 2CH2CH3), 3.69-3.78 (2H, m,
-NHCH(CH(CH3)CH2CH3)C0 2CH2CH3), 7.34 (2H, d, J=8.4Hz, ArH 3&5), 7.6 (2 H, d, 
J=8.4Hz, ArH 2&6), 8.19 (1H, d, J=9.4Hz, -NH).
13C-n.m.r.(100MHz)5(DMSO). 170.70 (-NHCH(CH(CH3)CH2CH3)C 0 2CH2CH3), 142.60, 
138.20, 129.36, 126.59 (aromatic carbons), 60.31 
(-NHCH(CH(CH3)CH2CH3)C 0 2CH2CH3), 59.96 
(-NHCH(CH(CH3)CH2CH3)C02CH2CH3), 36.76 
(-NHCH(CH(CH3)CH2CH3)C 0 2CH2CH3), 24.48
(-NHCH(CH(CH3)CH2CH3)C 0 2CH2CH3), 21.04 ((H3C )PhS02-) 15.12, 13.76, 10.58 
(-NHCH(CH(CH3)CH2CH3)C0 2CH2CH3, -NHCH(CH(CH3)CH2CH3)C 0 2CH2CH3 and
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Note: The signals at 15.12, 13.76 and 10.58 may be interchangeable. 
A^-Toluene-p-sulnhonvl-D-leucine (9h)
The synthesis o f iV-toluene-p-sulphonyl-D-leucine was achieved by the method described for 
;V-toluene-/>sulphonyl glycine. Toluene-p-sulphonyl chloride (2g, O.Olmol) in diethyl ether 
(25ml) was added to a solution of D-leucine (1.3lg, O.Olmol) in 1M sodium hydroxide 
(20ml). Recrystallization from ethanol/water furnished A^-toluene-p-sulphonyl-D-leucine as 
white needles (725mg, 25.4%). 
m.p. 118-122°C (uncorrected). Lit. 124°C.121
-NHCH(CH(CH3)CH2CH3)C02CH2 c h 3).
Spectroscopic analysis
i.r. vmax(KBr): 3300 (OH), 1725 (0= 0), 1350, 1150cm'1.
1H-n.m.r.(400MHz)5(DMSO): 0.66-0.80 (6H, d, J=6.4Hz, -NHCH(CH2CH(CH3)2)C 0 2H),
1.33-1.38 (2H, m, -NHCH(CH2CH(CH3)2)C 0 2H), 1.53-1.56 (1H, m, 
-NHCH(CH2CH(CH3)2)C 0 2H), 2.35 (3H, s, H3CPhS02-), 3.61 (1H, m, 
-NHCH(CH2CH(CH3)2)C 0 2H), 7.34 (2H, d, J=7.9Hz, ArH 3&5), 7.63 (2H, d, J=7.9Hz, 
ArH 2&6), 8.07 (1H, d, J=8.84Hz, -NH), 12.58 (1H, s, -NHCH(CH2CH(CH3)2)C 0 2H).
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13C-n.m.r.(100MHz)5(DMSO): 173.32 (-NHCH(CH2CH(CH3)2C 0 2H), 142.48, 138.30,
129.41, 126.56 (aromatic carbons), 53.91 (-NHCH(CH2CH(CH3)2C 0 2H), 40.93 
(-NHCH(CH2CH(CH3)2C 0 2H), 23.88 (-NHCH(CH2CH(CH3)2)C 0 2H), 22.64
((H3C)PhS02-), 21.01 (-NHCH(CH(CH2CH(CH3)2)C 0 2H).
iV-S-Nitrophthalovl-L-alanine (10a)
L-alanine (lg , O.Olmol) and 3-nitrophthalic anhydride (2.6g, O.Olmol) were heated in an oil 
bath at 145-150°C for 20min. The reaction mixture was poured into a small mortar and 
allowed to solidify. Recrystallisation of the solid from ethanol/water yielded N-3- 
nitrophthaloyl-L-alanine146 as very fine pale yellow needles (877mg, 33.2%). 
m.p. 148-150°C (uncorrected).
0
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Spectroscopic analysis
i.r. vmax(KBr): 1725 (carboxylic acid C=0), 1550, 1375cm'1.
1H-n.m.r.(400MHz)5(DMSO): 1.53 (3H, d, J=7.3Hz, -NCH(CH3)C 0 2H), 4.89 (1H, q, 
J=7.3Hz, -NCH(CH3)C 0 2H) 8.08 (1H, t, J=7Hz, ArH 5), 8.2 (1H, d, J=7Hz, ArH 6), 8.31 
(1H, d, J=7Hz, ArH 4), 13.22 (1H, s, -NCH(CH3)C 0 2H).
13C-n.m.r.(100MHz)8(DMSO): 170.70 (-NCH(CH3)C 0 2H), 165.19, 162.56 (phthaloyl
carbonyls), 144.41, 136.66, 133.12, 128.74, 127.18, 122.62 (aromatic carbons), 47.50 
(-NCH(CH3)C 0 2H), 14.56 (-NCH(CH3)C 0 2H).
./V-3-Nitrophthalovl-L-leucine (10b)
L-leucine (lg , 0.008mol) and 3-nitrophthalic anhydride (2.6g, O.Olmol) were heated in an oil 
bath at 145-150°C for 20min. The reaction mixture was poured into a small mortar and 
allowed to solidify. Purification by column chromatography on silica gel [chloroform (to 
which a small amount o f acetic acid was added)] furnished Ar-3-nitrophthaloyl-L-leucine146 
as a yellow oil (951mg, 38.8%).
Spectroscopic analysis
i r. vmax(CHCl3) 1725 (carboxylic acid C=0), 1550, 1400, 1350cm'1.
1 H-n.m.r .(400MHz)5(DMSO): 0.86 (6 H, d, J=6Hz,-NCH(CH2CH(CH3)2)C 0 2H), 1.47-1.54 
(1H, m, -NCH(CH2CH(CH3)2)C 0 2H), 1.79-1.87 (1H, m, -NCH(CH2CH(CH3)2)C 0 2H), 
2.08-2.15 (1H, m, -NCH(CH2CH(CH3)2C 0 2H), 4.77-4.81 (1H, m, 
-NCH(CH2CH(CH3)2)C 0 2H), 8.09 (1H, t, J=7.9Hz, ArH 5), 8.21 (1H, d, J=7.9Hz, ArH 6), 
8.32 (1H, d, J=7.9Hz, ArH 4).
O
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13C-n.m.r.(100MHz)5(DMSO): 170.49 (-NCH(CH2CH(CH3)2)C 0 2H), 165.56, 162.86 
(phthaloyl carbonyls), 144.52, 136.77, 132.90, 128.98, 127.37, 122.52 (aromatic carbons), 
50.70 (-NCH(CH2CH(CH3)2)C 0 2H), 36.72 (-NCH(CH2CH(CH3)2)C 0 2H), 24.36, 
(-NCH(CH2CH(CH3)2)C 0 2H), 23.06, 20.87 (-NCH(CH2CH(CH3)2)C 0 2H).
iV-3-Nitrophthaloyl-L-leucine methyl ester (10c)
Thionyl chloride (0 .6g, 0.005mol) was added to methanol (20ml) at 0°C. N-3- 
nitrophthaloyl-L-leucine (1.5g, 0.005mol) in methanol (5ml) was added dropwise and the 
temperature was slowly raised to 40°C. The reaction mixture was stirred for 4hr at 40°C 
and the excess methanol removed in vacuo. The resulting yellow oil was dissolved in ethyl 
acetate, washed with 10% sodium hydrogen carbonate and water. The organic layer was 
dried with magnesium sulphate filtered and the solvent removed in vacuo. Purification by 
column chromatography [chloroform] yielded 7V-3-nitrophthaloyl-L-leucine methyl ester as a 
yellow oil (677mg, 42.3%).
O
CH
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Spectroscopic analysis
i.r. vmix(CHCl3): 1787, 1723 (ester C=0), 1538, 1466, 1388cm'1.
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1H-n.m.r.(400MHz)5(CDCl3): 0.89 (6H, d, J=6.9Hz, -NCH(CH2CH(CH3)2)C 0 2CH3), 1.34- 
1.47 (1H, m, -NCH(CH2CH(CH3)2)C 0 2CH3) 1.89-1.96 (1H, m,
-NCH(CH2CH(CH3)2)C 0 2CH3), 2.23-2.30 (1H, m, -NCH(CH2CH(CH3)2)C 0 2CH3), 3.69 
(3H, s, -NCH(CH2CH(CH3)2)C 0 2CH3), 4.92 (1H, dd, JA=11.8Hz, JB=4.44Hz 
-NCH(CH2CH(CH3)2)C 0 2CH3), 7.93-8.10 (3H, m, ArH).
13C-n.m.r.(100MHz)8(CDCl3): 169.53, 165.20, 162.24 (-NCH(CH2CH(CH3)2)C 0 2CH3 and 
phthaloyl carbonyls), 145.08, 135.59, 133.67, 128.84, 127.30, 123.38 (aromatic carbons), 
52.86 (-NCH(CH2CH(CH3)2)C 0 2CH3), 51.18 (-NCH(CH2CH(CH3)2)C 0 2CH3), 36.90 
(-NCH(CH2CH(CH3)2)C 0 2CH3) 23 .01, (-NCH(CH2CH(CH3)2)C 0 2CH3) 20.80, 15.18 
(-NCH(CH2CH(CH3)2)C 0 2CH3).
A^-S-Nitrophthaloyl-L-leucine ethvl ester (lOd)
/V-3-Nitrophthaloyl-L-leucine ethyl ester was afforded by the procedure described for 
compound iV-3-nitrophthaloyl-L-leucine methyl ester. Thionyl chloride (0.6g, 0.005mol) 
was added to ethanol (20ml) at 0°C. A-3-Nitrophthaloyl-L-leucine (1.5g, 0.005mol) in 
ethanol (5ml) was added dropwise and the temperature was slowly raised to 40°C. 
Purification by column chromatography on silica gel [chloroform] yielded N-3- 
nitrophthaloyl-L-leucine ethyl ester as a yellow oil (622mg, 37.2%).
O
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Spectroscopic analysis
i.r. vmax(CHCl3): 1773, 1723 (ester C=0), 1545, 1452, 1367cm’1.
1H-n.m.r.(400MHz)5(CDCl3): 0.88 (6 H, d, J=6.9Hz, -NCH(CH2CH(CH3)2)C 0 2CH2CH3),
1.19 (3H, t, J=6.9Hz, -NCH(CH2CH(CH3)2)C 0 2CH2CH3), 1.41-1.46 (1H, m, 
-NCH(CH2CH(CH3)2)C 0 2CH2CH3), 1.87-1.95 (1H, m,
-NCH(CH2CH(CH3)2)C 0 2CH2CH3), 2.22-2.29 ( 1H, m,
-NCH(CH2CH(CH3)2)C 0 2CH2CH3), 4.11-4.17 (2H, m,
-NCH(CH2CH(CH3)2)C 0 2CH2CH3), 4.89 (1H, m, -NCH(CH2CH(CH3)2)C 0 2CH2CH3), 
7.92-8.10 (3H, m, ArH).
13C-n.m.r.(100MHz)5(CDCl3): 169.01, 165.23, 162.28 (-NCH(CH2CH(CH3)2)C 0 2CH2CH3 
and phthaloyl carbonyls), 145.04, 135.59, 133.67, 128.78, 127.24, 123.34 (aromatic 
carbons), 61.98 (-NCH(CH2CH(CH3)2)C 0 2CH2CH3), 51.36
(-NCH(CH2CH(CH3)2)C 0 2CH2CH3), 36.88 (-NCH(CH2CH(CH3)2)C 0 2CH2CH3), 24.97 
(-NCH(CH2CH(CH3)2)C 0 2CH2CH3), 23.00, 20.84 (-NCH(CH2CH(CH3)2)C 02CH2CH3),
13.96 (-NCH(CH2CH(CH3)2)C 0 2CH2CH3) .
Ai-3-Nitrophthaloyl-L-isoleucine (lOe)
L-Isoleucine (lg , 0.008mol) and phthalic anhydride (2.6g, O.Olmol) were heated in an oil 
bath at 145-150°C for 20min, The reaction mixture was poured into a small mortar and 
allowed to solidify. Purification by column chromatography on silica gel [chloroform (to 
which a small amount o f acetic acid was added)] furnished iV-3-nitrophthaloyl-L- 
isoleucine146 as a yellow oil (6 6 6 mg, 27.2%).
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3Spectroscopic analysis
i.r. vmax(CHCl3): 1725 (carboxylic acid C=0), 1550, 1400, 1350cm'1.
1H-n.m.r.(400MHz)5(DMSO): 0.78 (3H, t, J=7.4Hz, -NCH(CH(CH3)CH2CH3)C 0 2H), 1.03 
(3H, d, J=6.4Hz, -NCH(CH(CH3)CH2CH3)C 0 2H), 1.19-1.28 (1H, m, 
-NCH(CH(CH3)CH2CH3)C 0 2H), 1.45-1.52 (1H, m, -NCH(CH(CH3)CH2CH3)C 0 2H), 2.30-
2.36 (1H, m, -NCH(CH(CH3)CH2CH3)C 0 2H), 4.53 (1H, d, J=7.9Hz, 
-NCH(CH(CH3)CH2CH3)C 0 2H), 8.08 (1H, t, J=8Hz, ArH 5), 8.19 (1H, d, J=8Hz, ArH 6), 
8.31 (1H, d, J=8 Hz, ArH 4).
n C-n.m.r.(100MHz)§(DMSO): 169.49, 165.59, 162.96 (-NCH(CH(CH3)CH2CH3)C 0 2H 
and phthaloyl carbonyls), 144.52, 136.80, 132.80, 128.98, 127.30, 122.38 (aromatic 
carbons), 57.00 (-NCH(CH(CH3)CH2CH3)C 0 2H), 34.09 (-NCH(CH(CH3)CH2CH3)C 0 2H),
25.25 (-NCH(CH(CH3)CH2CH3)C 0 2H), 16.64, 10.98 (-NHCH(CH(CH3)CH2CH3)C 02H 
and -NHCH(CH(CH3)CH2CH3)C 0 2H).
Note: The signals at 169.49, 165.59 and 162.96 may be interchangeable. The signals at
16.64 and 10.98 may also be interchangeable.
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iV-3-Nitrophthalovl-L-isoleuciiie methyl ester (10f)
iV-3-Nitrophthaloyl-L-isoleucine methyl ester was synthesized by the procedure outlined for 
compound (10c). Thionyl chloride (0.6g, 0.005mol) was added to methanol (20ml) at 0°C. 
7V-3-Nitrophthaloyl-L-isoleucine (1.5g, 0.005mol) in methanol (5ml) was added dropwise, 
and the temperature was slowly raised to 40°C. Purification by column chromatography 
[chloroform] yielded the title compoundas a yellow oil (636mg, 39.7%).
i.r. vmax(CHCl3): 1787, 1729 (ester C =0), 1542, 1470, 1376cm'1.
1H-n.m.r.(400MHz)5(CDCl3): 0.84 (3H, t, J=7.4Hz, -NCH(CH(CH3)CH2CH3)C 0 2CH3),
1.08 (3H, d, J=6.9Hz, -NCH(CH(CH3)CH2CH3)C 0 2CH3), 1.42-1.51 ( 1H, m, 
-NCH(CH(CH3)CH2CH3)C 0 2CH3), 1.42-1.51 (1H, m, -NCH(CH(CH3)CH2CH3), 2.44-2.53 
(1H, m, -NCH(CH(CH3)CH2CH3)C 0 2CH3) 3.54 (3H, s,
-NCH(CH(CH3)CH2CH3)C 0 2CH3), 4.64 (1H, d, J=8.4Hz, 
-NCH(CH(CH3)CH2CH3)C 0 2CH3), 7.9-8.12 (3H, m, ArH).
13C-n.m.r.(100MHz)5(CDCl3): 168.73, 165.28, 162.34 (-NCH(CH(CH3)CH2CH3)C 0 2CH3 
and phthaloyl carbonyls), 145.12, 135.50, 133.62, 129.90, 127.50, 123.29 (aromatic 
carbons), 57.54 (-NCH(CH(CH3)CH2CH3)C 0 2CH3), 52.57
O
2 H 3C
Spectroscopic analysis
106
(-NCH(CH(CH3)CH2CH3)C 0 2CH3), 34.44 (-NCH(CH(CH3)CH2CH3)C 0 2CH3), 25.76 
(-NCH(CH(CH3)CH2CH3)C 0 2CH3), 16.74, 10.94 (-NCH(CH(CH3)CH2CH3)C 0 2CH3 and 
-NCH(CH(CH3)CH2CH3)C 0 2CH3) .
Note: The signals at 168.73, 165.28 and 162.34 may be interchangeable. The signals at 
16.74 and 10.94 may also be interchangeable.
Ai-3-Nitrophthaloyl-L-isoleucine ethyl ester (lOg)
The synthesis o f A-3-nitrophthaloyl-L-isoleucine ethyl ester was afforded by the method 
described for iV-3-nitrophthaloyl-L-leucine ethyl ester. Thionyl chloride (0.6g, 0.005mol) 
was added to ethanol (20ml) at 0°C. JV-3-Nitrophthaloyl-L-isoleucine (1.5g, 0.005mol) in 
ethanol (5ml), was added dropwise and the temperature was slowly raised to 40°C. 
Purification by column chromatography [chloroform] furnished 7V-3-nitrophthaloyl-L- 
isoleucine ethyl ester as a yellow oil (448mg, 26.8%).
0
2 H3C
OCH CH
3
Spectroscopic analysis
i.r. vmax(CHCl3): 1780, 1736 (ester (C=0), 1542, 1376, 1253cm'1.
107
lH-n.m.r.(400MHz)5(CDC13) : 0.85 (3H, t, J=7.4Hz,
-NCH(CH(CH3)CH2CH3)C 0 2CH2CH3), 1.08 (3H, d, J=6.9Hz, 
-NCH(CH(CH3)CH2CH3)C0 2CH2CH3), 1.19 (3H, t, J=7.1Hz, 
-NCH(CH(CH3)CH2CH3)C 0 2CH2CH3), 1.43-1.53 (1H, m, 
-NCH(CH(CH3)CH2CH3)C 0 2CH2CH3), 2.45-2.53 (1H, m, 
-NCH(CH(CH3)CH2CH3)C0 2CH2CH3), 4.16 (2H, q, J=7.1Hz, 
-NCH(CH(CH3)CH2CH3)C 0 2CH2CH3), 4.64 (1H, d, J=7.9Hz, 
-NCH(CH(CH3)CH2CH3)C 0 2CH2CH3), 7.93-8.10 (3H, m, ArH).
Note: The second -NHCH(CH(CH3)CH2CH3)C0 2CH2CH3 signal is obscured by the 
-NCH(CH(CH3)CH2CH3)C 0 2CH2CH3 signal.
13C-n.m.r.(100MHz)5(CDCl3): 168.24, 165.31, 162.39
(-NCH(CH(CH3)CH2CH3)C 0 2CH2CH3 and phthaloyl carbonyls), 145.12, 135.54, 133.66, 
128.80, 127.28, 123.30 (aromatic carbons), 58.29 
(-NHCH(CH(CH3)CH2CH3)C 0 2CH2CH3), 57.79
(-NHCH(CH(CH3)CH2CH3)C02CH2CH3), 34.5 (-NHCH(CH(CH3)CH2CH3)C02CH2CH3),
25.88 (-NHCH(CH(CH3)CH2CH3)C02CH2CH3), 15.27, 14.02, 10.98 
(-NHCH(CH(CH3)CH2CH3)C02CH2CH3, -NHCH(CH(CH3)CH2CH3)C02CH2CH3 and 
-NHCH(CH(CH3)CH2CH3)C02CH2CH3).
Note: The signals at 168.24, 165.31 and 162.39 may be interchangeable. The signals at 
15.27, 14.02 and 10.98 may also be interchangeable.
./V-Phenvlureido-L-alanine (11a)
Phenyl isocyanate (0.67g, 0.005mol) was added to a solution of L-alanine (0.5g, 0.005mol) 
in 1M sodium hydroxide (5ml). The reaction mixture was stirred for 3hr at room 
temperature and acidified with 10% hydrochloric acid. The precipitate was filtered, washed
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with cold water and recrystallized from ethanol/water to yield TV-phenylureido-L-alanine as
fine white needles (330mg, 32%).
m.p. 164-166°C (uncorrected). Lit. 174°C.121
Spectroscopic analysis
i.r. vmax(KBr): 3400 (OH), 3225, 1700 (carboxylic acid C=0), 1625 (urea C=0), 1600, 
1575, 1550, 1450, 1300cm'1.
1H-n.m.r.(400MHz)5(DMSO): 1.29 (3H, d, J=7.4Hz, -NCH(CH3)C 0 2H), 4.12-4.19 (1H, m, 
-NHCH(CH3)C 0 2H, 6.44 (1H, d, J=7.4Hz, -NHCH(CH3)C 0 2H), 6.86-6.90 (1H, m,
ArH 4), 7.18-7.22 (2H, m, ArH 3&5), 7.34-7.37 (2H, m, ArH 2&6), 8 .6  
(1H, s, PhTNHCO-).
13C-n.m.r.(100MHz)5(DMSO): 174.93 (-NHCH(CH3)C 0 2H), 154.62 (PhNHCO-), 140.23, 
128.73, 121.24, 117.57 (aromatic carbons), 47.97 (-NHCH(CH3)C 0 2H), 18.28 
(-NHCH(CH3)C 0 2H).
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iV-Phenvlureido-L-leucine (lib )
iV-Phenylureido-L-leucine was furnished by the method described for A^-phenylureido-L- 
alanine. Phenyl isocyanate (0.67g, 0.005mol) was added to a solution of L-leucine (0.5g,
0.004mol) in 1M sodium hydroxide (5ml). Recrystallization from ethanol/water yielded N- 
Phenylureido-L-leucine as fine white needles (280mg, 28%). 
m.p. 108-110°C (uncorrected). Lit. 115°C.121
i.r. vmax(KBr): 3400 (OH), 3350, 1725 (carboxylic acid C=0), 1650 (urea C=0), 1600, 
1500, 1475, 1200, 1150cm'1.
1H-n.m.r(400MHz),5(DM SO): 0.87-0.91(6H, d, J=6.9Hz, -NHCH(CH2CH(CH3)2)C 02H), 
1.44-1.56 (2H, m, -NHCH(CH2CH(CH3)C 0 2H), 1.62-1.72 (1H, m, 
-NHCH(CH2CH(CH3)2)C 0 2H), 4.13-4.19 (1H, m, -NHCH(CH2CH(CH3)2)C 0 2H), 6.37-
6.38 (1H, d, J=8.4Hz, -NHCH(CH2CH(CH3)2)C 0 2H), 6.86-6.90 (1H, m, ArH 4), 7.18-7.22 
(2H, m, ArH 3&5), 7.34-7.39 (2H, m, ArH 2&6), 8,54 (1H, s, PhNHCO-).
13C-n.m.r.(100)S(DMSO): 174.93 (-NHCH(CH2CH(CH3)2)C 0 2H), 154.84 (PhNHCO-), 
140.19, 128.72, 121.21, 117.50 (aromatic carbons), 50.65 (-NHCH(CH2CH(CH3)2C 0 2H),
40.92 (-NHCH(CH2CH(CH3)2)C 0 2H), 24.40 (-NHCH(CH2CH(CH3)2)C 0 2H), 22.85, 21.60 
(-NHCH(CH2CH(CH3)2)C 0 2H)
CH
Spectroscopic analysis
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iV-Phenvlureido-L-isoleucine (11c)
A/’-Phenylureido-L-isoleucine was afforded by the procedure described for compound N- 
phenylureido-L-alanine. Phenyl isocyanate (0.67g, 0.005mol) was added to a solution of L- 
isoleucine (0.5g, 0.004mol) in 1M sodium hydroxide (5ml). Recrystallisation from 
ethanol/water furnished 7V-phenylureido-L-isoleucine as fine white needles (210mg, 21.%). 
m.p 110-112°C (uncorrected). Lit. 120°C.121
i r. vmax(KBr): 3400 (OH), 1700 (carboxylic acid C =0), 1675 (urea C=0), 1600, 1575, 
1 2 0 0 cm'1.
1H-n.m.r.(400MHz)5(DMSO): 0.85-0.89 (6H, m, -NHCH(CH(CH3)CH2CH3)C 0 2H and 
-NHCH(CH(CH3)CH2CH3)C 0 2H), 1.09-1.20 (1H, m, -NHCH(CH(CH3)CH2CH3)C 0 2H), 
1.35-1.45 (1H, m, -NHCH(CH(CH3)CH2CH3)C 0 2H), 1.76-1.82 (1H, m, 
-NHCH(CH(CH3)CH2CH3)C 0 2H), 4.10-4.14 (1H, dd, JA=8.7Hz, JB-4.4HzHz, 
-NHCH(CH(CH3)CH2CH3)C 0 2H), 6.43 (1H, d, J=8.7Hz,
-NHCH(CH(CH3)CH2CH3)C 0 2H), 6.87 (1H, t, J=7.38Hz, ArH 4), 7.20 (2H, t, J=7.38Hz, 
ArH 3&5), 7.34-7.37 (2H, m, ArH 2&6), 8 .6 6  (1H, s, PhNHCO-).
H C
Spectroscopic analysis
ill
13C-n. m.r. (1 OOMHz)5(DMSO): 175.00 (-NHCH(CH(CH3)CH2CH3)C 0 2H), 154.93
(PhNHCO-), 140.31, 128.72, 121.10, 117.38 (aromatic carbons), 56.58 
(-NHCH(CH(CH3)CH2CH3)C 0 2H), 37.10 (-NHCH(CH(CH3)CH2CH3)C 0 2H), 24.65 
(-NHCH(CH(CH3)CH2CH3)C 0 2H), 15.77, 11.58 (-NHCH(CH(CH3)CH2CH3)C 02H and 
-NHCH(CH(CH3)CH2CH3)C 0 2H)
Note: The signals at 15.77 and 11.58 maybe interchangeable.
N -C hloroacetyl glycine (1 2 a)
Chloroacetyl chloride (2.26g, 0.02mol) was added to a stirred suspension of glycine (0.75g,
O.Olmol) in dry ethyl acetate (50ml) and gently heated under reflux for 4hr under anhydrous 
conditions. The unreacted glycine was filtered off, and the solvent and excess chloroacetyl 
chloride were removed from the filtrate, in vacuo. The resulting oil was washed with diethyl 
ether (3x20ml) to give iV-chloroacetyl glycine as an off-white solid, m.p. 94-96°C 
(uncorrected) Lit 100°C. 135
O
O
Spectroscopic analysis
i r. vmax(KBr): 3300 (OH), 1725 (carboxylic acid 0 = 0 ), 1650 (amide 0= 0), 1550, 1450,
1350cm'1
1H-n.m.r.(400MHz)5(DMSO): 3.78 (2H, d, J=5.8Hz, -NHCH2C 0 2H), 4.12 (2H, s, 
C1CH2C 0-), 8.54 (1H, t, J=5.7Hz, -NH).
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13C-n.m.r.(lOOMHz)S(DMSO): 170.96 (-NHCH2C 0 2H), 166.46 (C1CH2C 0-), 42.40 
(-NHCH2C 0 2H), 40.01 (C1CH2C0-).
Preparation of iV-chloroncetvl-L-leucine (12b)
Chloroacetyl chloride (2.26g, 0.02mol) was added to a stirred suspension of L-leucine 
(1.3 lg, O.Olmol) in dry ethyl acetate (50ml) and gently refluxed for lh r under anhydrous 
conditions. The unreacted L-leucine was filtered off and the solvent and excess chloroacetyl 
chloride were removed from the filtrate in vacuo. The resulting oil was crystallised with 
chloroform/tt-hexane to yield iV-chloroacetyl-L-leucine as fine white crystals (1.21g, 58.4%). 
m.p. 130-132°C (uncorrected) Lit 136°C.135
O
Spectroscopic analysis
i.r.vmax(KBr): 3300 (OH), 1700 (carboxylic acid C=0), 1650 (amide C=0), 1550, 1225cm'1
1H-n.m.r.(400MHz)5(DMSO): 0.82-0.88 (6H, d, J=6.4Hz, -NHCH(CH2CH(CH3)2)C 0 2H),
1.46-1.64 (3H, m, -NHCH(CH2CH(CH3)2)C 0 2H, and -NHCH(CH2CH(CH3)2)C 0 2H), 4.08 
(2H, s, ClCH2CO-), 4.18-4.24 (1H, m, -NHCH(CH2CH(CH3)2)C 0 2H), 8.48 (1H, d, 
J=7.9Hz, -NH).
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13C-n.m.r.(1 OOMHz)5(DMSO): 173.67 (-NHCH(CH2CH(CH3)2)C 0 2H) 165.99 
(C1CH2C 0-), 50.92 (C1CH2C0-), 42.40 (-NHCH(CH2CH(CH3)2)C 0 2H), 40.01 
(-NHCH(CH2CH(CH3)2)C 0 2H), 24.33 (-NHCH(CH2CH(CH3)2)C 0 2H), 22.86, 21.30 
(-NHCH(CH2CH(CH3)2)C 0 2H ).
N-Chloroacctyl-L-leucine methyl ester (12c)
Thionyl chloride (0.6g, 0.005mol) was added to methanol (20ml) at 0°C. iV-Chloroacetyl-L- 
leucine (lg , 0.005mol) was added in portions and the temperature was slowly raised to 
40°C. The reaction mixture was stirred for 4hr at 40°C and the excess solvent removed in 
vacuo. The resulting yellow oil was dissolved in ethyl acetate and washed with water 
(3x20ml). The organic layer was dried with magnesium sulphate, and the solvent removed 
in vacuo to give iV-chloroacetyl-L-leucine methyl ester as a colourless oil (358mg, 32.3%).
O
Spectroscopic analysis
i.r. Vmax(CHCl3): 3302 (NH), 2961, 1751 (ester C=0), 1673 (amide C=0), 1545, 1438, 
1374, 1210cm'1.
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1H-n.m.r.(400MHz)5(CDCl3): 0.87 (6H, d, J=5.9Hz, -NHCH(CH2CH(CH3)2)C 0 2CH3), 
1.51-1.64 (3H, m, -NHCH(CH2CH(CH3)2)C 0 2CH3 and -NHCH(CH2CH(CH3)2)C 0 2CH3), 
3.68 (3H, s, -NHCH(CH2CH(CH3)C 0 2CH3), 4.01 (2H, s, C1CH2C0-), 4.56 (1H, m, 
-NHCH(CH(CH2CH(CH3)2)C 0 2CH3), 6.95 (1H, d, J=8.4Hz, -NH).
13C-n.m.r.(100MHz)5(CDCl3): 172.66 (-NHCH(CH2CH(CH3)2C 0 2CH3), 165.82
(C1CH2C 0-), 52.33 (-NHCH(CH2CH(CH3)C 0 2CH3) 50.88 (ClCH2CO-); 42.28 
(-NHCH(CH2CH(CH3)2)C 0 2CH3), 41.10 (-NHCH(CH2CH(CH3)2)C 0 2CH3) 24.69 
(-NHCH(CH2CH(CH3)2)C 0 2CH3), 22.65, 21.71 (-NHCH(CH2CH(CH3)2)C 0 2CH3).
Af-Chloroacetyl-L-leucine ethyl ester (12d)
Thionyl chloride (0.6g, 0.005mol) was added to ethanol (20ml) at 0°C. TV-Chloroacetyl-L- 
leucine (lg , 0.005mol) was added in portions and the temperature was slowly raised to 
40°C. The reaction mixture was stirred for 4hr at 40°C and the excess ethanol removed in 
vacuo. The resulting yellow oil was dissolved in ethyl acetate and washed with water 
(3x20ml). The organic layer was dried with magnesium sulphate, and the solvent removed 
in vacuo to give A-chloroacetyl-L-leucine ethyl ester as a colourless oil (332mg, 28.2%).
Spectroscopic analysis
i.r. vmax(CHCl3): 3300 (NH), 2950, 1750 (ester C=0), 1650 (amide C=0), 1550,
1 2 0 0 cm'1.
1H-n.m.r.(400MHz)8(CDCl3): 0.84 (6H, d, J=5,44Hz,
-NHCH(CH2CH(CH3)2)C 0 2CH2CH3), 1.18 (3H, t, J=7.1Hz 
-NHCH(CH2CH(CH3)2)C 0 2CH2CH3), 1.47-1.59 (3H, m,
-NHCH(CH2CH(CH3)2)C 0 2CH2CH3 and -NHCH(CH2CH(CH3)C 0 2CH2CH3), 3.97 (2H, s, 
ClCH2CO-), 4.09 (2H, q, J=7.1Hz, -NHCH(CH2CH(CH3)2)C 0 2CH2CH3), 4.50 (1H, m, 
-NHCH(CH2CH(CH3)2)C 0 2CH2CH3), 7.00 (1H, d, J=7.88Hz, -NH).
13C-n.m.r.(1 00MHz)5(CDC13) : 172.12 (-NHCH(CH2CH(CH3)2)C 0 2CH2CH3), 165.73 
(-C1CH2C0-), 61.28 (-NHCH(CH2CH(CH3)2)C 0 2CH2CH3), 50.86 (C1CH2C0-), 42.20 
(-NHCH(CH2CH(CH3)2)C 0 2CH2CH3), 41.05 (-NHCH(CH2CH(CH3)2)C 0 2CH2CH3), 24.59 
(-NHCH(CH2CH(CH3)2)C 0 2CH2CH3), 22.54, 21.64
(-NHCH(CH2CH(CH3)2)C 0 2CH2CH3), 13.88 (-NHCH(CH2CH(CH3)2)C 0 2CH2CH3). 
A^-Chloroacetyl-D-leucine (12e)
Chloroacetyl chloride (2.26g, 0.02mol) was added to a stirred suspension of D-leucine 
(1.3 lg  ,0.01mol), in dry ethyl acetate (50ml), and gently refluxed for lhr under anhydrous 
conditions. The unreacted D-leucine was filtered off, and the sovent and excess chloroacetyl 
chloride were removed from the filtrate, in vacuo. Recystallisation of the resulting oil with 
chloroform/«-hexane, furnished 7V-chloroacetyl-D-leucine as fine white crystals (l.lg , 
52.5%). m.p. 128-132°C (uncorrected). Lit. 136°C.135
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Spectroscopic analysis
i.r. vmax(KBr): 3324 (OH), 1721 (carboxylic acid C=0), 1640 (amide C=0), 1558,
1239cm'1.
1H-n.m.r.(400MHz)8(CDCl3): 0.98 (6H, d, J=4.92Hz, -NHCH(CH2CH(CH3)2)C 02H), 1.62- 
1.79 (3H, m, -NHCH(CH2CH(CH3)2)C 0 2H and -NHCH(CH2CH(CH3)2)C 0 2H), 4.11 (2H, 
s, C1CH2C 0-) 4.61-4.67 (1H, m, -NHCH(CH2CH(CH3)2)C 0 2H), 6.95 (1H, d, J=8.4Hz, 
-NH).
13C-n.m.r.(100MHz)5(DMSO): 176.53 (-NHCH(CH2CH(CH3)2)C 0 2H), 166.36 
(C1CH2C 0-), 51.00 (CICHzCO-), 42.38 (-NHCH(CH2CH(CH3)2)C 0 2H), 40.97 
(-NHCH(CH2CH(CH3)2)C 0 2H), 24.88, 22.78 (-NHCH(CH2CH(CH3)2)C 0 2H), 21.79 
(-NHCH(CH2CH(CH3)2)C 0 2H),
yV-f2-triniethvlainmoniuni-acetvl)-L-leucine chloridc (13)
N -Chloroacetyl L-leucine (2g, O.Olmol) was added to a solution of trimethylamine (25%, 
4ml). The reaction mixture was stirred for 2hr at 45°C and the water and unreacted 
trimethylamine removed in vacuo. The resulting oil was triturated with chloroform and the
precipitate filtered to give the title compound as a white crystalline solid (760mg,24.6%). 
m.p. 212-216°C. Lit. 219°C.147
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Spectroscopic analysis
i.r. vmax(KBr): 3450 (OH), 2950, 1727 (carboxylic acid C=0), 1678 (amide C=0), 1552, 
1488, 1274, 1237, 1210cm'1.
1H-n.m.r.(400MHz)5(DMSO) : 0.91-0.96 (6H, d, J=5.9Hz, -NHCH(CH2CH(CH3)2C 0 2H), 
1.69-1.74 (3H, m, -NHCH(CH2CH(CH3)2)C 0 2H  and -NHCH(CH2CH(CH3)2C 0 2H), 3.33 
(9H, s, (H3C)3NCH2CO-), 4.18 (2H, s, (H3C)3NCH2CO-), 4.43 (1H, m, 
-NHCH(CH2CH(CH3)2C 0 2H), 5.02 (1H, d, J=8Hz, -NH).
13C-n.m.r.(100MHz)5(DMSO): 173.24 (-NHCH(CH2CH(CH3)2)C 0 2H), 163.49
((H3C)NHCH2CO-), 63.79 ((H3C)NHCH2CO-), 53.24 ((H3C)NHCH2CO-), 50.76 
(-NHCH(CH2CH(CH3)2)C 0 2H), 40.05 (-NHCH(CH2CH(CH3)2)C 0 2H), 24.35 
(-NHCH(CH2CH(CH3)2)C 0 2H), 22.85, 21.16 (-NHCH(CH2CH(CH3)2)C 0 2H).
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C H A PT E R  F O U R  
B ID EN TA TE LIG A N D  IN H IB IT O R S
In tro d u c tio n
Our initial studies into amino acid derivatives as potential inhibitors of the 
malarial aminopeptidase led us to believe that inhibitors with a similar structure to the N- 
cinnamoyl derivatives would make the best starting point for designing novel inhibitors 
o f the malarial aminopeptidase. However because the attempted epoxidation of the 
vinylic group was unsuccessful due to the low electron density around the -C=C- bond, 
we were unable to incorporate functionalities into the backbone of the molecules which 
could chelate the active site metal resulting in a potent inhibitor. It was then decided to 
prepare some simple aromatic carboxylic acids with functional groups a  to the carboxyl 
which could complex with the active site metal. This would then be coupled to an amine 
and the resulting molecule could form a bidentate ligand which could chelate the active 
site metal via the amide carbonyl and the functional group a  to it (fig. 4.1) in a similar 
manner to the model proposed for bestatin by Nishino and Powers.117 It was hoped that 
these molecules would be potent inhibitors of the malarial aminopeptidase.
R  H 
N  .
x  r  r '
O
M
Fig. 4.1 P roposed b ind ing  of b id en ta te  ligand inh ib ito rs 
to active site metal.
All o f the aromatic carboxylic acids were coupled to the same five amines, 
namely glycine, L-alanine, L-leucine, L-phenylalanine and phenethylamine (fig.4.2). This 
yielded a battery of results which were directly comparable and furnished information on 
the substrate specificity of the malarial aminopeptidase. It is known that the malarial 
aminopeptidase has a preference for amino acids with hydrophobic alkyl side chains such
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as L-alanine and L-leucine.20 These could be compared to glycine which has no side 
chain and L-phenylalanine which has a hydrophobic aryl side chain. Phenethylamine was 
chosen because of its similarity to the side chain o f L-phenylalanine. A comparison of 
activity o f inhibitors bearing these two amines would provide information on the 
importance o f a carboxylic acid group in binding to the active site o f the enzyme.
O
H N2 O H
G lycine
O
H N2 O H
C H
L- A lanine
0
H N2 O H
C H
C H
L - L e u c i n e
0
H N ' H N
2  O H  2
L -P henylalan ine Phenethylam ine
Fig. 4.2
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4 .1 7V-2-Hydi oxy-2-Dhenvlacetvl derivatives
16a R = C O C H 3, R ’=H , R ” = C H 3
16b R =C O C H 3, R ’=(S)-C H 3, R ” = C H 3
16c R =C O C H 3, R ’=(5 )-C H 2C H (C H 3)2, R ” =C H 3
16d R =C O C H 3, R ’=(*S)-CH2Ph, R ” =C H 3
17a R=H, R’=H , R ” =H
17b R=H, R ’= (5)-C H 2C H (C H 3)2, R ” =H
17c R=H, R ’=(S)-C H 2Ph, R ” =H
O
16e R =C O C H 3 
17d R=H
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It was decided to prepare the JV-2-hydroxy-2-phenylacetyl derivatives (17) 
because the starting material, mandelic acid (14) was cheap and freely available. It was 
hoped that the molecule would act as a bidentate ligand, which would chelate the active 
site metal via the hydroxyl and amide carbonyl (fig. 4.3). The phenyl group could 
interact favourably with the hydrophobic pocket Si. The binding site terminology of 
Berger and Schechter 148 is used in which the carboxyl side of the scissile bond is termed 
the Pi residue and it’s corresponding subsite is called Si.
Fig. 4.3 P roposed b ind ing  of ./V-2-hydroxy-2-phenylacetyl am ino acid 
to active site m etal.
The hydroxy group of the mandelic acid was protected as the acetate by 
treatment with acetyl chloride.149 This was then coupled with the amino acid methyl 
ester hydrochloride to yield the 2 -acetoxy-2 -phenylacetyl amino acid ester (16) 
Subsequent removal o f the acetate and methyl ester protecting groups by base catalysed 
hydrolysis yielded the 7V-2-hydroxy-2-phenylacetyl derivatives (17) (scheme II). Because 
formation o f the acetyl mandelyl chloride (15) strongly activated the 2-acetoxy-2- 
phenylacetic acid and would cause racemization of the chiral centre, it was decided to 
use D/L-mandelic acid (14) as the starting product rather than an enantiomerically pure 
form o f the acid. This gave us a mixture o f diastereomers in the final product (except for 
glycine and phenethylamine) which we could separate if the racemate showed high 
inhibitory activity. It was suspected that the 2(>S)-hydroxy derivative would be the 
stronger inhibitor by analogy with bestatin.116
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It should be noted, that because o f their large number o f hydrophillic substituents 
it may be difficult for these inhibitors to traverse the cell membrane. Hence we also 
tested the precursors of these molecules (16) in which the hydroxy group was protected 
as the acetate and the carboxylic acid functionality was protected as the methyl ester. 
These derivatives should be better able to interact more favourably with the lipophilic 
membranes thus allowing improved transport into the cell. Once inside the cell 
hydrolysis o f these esters should yield the active forms of the inhibitors.
Schem e II
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The i.r. spectra of the ZV-2-acetoxy-2-phenylacetyl derivatives (16a-e) show an 
NH stretch in the high frequency region at 3350cm'1. Peaks at 1740cm'1 and 1660cm'1 
correspond to ester and amide carbonyls respectively. Absorptions in the aromatic 
region are also noted. The ’H-n.m.r. spectra has a complex multiplet from 8 7.24-7.40 
which integrates as 10 protons due to the aromatic protons. A multiplet in the range 5 
6 .5-6.7 which integrates as two protons is due to the amide protons. Two singlets due 
to the to the two diasteromeric protons on the carbon attached to the acetoxy group 
which integrate as one proton each occur at 8 6.08 and 8 6.11. Two singlets are 
observed in the range 8 3.72-3.74 which together integrate as six protons corresponding 
to the methyl ester protons of the two diastereomers. Two singlets are also observed at 
8 2.17 and 8 2.19 which integrate as three protons each are due to the diastereomeric 
acetate protons. The 13C-n.m.r spectra have three characteristic carbonyl signals at 8 
173, 169.9 and 169.1 corresponding to the ester, acetate and amide carbonyl carbons 
The signal due to the a-carbon of the 2-acetoxy-2-phenylacetyl moiety occurs at 8 75. 
Signals at 8 52 and 8 21 are due to the ester and acetate methyl carbons respectively.
Hydrolysis of the A-2-acetoxy-2-phenylacetyl derivatives with 1M NaOH124,125 
yielded the A^-hydroxy^-phenylacetyl derivatives (17a-d). The L-alanine derivative 
could not be isolated in this manner even by using milder hydrolysis conditions
The i.r. spectra of the AL2-hydroxy-2-phenylacetyl derivatives (17a-d) have a 
sharp NH stretching peak at 3350cm'1 and a broad OH stretching absorption at 
3200cm'1. A peak due to the ester carbonyl stretching is observed at 1720cm'1 and one 
due to the amide carbonyl at 1630cm'1. Aromatic absorptions are also noted. The H- 
n.m.r. spectra has a signal at 8 8.0 which integrates as two due to the amide protons. A 
complex multiplet from 8 7.24-7.44 which integrates as five protons is due to the 
aromatic hydrogens. A signal at 8 6.3 which consists o f two broad doublets and which 
together integrate as one proton is due to the diastereomeric hydroxyl protons. Two 
singlets in the region 8 4.8-5.0 which again together integrate as two protons correspond 
to the a-protons o f the hydroxy acid moiety. The 13C-n.m.r. spectra has two carbonyl 
signals at 8 173 and 8 171 corresponding to the acid and amide carbonyl carbons. The 
signal due to the a-carbon of the 2-hydroxy-2-phenylacetyl moiety occurs at 8 73.
124
The molecular ion in the electron impact mass spectra appears very weak due to 
the instability o f the a-hydroxy acid functionality which loses water under these 
conditions to give a signal at [M-H2O] *+. The fragment at m/z 107 and at m/z 77 are 
due to the a-hydroxy acid moiety. Immonium ions characteristic of the amino acid 
present are also observed. The fragmentation patterns o f the 7V-2-hydroxy-2- 
phenylacetyl derivatives are described in greater detail in Figs. 4.4-4.6 .
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Fig. 4.4 E l  fragm en ta tion  of iV -2-hydroxy-2-phenylacetyl glycine (17a).
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Fig. 4.5 E l fragm en ta tion  of /V-2 -hyd io x y -2 -phenylacetyl-L -leucine (17b).
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Fig. 4.6 E l  fragm en ta tion  ofiV-2 -hydroxy-2 -phenyIacetyl-L -phenylalanine (17c).
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A crystal of 7V-((R)2-hydroxy-2-phenylacetyl)-L-leucine was isolated from the 
diastereomeric mixture and examined by x-ray crystallography (fig. 4.7). Extensive 
hydrogen bonding is present in the crystal structure consisting of an intramolecular 
N-H • • O and intermolecular O-H • • -0=C  hydrogen bonds, as well as C-H ■ • 0  and 
sp3 C-H ■ • ■ 7i (arene) interactions.
Fig. 4.7 C rystal structure of ^ -((^-l-hydroxy-Z -phenylacety^-L -leucine (17b).
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4.2 /V-2-Hvdroxv-3-phenvlpropionyl derivatives
20a R C O C H 3, R ’=H , R ” =C H 3
20b R =C O C H 3, R ’=(iS)-CH3, R ” =C H 3
20c R = C O C H „ R ’=(S)-C H 2C H (C H 3)2, R ” =C H 3
20d R =C O C H 3, R ’=(S)-C H 2Ph, R ” =C H 3
21a R=H, R ’=H, R ” =H 
21b R=H, R ’=(S)-C H 3, R ” =C H 3 
21c R=H, R ’=(5)-C H 2C H (C H 3)2, R ” =H 
21 d R -H , R ’=(5)-C H 2Ph, R ” =H
20e R =C O C H 3 
21e R=H
129
Ar-2-Hydroxy-3-phenylpropionyl derivatives were prepared to observe the effect 
o f increasing the length of the carbon chain. It was hoped that the increased length of 
the aromatic side chain would allow the aromatic ring to interact more favourably with 
the hydrophobic pocket S1 in the active site (fig. 4.8).
Fig. 4.8 Proposed  b ind ing  of ./V-2-hydroxy-3-phenylpropionyl am ino acid 
to active site metal.
The starting material L-phenyllactic acid (18) was prepared in an 
enantiomericallly pure form via a diazotization o f L-phenylalanine in acidic conditions 150 
L-phenyllactic acid is an inhibitor of the protease pepsin151 as well as yeast phenylalanine 
lyase.152 Attempts to prepare phenyllactic acid by forming the cyanohydrin of 
phenylacetaldehyde and subsequent acidic hydrolysis in a similar manner to that used for 
the synthesis of mandelic acid121 failed. This may be because some aldehydes do not 
form the bisulphite addition product readily.153
By analogy to bestatin (fig. 2.14a) where the 2-(,S)-hydroxy is essential for 
activity, L-phenyllactic acid (18) was chosen as the starting material in order to furnish a
2-(iS)-hydroxy group in the final product. The hydroxyl group was protected as the 
acetate, and the resulting 2-acetoxy-3-phenylpropionic acid (19) was coupled to the 
amino acid methyl ester with q c c D 123,124,132,133 to yield the jV-2-acetoxy-3- 
phenylpropionyl amino acid ester derivative (20). Removal of the ester and acetate 
protecting groups by careful base hydrolysis124,125 yielded the 7V-2-hydroxy-3- 
phenylpropionyl amino acid derivatives (21) (Scheme III).
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The i.r. spectra of the Af-2-acetoxy-3-phenylpropionyl derivatives (20a-e) show 
characteristic NH peaks at 3300cm'1. Peaks at 1750cm"1 and 1670cm'1 are due to the 
ester and amide funtionalities respectively. Aromatic absorbtions are also noted The 
^ -n .m .r. spectra have a complex multiplet at 8 7.1-7.3 which integrates as five protons 
corresponding to the aromatic protons. The signal at 6 6.6 which integrates as one 
proton is due to the amide proton. A multiplet in the range 8 5.39-5.43 which integrates 
as one proton is due to the a-proton of the hydroxy acid moiety. The signal due to the 
benzylic methylene protons appears at 8 4.0 as two doublets which integrate as one 
proton each. Singlets at 8 2.1 and 8 3.1 which both integrate as three protons are due to 
the acetate and methyl ester protons respectively. The 13C-n.m.r. spectra have three 
carbonyl signals in the region 8 169-173 corresponding to the ester, acetate and amide 
carbonyls. Four peaks are observed in the region 8 126-136 due to four non-equivalent 
aromatic carbons.
The i.r. spectra of the A-2-hydroxy-3-phenylpropionyl derivatives (21a-e) have a 
characteristic broad OH stretching peak at 3400cm'1 and an NH stretching peak at 
3350cm'1. Absorptions at 1730cm'1 and 1650cm'1 are due to the carboxylic acid and 
amide carbonyls stretches respectively. The ^-n .m .r. spectra has a signal at 8 8.0 
which integrates as one proton due to the amide proton. A complex multiplet which 
integrates as five protons in the region 8 7.1-7.3 corresponds to the aromatic protons. 
A signal at 8 4.1 which integrates as one proton is due to the a-proton of the 2-hydroxy-
3-phenylpropionyl moiety. Two pairs of doublets at 8 2.6 and 8 3.0 which integrate as 
one proton each are due to the benzylic protons. The unusual splitting is due to the 
adjacent chiral centre. The 13C-n.m.r. spectra have two carbonyl signals at 8 171 and 8 
173 due to the amide and carboxylic acid carbonyls. Four signals in the region 5 126- 
139 are due to the four non-equivalent aromatic carbons.
The electron impact mass spectra of the 7V-2-hydroxy-2-phenylpropionyl 
derivatives are similar to those of the Ar-2-hydroxy-2-phenylacetyl derivatives. The 
molecular ion again appears very weak due to the instability of the a-hydroxy acid 
functionality. The fragment at m/z 121 and at m/z 131 are due to the a-hydroxy acid 
moiety. Unlike the mass spectra o f the iV-2-hydroxy-2-phenylacetyl derivatives, a 
tropyllium ion is observed at m/z 91. This rearrangement is facillitated by the presence
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o f the methylene group of the 2-hydroxy-2-phenylpropionic acid moiety. Immonium 
ions characteristic o f the amino acid present are also observed. The fragmentation 
patterns o f the /V-2 -hydroxy-2-phenylpropionyl derivatives are described in greater detail 
in Figs. 4.9-4.1 1.
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Fig. 4.9 EX fragm en ta tion  o f 7V -2-hydroxy-3-phenylpropionyl glycine (21a).
133
Ph
0+ m / z  1 3 1
- C O
m / z  1 0 3
H 2 N = \
m / z  8 6
Fig. 4.10 E l fragm en tation  of /V -2-hydroxy-3-phenylpropionyl-L- 
leucine (2 1 c).
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4.3 ./V-3-Hvdroxv-3-phenvlpropionvl derivatives
O
II
O R " 
R '
25a R = C O C H 3, R ’=H, R ” = C H 3
25b R = C O C H 3, R ’=(5)-C H 3, R ” = C H 3
25c R = C O C H 3, R ’=(S)-C H 2P h , R ” = C H 3
26a R=H, R ’=H , R ” =H
26b R=H , R ” =(^)-C H 2P h , R ” =H
25d R = C O C H 3 
26c R =H
It was decided to prepare the TV-3-hydroxy-3-phenylpropionyl derivatives (26a-c) 
in order to observe the effect o f placing a methylene spacer between the carbonyl and 
hydroxy groups o f the iV-2-hydroxy-2-phenylacetyl derivatives. In these derivatives the 
hydroxy group is P to the amide carbonyl unlike the previously described inhibitors in 
which the hydroxy group is a  to the carbonyl. This type o f derivative may yield more 
information about the binding of the inhibitors to the active site. Another interesting
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feature o f these derivatives is that intramolecular hydrogen bonding between the hydroxy 
and carbonyl groups may occur (fig. 4.12). This type o f interaction reduces 
intermolecular interactions and may allow this type of inhibitor improved transport 
across cell membranes.
Fig. 4.12 Possible in tram o lecu lar hydrogen  bond ing  in 
,/V-3-hydroxy-3-phenylpropionyl am ino acid.
The starting material 3 -hydroxy-3-phenylpropionic acid (23) was prepared by a 
Reformatsky reaction by treating benzaldehye with zinc and ethyl bromoacetate to yield a 
racemic mixture o f ethyl-3-hydroxy-3-phenylpropanoate (22).121 Alkaline hydrolysis of 
the ester yielded the P-hydroxy acid. The hydroxy group was protected as the acetate by 
treatment with acetyl chloride to yield the 3-acetoxy-3-phenylpropionic acid (24) which 
was coupled with DCCD to the amino acid methyl ester to yield the N-3-acetoxy-3- 
phenylpropionyl derivatives (25). Subsequent base catalyzed hydrolysis yielded the N-3- 
hydroxy-3-phenylpropionyl derivatives (26) as diastereomeric mixtures, which were not 
separated for reasons decribed previously for the jV-2 -hydroxy-2 -phenylacetyl 
derivatives. We were unable to prepare the N-3-acetoxy-3-phenylpropionyl-L-leucine 
methyl ester and were unable to isolate 7V-3-hydroxy-3-phenylpropionyl-L-alanine after 
hydrolysis o f N-3-acetoxy-3 -phenylpropionyl-L-alanine methyl ester.
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The i.r. spectra of the 3-acetoxy-3-phenypropionyl derivatives have a 
characteristic NH peaks at 3300cm'1 and carbonyl peak at 1740cm'1 due to the ester or 
acetate carbonyl. A peak observed at 1650cm1 is due to the amide carbonyl. Aromatic 
absorptions are also noted. The ^-n .m .r. spectra have a complex multiplet stretching 
from 57.25 to 67.35 which integrates as ten protons due to the aromatic protons. Two
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signals in the region 8 6 .0-6.2 which integrate as two protons each and may actually 
obscure each other are due to the amide protons and the (3-protons of the 3-acetoxy-3- 
phenylpropionyl moiety. The (3-protons of the 3-acetoxy-3-phenylpropionyl moiety 
appear as two doublets. This is due to the fact of being split by two protons which are 
non-equivalent because they are adjacent to a chiral centre. Singlets at 5 3.7 and 5 2.0 
which both integrate as six protons correspond to the methyl ester and acetate protons 
respectively. Two pairs of doublets at 5 2.65 and 5 2.85 which integrate as two protons 
each are due to the methylene protons o f the 3-acetoxy-3-phenylpropionyl moiety. The 
L3C-n.m.r spectra have three carbonyl signals at 8 168, 5 170 and 5 172 corresponding to 
the methyl ester acetate and amide carbonyl carbons. Four signals due to the four non­
equivalent aromatic carbons are seen in the region 8 126-140. The signals due to the 
methylene and (3-carbons of the 3-acetoxy-3-phenylpropionyl moiety occur at 8 41 and 8 
72 respectively.
The i.r. spectra of the 3-hydroxy-3-phenylpropionyl derivatives exhibit an OH 
peak at 3300cm'1. Two carbonyl peaks are observed at 1720cm'1 and 1650cm'1 due to 
the acid and amide carbonyls respectively. Aromatic absorptions are also noted. The 
^ -n .m .r. spectra of the 3-hydroxy-3-phenylpropionyl derivatives are similar to the 
spectra of the 3-acetoxy-3-phenylpropionyl deivatives. A signal at 8 8.2 which integrates 
as two protons is due to the amide protons. A complex multiplet which is observed in 
the region 8 7.2-7.4 and which integrates as ten protons corresponds to the aromatic 
protons. A pair of doublets in the range 8 4.9-5.1 which integate as two protons are due 
to the P-protons of the 3-hydroxy-3-phenylpropionyl-moiety. A pair of doublets which 
is observed in the region 8 3.65-3.85 and which integrate as four protons correspond to 
the methylene protons of the 3-hydroxy-3-phenylpropionyl moiety. The 13C-n.m.r. 
spectra have two carbonyl signals at 8 171 and 170 which correspond to the carboxylic 
acid and amide carbonyl carbons. Four signals due to the four non-equivalent aromatic 
carbons are observed in the region 8 125-145. Signals at 8 70 and 8 45 are due to the 
methylene and a  carbons of the 3-hydroxy-3-phenylpropionyl moiety respectively.
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4.4 /V-2-Thio-2-phenvlacetyl derivatives
O R "
27a R = O H ,R ’=C H 2C H (C H 3)2, R ” = C H 3 
27b R =O H , R ’=C H 2Ph, R ” = C H 3
28a R = 0 S 0 2C H 3, R ’=C H 2C H (C H 3)2, R ” = C H 3 
28b R = 0 S 0 2CH 3, R ’= C H 2P h , R ” =C H 3
29a R =SC O C H 3, R ’= C H 2C H (C H 3)2, R ” =C H 3 
29b R =SC O C H 3, R ’=C H 2PIi, R ” =C H 3
a " Y
0
28c R = 0 S 0 2C H 3 
29c R = SC O C H 3 
30 R=SH
14)
The 7V-2-thio-2-phenylacetyl derivatives were prepared in order to observe the 
effect o f replacing the hydroxy group of the 7V-2-hydroxy-2-phenylacetyl derivatives with 
a thiol fimtionality. It is known that sulphur has a high affinity for metals found at the 
active site o f metalloproteases and it was hoped that a strong hydrogen bonding 
interaction between the sulphydryl group and active site metal (fig. 4.13) would make 
these derivatives potent inhibitors. Many of the most potent aminopeptidase inhibitors 
contain a thiol group.
The jV-2-thio-2-phenylacetyl derivatives (30) were prepared from the 
corresponding Ar-2-hydroxy-2-phenylacetyl derivatives (17). It was chosen to prepare 
only the derivatives of L-leucine, L-phenylalanine and phenethylamine since these were 
the derivatives for which we had the starting material in greatest abundance. The 
carboxylic acid was first protected as the methyl ester by treatment with thionyl chloride 
and methanol. Treatment o f the resulting protected iV-2-hydroxy-2-phenylacetyl 
derivative (27) with methanesulphonyl chloride119 yielded the corresponding mesylates 
(28). Displacement o f the mesylate with potassium thioacetate yielded the A-acethio^- 
phenylacetyl (29) derivatives as a mixture o f diastereomers. We were unable to isolate 
the thiol derivatives o f L-leucine and L-phenylalanine, perhaps due to the high reactivty 
o f the thiol, or hydrolysis conditions which were too severe. However we did prepare
S
, O  R
- M  '
J x q
Fig. 4.13 Proposed  binding  of TV -2-thio-2-phenylacetyl-am ino acid 
to th e  active site m etal.
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the thiol derivative o f phenethylamine (30). The acethio derivatives may be active in 
vivo, as enzymatic degradation of the thioester and acetate may furnish the active thiol 
metabolite, and so these compounds were also tested. They may also be better able to 
cross the cell membrane.
Schem e V
(i) SO C I2, M eO H
(ii) M sCI, E t3N , DCM
(iii) Potassium  th ioacetate , D M F
(iv) 1M N aO H , M eO H
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The i.r. spectra of the mesylates (28a-c) exhibit an NH stretching frequency peak 
at 3400cm'1. Peaks observed at 1730 and 1660cm'1 are due to the ester and amide 
carbonyls respectively. Aromatic absorptions are also noted. The ’H-n.m.r. spectra of 
the mesylates (28a-c) are similar to the spectra o f JV-2 -acetoxy-2 -phenylacetyl derivatives 
(16) The signal due to methanesulphonyl substituent protons is observed at 8 2.85 and 
8 2.95 as two diastereomeric singlets which together integrate as six protons. The 
singlet at 5 5.9 which integrates as two protons corresponds to the a-protons of the O- 
methanesulphonyl-2-hydoxy-2-phenylacetyl moiety. A signal observed at 6 39 in the 
13C-n.m.r. spectra is due to the methanesulphonyl methyl carbon. The signal due to the 
a-carbon of the 0 -methanesulphonyl-2 -hydroxy-2 -phenylacetyl moiety occurs at 8 81. 
The ester and amide carbonyl carbons give signals at 8 173 and 8 167 respectively.
The i.r. spectra of the thioacetates (29a-c) exhibit an NH peak at 3309cm'1. The 
peaks observed at 1740cm’1 and 1650cm’1 are due to the ester and amide carbonyls 
respectively. Aromatic absorptions are observed. The ^-n .m .r. spectra of the 
thioacetates (29a-c) are also similar to the A-2-acetoxy-2-phenylacetyl derivatives (17). 
The signal due to the thioacetate group protons are observed at in the range 8 2.33-2.35 
as two diastereomeric singlets which together integrate as six protons. The two 
diastereomeric singlets in the region 8 5.18-5.20 which together integrate as two protons 
correspond to the a-proton of the 2-acethio-2-phenylacetyl moiety. A signal observed at 
8 30 in the 13C-n.m.r. is due to the thioacetate methyl carbon. The a-carbon of the 2- 
acethio-2-phenylacetyl moiety occurs at 8 52. A signal corresponding to the thioacetate 
carbonyl carbon is observed at 8 195.
The i.r. spectrum of 7V-2-thio-2-phenylacetyl-phenethylamide (30) exhibits an NH 
peak at 3293cm’1. The peak observed at 1652cm’1 is due to the amide carbonyl 
Aromatic absorptions are also observed. The ^ -n .m .r. spectrum of A'r-2-thio-2- 
phenylacetyl-phenethylamide (30) is similar to Ar-2-hydroxy-2-phenylacetyl 
phenethylamide (17d). The two diastereomeric singlets observed at 8 4.74 correspond 
to the a-proton of the 2-thio-2-phenylacetyl moiety. The 13C-n.m.r. has a signal at 8 168 
due to the amide carbonyl. The signal due to the a-carbon of the 2-thio-2-phenylacetyl 
moiety occurs at 8 58.
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4.5 A ttem pted synthesis of a-hydroxv-6-am ino acid (AHBA) isosteres
Paradoxically most of the problems associated with peptide-based protease 
inhibitors as therapeutic agents are due to their very nature as peptides. The peptide 
bond is capable of forming hydrogen bonding interactions and is thus very hydrophilic. 
For this reason peptide-based inhibitors interact poorly with lipophilic cell membranes 
and their transportation across the cell membrane is reduced. In addition rapid enzymatic 
degradation of the peptide bond results in short lifetimes in vivo.
To overcome this problem it was decided to prepare some simple a-hydroxy-P- 
amino acid isosteres where the amide bond was replaced with a trans -C=C- bond. 
These compounds would mimic the AHBA moiety found in bestatin and amastatin 
(fig.4.14) and may be able to chelate the active-site metal via the amino and hydroxyl 
functionalities (fig. 4.15) in a similar manner to that described by Nishizawa et cil for 
bestatin.116 They would not however have the problems associated with their peptidyl 
counterparts. Examples of such compounds occur in nature. Merucathin (fig. 4.16) is a 
P-amino-allylic alcohol found in the CNS-active khatamines o f Catha edulis.15 It has 
been synthesized by treating ^-protected alanine with stryllithium followed by 
deprotection,155 or via a Schenk reaction from the corresponding acylated allylic 
amine.156
R 0  R
(a) R =C H 2C H (C H 3)2 (A m asta tin -type)
(b) R =C H 2Ph (B estatin-type) 
Fig. 4.14 C om parison o f of AHBAs an d  A H BA  isosteres.
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sFig. 4.15 Possible mode of b ind ing  of A HBA  isostere to  active site metal.
O H
Fig. 4.16 M erucath in .
The trans -C=C- bond has similar spatial requirements to the amide bond and 
there is a surprisingly similar geometrical disposition of substituents attached to either of 
these functional groups (fig. 4.16).157 X-ray crystallographic data show that amide bonds 
in peptides usually adopt a planar configuration with groups attached to the central bond 
in a /ram-orientation. Upon comparing both structures it is observed that the distance a- 
b is 3.8 A. The difference in direction of bond approach is only 5° but in flexible 
molecules such as peptides this becomes almost irrelevant to the overall geometry. Thus 
assuming the amide bond in bestatin was o f secondary importance to the amino and 
hydroxyl groups in terms of tight binding to the active site o f the aminopeptidase it 
should be possible to prepare simple AHBA analogues with improved abilities to traverse 
cell membranes and a longer lifetime in vivo.
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0Fig. 4.17 Spatial a rran g em en t of am ide and  trans -C =C - bonds.137
The starting material for these compounds was the corresponding D-amino acid 
This would give the correct 3(R) stereochemistry at the carbon attached to the amino 
group. It was decided to prepare the derivatives of D-phenylalanine and D-leucine to 
yield the bestatin-type and amastatin-type AHBA isosteres respectively. The carboxylic 
acid was converted to the methyl ester by treatment with thionyl chloride in methanol 
The amino group was then protected as the /er/-butyl carbamate using di-tert-butyl- 
dicarbonate. Reduction of the BOC amino acid methyl esters (31a,b) with 
diisobutylaluminium hydride yielded the corresponing BOC amino aldehydes (32a,b) It 
was then attempted to react the aldehyde with vinyl magnesium bromide to yield the 
BOC amino allylic alcohol as a mixture of diastereomers.158 Removal of the BOC 
protecting group with trifluoroacetic acid123,124 would then yield the desired product 
H owever we were unable to isolate the BOC amino allylic alcohols from the reaction 
mixture.
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(I) D i-tert-bu ty l-d icarbonate , EtaN, D C M
(ii) DEBAL, Toluene
(iii) V inyl m agnesium  brom ide, T H F
(iv) T FA
The i.r. spectra o f the BOC amino acid esters (31a,b) have an NH stretching frequency 
peak at 3400cm'1. An ester carbonyl peak is observed at 1750cm'1. A singlet observed 
at 8 1.4 in the ^I-n.m.r. spectra which integrates as nine protons is due to the tert-butyl 
protons. The tert-butyl methyl carbons give a signal at 8 28 in the 13C-n.m.r.
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The i.r. spectra of the BOC amino aldehydes exhibits a signal at 3400cm'1 due to 
the NH stretching frequency. The aldehydic carbonyl gives a singlet at 1690cm'1. A 
signal observed at 5 1.44 in the ‘H-n.m.r. spectra is due to the /e/Y-butyl protons. The 
aldehydic proton is observed at 8 9.6. The 13C-n.m.r. spectra o f the BOC-amino 
aldehydes again shows a characteristic signal at 8 28 corresponding to the fe/7-butyl 
methyl carbons. The signal due to the aldehydic carbonyl carbon occurs at 5 200.
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4.6 E xperim ental
TV-((/?/.y)-2-Acetoxv-2-phenvlacetyl) glycine m ethyl ester (16a)
O-Acetylmandelic chloride (2.25ml, O.Olmol) in dichloromethane (50ml) was added 
dropwise to a solution of glycine methyl ester hydrochloride (1.26g, O.Olmol) and 
triethylamine (2.1ml, 0.015mol) in dichloromethane (50ml) at 0°C After 30min the reaction 
temperature was increased to room temperature and the reaction allowed to proceed for 4hr. 
The solution was washed with 10% sodium hydrogen carbonate, 5% hydrochloric acid, 
water and dried. The solvent was removed in vacuo. Recrystallization from ethyl 
acetate/petroleum ether furnished the title compound as an off-white solid (2.18g, 82%). 
m.p. 124-126°C (uncorrected).
i r. vmax(KBr):3312 (NH), 1747 (ester/acetate C =0), 1670 (amide C=0), 1538, 1455, 1436, 
1374, 1226, 1155, 1046cm'1.
1H-n.m.r.(400MHz)5(CDCl3): 2.19 (6H, s, PhCH(OCOCH3)CO-), 3.76 (6H, s, 
-NHCH2C 0 2CH3), 4.07 (4H, m, -NHCH2C 0 2CH3), 6.13 (2H, s, PhCH(COOCH3)CO-), 
6.79 (2H, s, -NH), 6.79-7.80 (10H, m, ArH).
13C-n.m.r.(100MHz)S(CDCl3): 172.69 (-NHCH2C 0 2CH3), 169.98, 169.11,
(PhCH(OCOCH3)CO- and PhCH(OCOCH3)CO-), 135.18, 129.06, 128.73, 127.49
(aromatic carbons), 75.27 (PhCH(OCOCH3)CO-), 52.44, (-NHCH2C 0 2CH3), 40.95 
(-NHCH2C 0 2CH3), 20.93 (PhCH(OCOCH3)CO-).
O
Spectroscopic analysis
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A^-if/gASyZ-Hydroxv-l-phenylacetvr) glycine (17a)
1M NaOH (25ml) was added to a solution o f #-((7?/5)-2-acetoxy-2-phenylacetyl) glycine 
methyl ester (3.2g, 0.01 mol) in methanol (20ml) and allowed to stir at room temperature for 
lhr. The solution was then cooled to 0°C and acidified with 10% hydrochloric acid. The 
solvent was allowed to evaporate over a period o f time. The resulting solid was extracted 
into acetone, filtered and the solvent removed in vacuo. Recrystallization from acetone/«- 
hexane yielded the title compound as a white crystalline solid (1.95g, 93%). 
m.p. 122-124°C (uncorrected).
Spectroscopic analysis
i.r. vmax(KBr): 3237 (OH), 3053, 1724 (carboxylic acid C =0), 1647 (amide C=0), 1536, 
1451, 1413, 1271, 1240, 1062cm'1.
1H-n.m.r.(400MHz)5(DMSO): 3.78 (4H, d, J=4Hz, -NHCH2C 0 2H), 4.96 (2H, s, 
PhCH(OH)CO-), 7.24-7.44 (10H, m, ArH), 8.25 (2H, d, J=4Hz, -NH).
13C-n.m.r.(100MHz)5(DMSO): 172.60, 171.29 (-NHCH2C 0 2H and PhCH(OH)CO-), 
141.29, 128.06, 127.57, 126.99 (aromatic carbons), 73.45 (PhCH(OH)CO-), 40.56 
(-NHCH2C 0 2H).
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Mass spectrum m/z (%): 209 (1.5), 191 (0.7) [M-H20 ] ,+, 107 (100), 77 (24), 30 (15) 
(immonium ion o f Gly).
Calc, for CioHuN 0 4 M*+ m/z: 209
A i - f f / j f A y i - l - A c e t o x v - l - D h e n v l a c e t v Q - L - a l a n i n e  m e t h y l  e s t e r  ( 1 6 b )
O-Acetylmandelic chloride (2.25ml, O.Olmol) in dichloromethane (50ml) was added 
dropwise to a solution of L-alanine methyl ester hydrochloride (1.4g, O.Olmol) and 
triethylamine (2.1ml, 0.015mol) in dichloromethane (50ml), at 0°C. After 30min, the 
reaction temperature was increased to room temperature, and the reaction allowed to 
proceed for 4hr. The solution was washed with 10% sodium hydrogen carbonate, 5% 
hydrochloric acid , water, and dried. The solvent was removed in vacuo, and purification of 
the resultant oil by recrystallization from ethyl acetate/petroleum ether furnished the title 
compound as a yellow solid (2.18g, 78%). 
m.p. 54-56°C (uncorrected).
O C H
3
Spectroscopic analysis
i.r. vmax(KBr): 3319 (NH), 1748 (ester/acetate C=0), 1662 (amide C=0), 1537, 1435, 1419, 
1371, 1229, 1048cm'1.
1H-n.m.r.(400MHz)8(CDCl3): 1.41 (6H, d, J=7.4Hz, -NHCH(CH3)C 0 2CH3), 2.17&2.19 
(6H, 2 diastereomeric singlets, PhCH(OCOCH3)CO-), 3.73 (6H, 2 diastereomeric singlets,
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-NHCH(CH3)C 0 2CH3), 4.55-4.63 (2H, m, -NHCH(CH3)C 0 2CH3), 6.08&6.11 (2H, 2 
diastereomeric singlets, PhCH(OCOCH3)CO-), 6.91 (2H, m, -NH), 7.33-7.45 (10H, m, 
ArH).
13C-n.m.r.(100MHz)§(CDCl3): 172.70 (-NHCH(CH3)C 0 2CH3), 169.02, 168.93, 167.70, 
167.67 (PhCH(OCOCH3)CO- and PhCH(OCOCH3)CO-), 135.18, 135.00, 128.63, 128.46,
128.35, 127.33, 127.28, 127.12 (aromatic carbons), 74.94 (PhCH(OCOCH3)CO-), 52.24, 
52.14 (-NHCH(CH3)C 0 2CH3), 47.63, 47.60 (-NHCH(CH3)C 0 2CH3), 20.58, 20.54 
(PhCH(OCOCH3)CO-), 17.74, 17.66 (-NHCH(CH3)C 0 2CH3).
Mass spectrum: [M+H]" found 280.11833 C)4HigN0 5 requires 280.0517
A ttem pted  p rep a ra tio n  of N -ffflA Syi-hydroxv-l-phenvlacetvD -L -alanine
lM N aO H  (25ml) was added to a solution o f vV-((/?AS1)-2-acetoxy-2-phenylacetyl)-L-alanine 
methyl ester (2.8g, O.Olmol) in methanol (20ml) and allowed to stir at room temperature for 
lhr. The solution was then cooled to 0°C and acidified with 10% hydrochloric acid . The 
solvent was allowed to evaporate over a period of time. The resulting yellow oil was 
extracted into acetone, filtered and the solvent removed in vacuo. Purification by flash 
chromatography [chloroform/methanol(9.5:0.5)] did not yield the desired product and the 
reaction was not investigated further.
/V-((j?/.Sy2-Acetoxv-2-phenvlacetvl)-L-lc!icine m ethyl este r f 16c)
O-Acetylmandelic chloride (2.25ml, O.Olmol) in dichloromethane (50ml) was added 
dropwise to a solution of L-leucine methyl ester hydrochloride (1.8g, O.Olmol) and 
triethylamine (2.1ml, 0.015mol) in dichloromethane (50ml) at 0°C. After 30min the reaction 
temperature was increased to room temperature and the reaction allowed to proceed for 4hr. 
The solution was washed with 10% sodium hydrogen carbonate, 5% hydrochloric acid, 
water and dried. The solvent was removed in vacuo and purification of the resultant oil by
153
recrystallization from ethyl acetate/petroleum ether furnished the title compound as a white 
crystalline solid (2.31, 72%). m.p. 64-66°C (uncorrected).
Spectroscopic analysis
i.r. vmax(KBr): 3329 (NH), 2961, 1753, 1733 (ester/acetate O O ) , 1661 (amide C=0), 1539, 
1372, 1233, 1155cm'1.
1H-n.m.r.(400MHz)5(CDCl3): 0.87-0.90 (12H, dd, JA=9.36Hz, JB=6.4Hz, 
-NHCH(CH2CH(CH3)2)C 0 2CH3), 1.49-1.69 (6H, m, -NHCH(CH2CH(CH3)2)C 02CH3 and 
-NHCH(CH2CH(CH3)2)C 0 2CH3), 2.17&2.19 (6H, 2 diastereo meric singlets, 
PhCH(OCOCH3)CO-), 3.70&3.71 (6H, 2 diastereomeric singlets,
NHCH(CH2CH(CH3)2)C 0 2CH3), 4.60-4.66 (2H, m -NHCH(CH2CH(CH3)2)C 02CH3), 
6.06&6.09 (2H, 2 diastereomeric singlets, PhCH(OCOCH3)CO-), 6.54 (2H, m, -NH), 
7.30-7.50 (10H, m, ArH).
13C-n.m.r.(l00MHz)5(CDCl3): 173.03 (-NHCH(CH2CH(CH3)2)C 0 2CH3), 169.09, 168.02, 
167.98 (PhCH(OCOCH3)CO- and PhCH(OCOCH3)CO-), 135.30, 135.24, 129.02, 128.97, 
128.70, 127.60, 127.27 (aromatic carbons), 75.38, 75.33 (PhCH(OCOCH3)CO-), 50.52, 
50.49 (-NHCH(CH2C H (0C 0C H 3)C 0 2CH3), 41.60, 41.48
(-NHCH(CH2CH(CH3)2)C 0 2CH3), 24.80, 24.76 (-NHCH(CH2CH(CH3)2C 0 2CH3), 22.70, 
22.65 (-NHCH(CH2CH(CH3)2C 0 2CH3), 21.93, 21.82 (PhCH(OCOCH3)CO-), 20.93 
(-NHCH(CH2CH(CH3)2C 0 2CH3),
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N-((R/S)-2-H y d r o x y - 2 - p h e n y t a c e t y Q - L - l e u c i n e  ( 1 7 b )
1M NaOH (25ml) was added to a solution o f N-((7?AS)-2-acetoxy-2-phenylacetyl)-L-leucine 
methyl ester (3.2g, O.Olmol) in methanol (20ml) and allowed to stir at room temperature for 
lhr. The solution was then cooled to 0°C and acidified with 10% hydrochloric acid. The 
methanol was removed in vacuo and the solution allowed to cool. The resultant white 
precipitate was filtered and recrystallized from acetone/«-hexane to yield the title compound 
as a white rhombs (2.3g, 87%). 
m.p. 116-118°C (uncorrected).
Spectroscopic analysis
i.r. vmax(KBr): 3459 (OH), 3389 (NH), 3296, 1725 (carboxylic acid O O ), 1639 (amide 
O O ) , 1556, 1267, 1160cm'1.
1H-n.m.r.(400MHz)5(DMSO): 0.75-0.85 (12H, m, -NHCH(CH2CH(CH3)2)C 0 2H), 1.46- 
1.66 (6H, m, -NHCH(CH2CH(CH3)2)C 0 2H and -NHCH(CH2CH(CH3)2)C 0 2H), 4.22-4.28 
(2H, m, -NHCH(CH2CH(CH3)2)C 0 2H), 4.93 (2H, s, PhCH(OH)CO-), 6.25 (2H, s, 
PhCH(OH)CO-), 7.22-7.40 (10H, m, ArH), 7.98-8.00 (2H, d, J=8.88Hz, -NH).
13C-n.m.r.(100MHz)5(DMSO): 173.79, 171.94 (-NHCH(CH2CH(CH3)2)C 02H and
PhCH(OH)CO-), 141.25, 127.89, 127.38, 126.62 (aromatic carbons), 73.28 
(PhCH(OH)CO-), 49.75 (-NHCH(CH2CH(CH3)2)C 0 2H), 24.32
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(-NHCH(CH2CH(CH3)2)C 02H), 22.83, 21.36 (-NHCH(CH2CH(CH3)2)C 02H)
N ote: The signals at 173.79 and 171.94 may be interchangeable.
Mass spectrum [M-H20 ] ’+ found: 247.1322, ChH i7N 0 3 requires 247.1207 
m/z (%): 247 (0.5) [M-H20 ] ‘+, 107 (100), 86 (22) (immonium ion of Leu), 77 (19).
-/V-((i?/iSr)-2-A cetoxv-2-phenvlacetvl)-L -phenylalanine m ethyl ester (16d)
O-Acetylmandelic chloride (2.25ml, O.Olmol) in dichloromethane (50ml) was added 
dropwise to a solution of L-phenylalanine methyl ester hydrochloride (2.16g, O.Olmol) and 
triethylamine (2 .1 ml, 0.015mol) in dichloromethane (50ml) at 0°C. After 30min the reaction 
temperature was increased to room temperature and the reaction allowed to proceed for 4hr. 
The solution was washed with 10% sodium hydrogen carbonate, 5% hydrochloric acid, 
water and dried. The solvent was removed in vacuo and purification of the resultant oil by 
recrystallization from ethyl acetate/petroleum ether furnished the title compound as a white 
crystalline solid (2.99g, 84%). 
m.p. 88-90°C (uncorrected).
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Spectroscopic analysis
i r. vmax(KBr):3367 (NH), 1740 (ester/acetate O O ) , 1674 (amide C=0), 1533, 1371, 1220, 
1186, 1179, 1123cm'1.
1H-n.m.r.(400MHz)5(CDCl3): 2.15&2.16 (6H, 2 diastereomeric singlets,
PhCH(OCOCH3)CO-), 3.06-3.19 (4H, m, -NHCH(CH2Ph)C 02CH3), 3.74 (6H, s, 
-NHCH(CH2P h)C 02CH3), 4.84-4.89 (2H, m, -NHCH(CH2Ph)C 02CH3), 6.04 (2H, s, 
PhCH(OCOCH3)CO-), 6.65 (2H, d, J=7.4Hz, -NH), 6.96-7.36 (20H, m, ArH).
13C-n.m.r.(100MHz)5(CDCl3): 171.56 (-NHCH(CH2Ph)C 02CH3), 169.01, 167.84
(PhCH(OCOCH3)CO- and PhCH(OCOCH3)CO-), 135.36, 135.07, 129.32, 128.91, 128.67, 
128.50, 127.10 (aromatic carbons), 75.39 (PhCH(OCOCH3)CO-), 52.81, 52.43 
(-NHCH(CH2Ph)C 02CH3), 37.51 (-NHCH(CH2P h)C 02CH3), 20.86 
(PhCH(OCOCH3)CO-).
A i-dRA SV Z-H vdroxv-l-phenvlacetvD -L-phenylalanine (17c)
1M NaOH (25ml) was added to a solution of Ar-((i?/5)-2-acetoxy-2-phenylacetyl)-L- 
phenylalanine methyl ester (3.55g, 0.01 mol) in methanol (20ml) and allowed to stir at room 
temperature for lhr. The solution was then cooled to 0°C and acidified with 10% 
hydrochloric acid. The methanol was removed in vacuo, and the solution allowed to cool. 
The resultant white precipitate was filtered and recrystallized from acetone/rc-hexane to yield 
the title compound as a white rhombs (2.8g, 94 %). 
m.p. 174-176°C (uncorrected).
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Spectroscopic analysis
i.r. vmax(KBr): 3357 (OH), 1748, 1722 (carboxylic acid C=0), 1623 (amide 0 0 ) ,  1526, 
1211, 1174, 1062cm'1.
1H-n.m.r.(400MHz)8(DMSO): 2.98-3.09 (4H, m, -NHCH(CH2Ph)C02H), 4.47-4.52 (2H, 
m, NHCH(CH2Ph)C 02H), 4.88 (2H, 2 diastereomeric singlets, PhCH(OH)CO-), 6.32 (2H, 
2 diastereomeric singlets, PhCH(OH)CO-), 7.07-7.26 (20H, m, ArH), 7.92 (2H, d, J=8.4Hz, 
-NH).
13C-n.m.r.(100MHz)5(DMSO): 172.69, 171.70 (-NHCH(CH2Ph)C 02H  and 
PhCH(OH)CO-), 140.97 137.18, 129.27, 128.21, 128.16, 127.87, 127.40, 126.82, 126.47 
(aromatic carbons), 73.36 (PhCH(OH)CO-), 52.54 (-NHCH(CH2Ph)C02H), 36.35 
(-NHCH(CH2P h) C 0 2H).
Mass spectrum: M‘+ found: 299.115758 C 17H 17NO4 requires 299.11561
m/z (%): 299 (1.6), 281 (5) [M-H20]*+, 192 (12), 120 (15) (immonium ion o f Phe) 107
(100), 91 (76).
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Ar-((/?Ay)-2-Acetoxv-2-uhcnvlacetvn phenethy lam idc (16e)
O-Acetylmandelic chloride (2.25ml, O.Olmol) in dichloromethane (50ml) was added 
dropwise to a solution of phenethylamine (1.26ml, O.Olmol) and triethylamine (2.1ml,
0.015mol) in dichloromethane (50ml) at 0°C. After 30min the reaction temperature was 
increased to room temperature and the reaction allowed to proceed for 4hr. The solution 
was washed with 10% sodium hydrogen carbonate, 5% hydrochloric acid, water and dried. 
The solvent was removed in vacuo and purification of the resultant oil by recrystallization 
from ethyl acetate/petroleum ether furnished the title compound as an off-white crystalline 
solid (2.6g, 87%). 
m.p. 78-80°C (uncorrected).
i.r. vmax(KBr): 3334 (NH), 1736 (acetate C =0), 1652 (amide O O ), 1541, 1454, 1371, 
1245, 1041cm'1.
1H-n.m.r.(400MHz)5(CDCl3): 2.08 (6H, s, PhCH(OCOCH3)CO-), 2.73-2.84 (4H, m, 
-NHCH2CH2Ph), 3.43-3.61 (4H, m, -NHCH2CH2Ph), 6.02 (2H, s, PhCH(OCOCH3)CO-), 
6.21 (2H, t, J=5.9Hz, -NH), 7.09-7.37 (20H, m, ArH).
Spectroscopic analysis
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13C-n.m.r.(100MHz)5(CDCl3): 169.06, 168.16, (PhCH(OCOCH3)CO- and
PhCH(OCOCH3)CO-), 138.47, 135.40, 128.85, 128.74, 128.64, 128.55, 127.24, 126.49 
(aromatic carbons) 75.37 (PhCH(OCOCH3)CO-), 40.33 (-NHCH2CH2Ph), 35.09 
(-NHCH2CH2Ph), 20.84 (PhCH(OCOCH3)CO-).
/V-((j?Ay)-2-Hvdroxv-2-Dhenylacetvl) phenethy lam ide (17d)
1M NaOH (25ml), was added to a solution o f Ar-((7 A^ST)-acetoxy-2 -phenyacetyl) 
phenethylamide (2.97g, O.Olmol) in methanol (20ml) and allowed to stir at room 
temperature for lhr. The solution was then cooled to 0°C and acidified with 10% 
hydrochloric acid. The methanol was removed in vacuo, and the solution allowed to cool. 
The resultant white precipitate was filtered and recrystallized from ace tone/«-hexane to yield 
the title compound159 as white rhombs (2.27g, 89%). 
m.p. 94-96°C (uncorrected).
Spectroscopic analysis
i.r. vmax(KBr): 3355 (OH), 3164, 1644 (amide O O ), 1551, 1454, 1294, 1194, 1062cm'1.
1H-n.m.r.(400MHz)5(DMSO): 2.71 (4H, t, J=7.4Hz -NHCH2CH2Ph), 3.27-3.34 (4H, m, 
-NHCH2CH2Ph), 4.88 (2H, d, J=4.5Hz, PhCH(OH)CO-), 6.13 (2H, d, J=4.5Hz, 
PhCH(OH)CO-), 7.14-7.37 (20H, m, ArH), 8.00 (2H, t, J=5.9Hz, -NH).
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13C-n.m.r.(100MHz)5(DMSO): 172.23 (PhCH(OH)ÇO-), 139.43, 138.40, 128.66, 128.63, 
128.52, 128.40, 126.67, 126.43 (aromatic carbons), 73.95 (PhCH(OH)CO-), 40.50 
(-NHÇH2CH2Ph), 35.43 (-NHCH2CH2Ph).
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Ar-f(.y)“2-A cetoxv-3-i)hcnvlpropionvl) glycine m ethyl ester (20a)
Dicyclohexylcarbodiimide (2.1g, O.Olmol) was added to a solution o f 0-acetyl-L-a- 
phenyllactic acid (2.1g, O.Olmol), glycine methyl ester hydrochloride (1.26g, O.Olmol) and 
dry pyridine (1.6ml, 0.02mol) in dichloromethane (100ml) at 0°C. After 30min the reaction 
temperature was raised to room temperature and the reaction allowed to proceed for 6hr. 
The precipitate o f dicyclohexylurea was then removed by filtration. The filtrate was washed 
with sodium hydrogen carbonate (10%), hydrochloric acid (5%), water and dried. The 
solvent was removed in vacuo and the resultant oil purified by flash chromatography on 
silica gel [petroleum ether 40-60/ethyl acetate (7:3)] to furnish the title compound as a 
colourless oil. (2.34g, 84%).
i.r. vmax(CHCl3): 3324 (NH), 1746 (ester/acetate C=0), 1671 (amide C=0), 1529, 1535, 
1498, 1454, 1438, 1409, 1217, 1183, 1081, 1063cm'1.
1H-n.m.r.(400MHz)5(CDCl3): 2.06 (3H, s, PhCH2CH(OCOCH3)CO-), 3.11 (1H, dd, 
Ja=14.28Hz, Jb=7.5Hz, PhCH2CH(OCOCH3)CO-), 3.24 (1H, dd, JA=14.28Hz, JB=4.4Hz, 
PhCH2CH(OCOCH3)CO-) 3.73 (3H, s, -NHCH2C 0 2CH3), 4.00 (2H, m, -NHCH2C 0 2CH3),
5.41 (1H, dd, Ja=7.5Hz, Jb=4.4Hz, PhCH2CH(OCOCH3)CO-), 6.66 (1H, t, J=4.6Hz, -NH), 
7.17-7.30 (5H, m, ArH).
O
Spectroscopic analysis
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13C-n.m.r.(100MHz)5(CDCl3): 169.75, 169.37, 169.33 (-NHCH2C 02CH3,
PhCH2CH(OCOCH3)CO-, and PhCH2CH(OCOCH3)CO-), 135.68, 129.32, 128.24, 126.79 
(aromatic carbons), 74.00 (PhCH2CH(OCOCH3)CO-), 52.28 (-NHCH2C 0 2CH3), 40.72 
(-NHCH2C 0 2CH3), 37.54 (PhCH2CH(OCOCH3)CO-), 20 64 (PhCH2CH (0C 0CH 3)C0-).
iY -^W l-H vdroxv-S -phenvlprop ionvO  glycine (21a)
lM N aO H  (25ml) was added to a solution of 7V-((iS)-2-acetoxy-3-phenylpropionyl) glycine 
methyl ester (2.8g, O.Olmol) in methanol (20ml) and stirred at room temperature for lhr. 
The solution was then cooled to 0°C and acidified with 10% hydrochloric acid. The solvent 
was evaporated and the resulting solid extracted with acetone. The acetone was then 
removed in vacuo. The resultant white precipitate was recrystallized from acetone/«-hexane 
to yield the title compound as white needles (2.03g, 91%). 
m.p. 126-128°C (uncorrected).
O H  
O
Spectroscopic analysis
i.r. vmax(KBr): 3404 (OH), 3343 (NH), 1752, 1712 (carboxylic acid C=0), 1609, 1537, 
1419, 1211, 1191, 1093cm'1.
1H-n.m.r.(400MHz)5(DMSO): 2.68 (1H, dd, JA=13.8Hz, JB=8 .8Hz, PhCH2CH(OH)-), 3.01 
(1H, dd, Ja=13.8Hz, Jb=3Hz, PhCH2CH(OH)-), 3.77 (2H, t, J=6.9Hz, -NHCH2C 0 2H), 4.09 
(1H, dd, Ja=8 .8Hz, Jb=3Hz, PhCH2CH(OH)-), 5.71, 1H, s, PhCH2CH(OH)-), 7.17-7.29 
(5H, m, ArH), 8.03 (1H, t, J=5.66Hz, NH), 12.59 (1H, s, -NHCH2C 0 2H).
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13C-n. m.r.(1 OOMHz)S(DMSO): 173.84, 171.22 (-NHCH2C 0 2H and PhCH2CH(OH)CO-), 
138.77, 129.50, 128.00, 126.03 (aromatic carbons), 72.18 (PhCH2CH(OH)CO-), 40.48 
(-NHCH2C 0 2H).
N ote: The PhCH2CH(OH)CO- signal is obscured by the DMSO signal.
Mass spectrum: [M-H20 ] '+ found: 205.073893 C 11H 11NO3 requires 205.07377. 
m/z (%): 205 (10) [M-H20 ] * \  161 (55), 131 (93), 103 (42), 91 (100), 77 (24).
N -ffiSyi-A cetoxv-S-nhenvInropioH vD -L-alanine m ethyl ester (20b)
Dicyclohexylcarbodiimide (2.1g, O.Olmol) was added to a solution of 0-acetyl-L-oc- 
phenyllactic acid (2.1g, O.Olmol), L-alanine methyl ester hydrochloride (1.4g, O.Olmol) and 
dry pyridine (1.6ml, 0.02mol) in dichloromethane (100ml) at 0°C. After 30min the reaction 
temperature was increased to room temperature and the reaction allowed to proceed for 6hr. 
The precipitate of dicyclohexylurea was then removed by filtration. The filtrate was washed 
with sodium hydrogen carbonate (10%), hydrochloric acid (5%>), water and dried. The 
solvent was removed in vacuo and the resultant oil purified by flash chromatography on 
silica gel [petroleum ether 40-60/ethyl acetate (7:3)] furnishing the title compound as white 
needles. (2.73g, 93%). 
m.p. 78-80°C (uncorrected).
O C H 3
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Spectroscopic analysis
i r. vmax(KBr): 3297 (NH), 1746 (ester/acetate C=0), 1666 (amide C=0), 1565, 1369, 
1271, 1241, 1215, 1196, 1056cm'1.
1H-n.m.r.(400MHz)8(CDCl3): 1.27 (3H, d, J=7.36Hz, -NHCH(CH3)C 0 2CH3), 2.12 (3H, s, 
PhCH2CH(OCOCH3)CO-), 3.13-3.23 (2H, m, PhCH2CH(OCOCH3)CO-), 3.72 (3H, s, - 
NHCH(CH3)C 0 2CH3), 4.51-4.58 (1H, m, -NHCH(CH3)C 0 2CH3), 5.38-5.41 (1H, m, 
PhCH2CH(OCOCH3)CO-), 6.56 (1H, d, J=7.36Hz, -NH), 7.16-7.30 (5H, m, ArH).
13C-n.m.r.(100MHz)5(CDCl3): 172.98 (-NHCH(CH3)C 0 2CH3), 169.23, 168 27
(PhCH2C H (0C 0 CH3) CO - and PhCH2CH(OCOCH3)CO-), 135.52, 129.56, 128.22, 126.86 
(aromatic carbons), 73.88 (PhCH2CH(OCOCH3)CO-), 52.46 (-NHCH(CH3)C 0 2CH3), 
47.55 (-NHCH(CH3)C 0 2CH3), 37.49 (PhCH2CH(OCOCH3)CO-), 20.81
(PhCH(OCOCH3)CO-), 18.23 (-NHCH(CH3)C 0 2CH3).
N ote: The signals at 169.23 and 168.27 maybe interchangeable.
Af-((t.ST)-2-H vdroxv-3-nhenvlpropionvl,)-L -alanine (21b)
1M NaOH (25ml) was added to a solution of 7V-((S')-2-acetoxy-3-phenylpropionyl)-L- 
alanine methyl ester (2.93g, O.Olmol) in methanol (20ml) and stirred at room temperature 
for lhr. The solution was then cooled to 0°C and acidified with 10% hydrochloric acid 
The methanol was removed in vacuo and the solution allowed to cool. The resultant white 
precipitate was filtered and recrystallized from acetone/w-hexane to yield the title compound 
as a white crystalline solid (2.05g, 86 %). 
m.p. 102-104°C (uncorrected). Lit. 111°C.160
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Spectroscopic analysis
i.r. vmax(KBr): 3383 (OH), 3354 (NH), 1719 (carboxylic acid C=0), 1615 (amide C=0), 
1534, 1454, 1212, 1159, 1091cm'1.
1H-n.m.r.(400MHz)8(DMSO): 1.22 (3H, d, J=7.36Hz, -NHCH(CH3)C 0 2H), 2.71 (1H, dd, 
JA=13.28Hz, Jb=8Hz, PhCH2CH(OH)CO-), 2.98 ( 1 H, dd, JA=13.28Hz, JB=3.4Hz, 
PhCH2CH(OH)CO-), 4.10 (1H, dd, JA=8Hz, JB=3.4Hz, PhCH2CH(OH)CO-), 4.12-4.28 1H, 
m, -NHCH(CH3)C 0 2H), 5.67, (1H, s, PhCH2CH(OH)CO-), 7.17-7.27 (5H, m, ArH), 7.77 
(1H, t, J=8Hz, -NH).
13C-n.m.r.(100MHz)8(DMSO): 173.97, 172.91 (-NHCH(CH3)C 0 2H  and PhCH(OH)CO-),
138.43, 129.58, 128.04, 126.17 (aromatic carbons), 71.89 (PhCH2CH(OH)CO-), 47.09 
(-NHCH(CH3)C 0 2H), 40.36 (PhCH2CH(OH)CO-), 17.57 (-NHCH(CH3)C 0 2H).
Ar- ( ( iy ) - 2 - A c e t o x v - 3 - p h c n v l n i o D i o n y l ) - L - l e u c i n e  m e t h y l  e s t e r  ( 2 0 c )
Dicyclohexylcarbodiimide (2.1g, O.Olmol) was added to a solution of (3-acetyl-L-a- 
phenyllactic acid (2.1g, O.Olmol), L-leucine methyl ester hydrochloride (1 81g, O.Olmol), 
and dry pyridine (1.6ml, 0.02mol) in dichloromethane (100ml) at 0°C. After 30min the 
reaction temperature was raised to room temperature and the reaction continued for 6hr. 
The precipitate of dicyclohexylurea was then removed by filtration. The filtrate was washed 
with 10% sodium hydrogen carbonate, 5% hydrochloric acid, water and dried, The solvent
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was removed in vacuo and the resultant oil purified by flash chromatography on silica gel 
[petroleum ether 40-60/ethyl acetate (7:3)] yielding the title compound as a white needles 
(2.8g, 85%).
m.p. 64-66°C (uncorrected).
O  
O C H
3
C H
3
C H
3
Spectroscopic analysis
i.r. vmax(KBr): 3267 (NH), 1752 (ester/acetate C=0), 1656 (amide C=0), 1555, 1371, 
1239, 1157cm'1.
1H-n.m.r.(400MHz)6(CDCl3): 0.87 (6H, dd, JA=9.36Hz, JB=6.4Hz, 
-NHCH(CH2CH(CH3)2)C 0 2CH3), 1.32-1.57 (3H, m, -NHCH(CH2CH(CH3)2)C 0 2CH3 and 
-NHCH(CH2CH(CH3)2)C 0 2CH3), 2.13 (3H, s, PhCH2CH(OCOCH3-), 3.13-3.24 (2H, m, 
PhCH2CH(OCOCH3-)CO-), 3.41 (3H, s, -NHCH(CH2CH(CH3)2)C 0 2CH3), 4.56-4.63 
(1H, m, -NHCH(CH2CH(CH3)2)C 0 2CH3), 5.39-4.43 (1H, dd, JA=5.92Hz, JB=4.92Hz, 
PhCH2CH(OCOCH3)CO-), 6.32 (1H, d, J=8.36Hz, -NH), 7.16-7.29 (5H, m, ArH).
13C-n.m.r.(100MHz)5(CDCl3): 173.07 (-NHCH(CH2CH(CH3)2)C 0 2CH3), 169.27, 168.24 
(PhCH2CH(OCOCH3)CO- and PhCH2CH(OCOCH3)CO-), 135.65, 129.64, 128.31, 126.90 
(aromatic carbons), 74.14 (PhCH2CH(OCOCH3)CO-), 52.33 
(-NHCH(CH2CH(CH3)2)C 0 2CH3), 50.22 (-NHCH(CH2CH(CH3)2)C 0 2CH3), 41.59
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(-NHCH(CH2CH(CH3)3)C02CH3), 37.40 (PhCH2CH(OCOCH3)CO-), 24.48, 
(-NHCH(CH2CH(CH3)2)C 0 2CH3), 22.69, 21.87 (-NHCH(CH2CH(CH3)2)C 0 2CH3), 20.93 
(PhCH2CH(OCOCH3)CO-).
N ote: The signals at 169.27 and 168.24 may be interchangeable. 
AL((>Sr)-2-H vdroxv-3-phenvlpropionvl)-L -leucine (21c)
1M NaOH (25ml) was added to a solution of Ar-((lS)-2-acetoxy-3-phenylpropionyl)-L- 
leucine methyl ester (3.35g, O.Olmol) in methanol (20ml) and allowed to stir at room 
temperature for lhr. The solution was cooled to 0°C and acidified with 10% hydrochloric 
acid. The methanol was removed in vacuo and the solution allowed to cool. The resultant 
white precipitate was filtered and recrystallized from acetone/«-hexane to yield the title 
compound as a white rhombs (2.35g, 84%). 
m.p. 126-128°C (uncorrected).
i.r. vmax(KBr): 3390 (OH), 3065, 1732 (carboxylic acid O O ), 1651 (amide O O ), 1539, 
1261, 1187, 1146cm"1.
1H-n.m.r.(400MHz)5(DMSO): 0.81 (6H, dd, JA=10.8Hz, JB=5.92Hz, 
-NHCH(CH2CH(CH3)2)C 0 2H), 1.35-1.57 (3H, m, -NHCH(CH2CH(CH3)2)C 02H and
3
C H
3
Spectroscopic analysis
1 6 8
-CH2CH(CH3)2), 2.73 (1H, dd, JA=13.76Hz, JB=7.88Hz, PhCH2CH(OH)CO-) & 2 96 
(1H, dd, Ja=13.76Hz, Jb=3.44Hz, PhCH2CH(OH)CO-), 4.12
(1H, m, PhCH2CH(OH)CO-), 4.23-4.29 (1H, m, -NHCH(CH2CH(CH3)2)-), 5.69 (1H, d, 
J=4.9Hz, PhCH2CH(OH)CO-) 7.14-7.26 (5H, m, ArH), 7.65 (1H, d, J=8.36Hz, -NH), 
12.64 (1H, s, -NHCH(CH2CH(CH3)2)C 0 2H).
13C-n.m.r.(100MHz)5(DMSO): 173.92, 173.00 (PhCH2CH(OH)CO- and 
-NHCH(CH2CH(CH3)2)C 0 2H), 138.27, 129.58, 127.85, 125.98 (aromatic carbons), 71.85 
(PhCH2CH(OH)CO-), 49.60 (-NHCH(CH2CH(CH3)2)C 0 2H), 24.08 
(-NHCH(CH2CH(CH3)2)C 0 2H), 22.90, 21.38 (-NHCH(CH2CH(CH3)2)C 0 2H).
Note: The PhCH2CH(OH)CO- and -NHCH(CH2CH(CH3)2)C 0 2H signals are obscured by 
the DMSO signal.
Mass spectrum: [M-H20]*+ found 261.1264 Ci5HigN03 requires 261.13633.
m/z (%): 261 (3) [M-H20]*+, 205 (84), 131 (93), 91 (29), 103 (41), 86 (60) (immonium ion
of Leu).
^ /-((^^ -A cetoxv-S -nhenv lp rop ionvD -L -phe iiy la lan ine  m ethyl ester (20d)
Dicyclohexylcarbodiimide (2.1g, O.Olmol) was added to a solution of 0-acetyl-L-a- 
phenyllactic acid (2.1g, O.Olmol), L-phenylalanine methyl ester hydrochloride (2.16g,
O.Olmol) and dry pyridine (1.6ml, 0.02mol) in dichloromethane (100ml) at 0°C. After 30min 
the reaction temperature was raised to room temperature and the reaction allowed to 
proceed for 6hr. The precipitate of dicyclohexylurea was removed by filtration. The filtrate 
was washed with 10% sodium hydrogen carbonate, 5% hydrochloric acid, water and dried. 
The solvent was removed in vacuo and the resultant oil purified by flash chromatography on 
silica gel [petroleum ether 40-60/ethyl acetate (7:3)] yielding the title compound as white 
needles. (3.2lg, 87%). 
m.p. 64-66°C (uncorrected)
1 6 9
Spectroscopic analysis
i r. vmax(KBr): 3313 (NH), 1730 (ester/acetate C=0), 1653 (amide 0= 0 ), 1540, 1445, 1353, 
1250, 1223, 1206, 979.57cm'1.
1H-n.m.r.(400MHz)5(CDCl3): 2.02 (3H, s, PhCH2CH(OCOCH3)CO-), 2.92 (1H, dd, 
Ja=13.76Hz, Jb=5.92Hz, PhCH2CH(OCOCH3)CO-), 3.04-3.21 (3H, m,
PhCH2CH(OCOCH3)CO- and -NHCH(CH2Ph)C 02CH3), 3.68 (3H, s, 
-NHCH(CH2Ph)C 02CH3), 4.83-4.88 (1H, m, -NHCH(CH2Ph)C 02CH3), 5.35-5.40 (1H, m, 
PhCH2CH(OCOCH3)CO-), 6.41 (1H, d, J=7.88Hz, -NH), 6.82-7.32 (10H, m, ArH).
13C-n.m.r.(100MHz)5(CDCl3): 171.33 (-NHCH(CH2Ph)C 02CH3), 169.20, 168.30 
(PhCH2CH(OCOCH3)CO- and PhCH2CH(OCOCH3)CO-), 135.66, 135.26, 129.69, 129.23,
128.43, 128.35, 127.10, 127.02 (aromatic carbons), 73.96 (PhCH2CH(OCOCH3)CO-),
52.41 (-NHCH(CH2Ph)C 02CH3), 52.29 (-NHCH(CH2P h)C 02CH3), 37.82, 37.39 
(-NHCH(CH2P h)C 02CH3 and PhCH2CH(OCOCH3)CO-), 20.74 
(PhCH2CH(OCOCH3)CO-).
Note: The signals at 169.20 and 168.30 may be interchangeable. The signals at 37.82 and
37.39 may also be interchangeable.
Ar-(Cy)-2-H vdroxv--3-phenvlpropionvr)-L-phenvlalanine (21d)
1M NaOH (25ml) was added to a solution o f A^-((5)-2-acetoxy-2-phenylpropionyl)-L- 
phenylalanine methyl ester (3.69g, O.Olmol) in methanol (20ml) and allowed to stir at room 
temperature for lhr. The solution was cooled to 0°C and acidified with 10% hydrochloric 
acid. The methanol was removed in vacuo and the solution allowed to cool. The resultant 
white precipitate was filtered and recrystallized from acetone/«-hexane furnishing the title 
compound as a white rhombs (3.14g, 92%). 
m.p. 156-158°C (uncorrected).
O
Spectroscopic analysis
i.r. vraax(KBr): 3376 (OH), 1737 (carboxylic acid C=0), 1711, 1609, 1533, 1496, 1230, 
1223, 1199, 1130, 1086cm'1.
1H-n.m.r.(400MHz)5(DMSO): 2.59 (1H, dd, JA=13.8Hz, JB=8.4Hz, PhCH2CH(OH)CO-), 
2.87 (1H, dd, JA—13.8Hz, JB=2.96Hz, PhCH2CH(OH)CO-), 2.98 (2H, d, J=6.4Hz, 
-NHCH(CH2P h)C 02H), 4.05 (1H, m, PhCH2CH(OH)CO-), 4.54-4.56 (1H, m, 
-NHCH(CH2P h)C 0 2H), 5.72 (1H, d, J=5.4Hz, PhCH2CH(OH)CO-), 7.03-7.27 (10H, m, 
ArH), 7.66 (1H, d, J=8.4Hz, -NH).
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13C-n.m.r.(100MHz)5(DMSO): 172.90, 172.61 (-NHCH(CH2Ph)C02H and
PhCH2CH(OH)CO-), 138.39, 137.01, 129.56, 129.27, 128.18, 127.95, 126.52, 126.07 
(aromatic carbons), 71.94 (PhCH2CH(OH)CO-), 52.35 (-NHCH(CH2Ph)C 02H), 40.34 
(-NHCH(CH2P h)C 02H), 36.75 (PhCH2CH(OH)CO-).
Mass spectrum: [M-H20 ] *+ found: 295.120844 C 18H 17NO3 requires 295.12069.
m/z (%): 295 (6) [M-H20 ] ,+, 251 (3), 131 (40), 120 (27) (immonium ion ofPhe), 103 (29),
91 (100).
Ar-((ty)-2-acetoxv-3-phenylpropionyl) phenethy lam ide  (20e)
Dicyclohexylcarbodiimide (2.1g, O.Olmol) was added to a solution of O-acetyl-L-a- 
phenyllactic acid (2.1g, O.Olmol), phenethylamine (1.26ml, O.Olmol) and dry pyridine 
(1.6ml, 0.02mol) in dichloromethane (100ml) at 0°C. After 30min the reaction temperature 
was increased to room temperature and the reaction allowed to proceed for 6hr. The 
precipitate o f dicyclohexylurea was then removed by filtration. The filtrate was washed with 
10% sodium hydrogen carbonate, 5%o hydrochloric acid, water and dried, the solvent was 
removed in vacuo and the resultant oil purified by flash chromatography on silica gel 
[petroleum ether 40-60/ethyl acetate (7:3)] to yield the title compound as a colourless oil
(2.83g, 92%).
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Spectroscopic analysis
i.r. vmax(CHCl3): 3308 (NH), 2933, 1743 (acetate C =0), 1654 (amide C=0), 1534, 1497, 
1455, 1437, 1372, 1230, 1080, 1046cm'1.
1H-n.m.r.(400MHz)5(CDCl3): 1.96 (3H, s, PhCH2CH(OCOCH3)CO-), 2.63-2.75 (2H, m, 
-NHCH2CH2Ph), 3.10 (1H, dd, JA=14.2Hz, JB=6.4Hz, PhCH2CH(OCOCH3)-), 3.18 (1H, 
dd, Ja=14.2Hz, Jb=4.92Hz, PhCH2CH(OCOCH3)CO-), 3.42-3.47 (2H, t, J=5.9Hz, 
-NHCH2CH2Ph), 5.33 (1H, m, PhCH2CH(OCOCH3)CO-), 6.01 (1H, m, -NH), 7.02-7.30 
(10H, m, ArH).
13C-n.m.r.(100MHz)5(CDCl3): 169.15, 168.69 (PhCH2CH(OCOCH3)CO- and
PhCH2CH(OCOCH3)CO-), 138.39, 135.72, 129.47, 128.62, 128.44, 128.20, 126.80,
126.39 (aromatic carbons), 74.10 (PhCH2CH(OCOCH3)CO-), 40.00 (-NHCH2CH2Ph), 
37.49, (PhCH2CH(OCOCH3)CO-) 35.31 (-NHCH2CH2Ph), 20.64 
(PhCH2CH(OCOCH3)CO-).
Ar-((iy)-2-?lvdroxv-3-phenvlnropionvl) phenethy lam ide (21e)
1M NaOH (25ml) was added to a solution of iV-((5)-2-acetoxy-3-phenylpropionyl) 
phenethylamide (3. lg, O.Olmol) in methanol (20ml) and stirred at room temperature for lhr. 
The solution was cooled to 0°C and acidified with 10% hydrochloric acid. The methanol 
was removed in vacuo and the solution cooled. The resultant white precipitate was filtered 
and recrystallized from acetone/«-hexane to yield the title compound161 as a white crystalline 
solid (2.4g, 89%>). 
m.p. 96-98°C (uncorrected)
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Spectroscopic analysis
i.r. vmax(KBr): 3351 (OH), 3029, 1643 (amide C=0), 1547, 1496, 1454, 1398, 1308, 1084,
1067cm'1.
1H-n.m.r.(400MHz)8(DMSO): 2.64-2.7 (3H, m, PhCH2CH(OH)CO- and -NHCH2CH2Ph), 
2.94 (1H, dd, Ja=13.8Hz, Jb=3.44Hz, PhCH2CH(OH)CO-), 3.24-3.33 (2H, m, 
-NHCHzCH^h), 4.03 (1H, m, PhCH2CH(OH)CO-), 5.56 (1H, d, J=5.9Hz;
PhCH2CH(OH)CO-), 7.14-7.29 (10H, m, ArH), 7.76 (1H, t, J=5.9Hz, -NH).
13C-n.m.r.(100MHz)8(DMSO): 173.12 (PhCH2CH(OH)CO-), 139.40, 138.59, 129.49, 
128.60, 128.33, 127.90, 126.08, 125.97 (aromatic carbons), 72.18 (PhCH2CH(OH)CO-),
40.41 (-NHCH2CH2Ph), 35.21 (-NHCH2CH2Ph)).
N ote: The PhCH2CH(OH)CO- signal is obscured by the DMSO signal.
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Ar-((/?Ay)-3-Acctoxv-3-phcnvlpropionvl) glycine m ethyl ester (25a) 
Dicyclohexylcarbodiimide (2.1g, O.Olmol) was added to a solution of 0-acetyl-D/L-f3- 
phenyllactic acid (2.1g, O.Olmol), glycine methyl ester hydrochloride (1.26g, O.Olmol) and 
dry pyridine (1.6ml, 0.02mol) in dichloromethane (100ml) at 0°C. After 30min the reaction 
temperature was increased to room temperature and the reaction allowed to proceed for 6hr. 
The precipitate o f dicyclohexylurea was then removed by filtration. The filtrate was washed 
with 10% sodium hydrogen carbonate, 5% hydrochloric acid, water and dried. The solvent 
was removed in vacuo. Recrystallization o f the resulting oil from ethyl acetate/pet ether 40- 
60 yielded the title compound as a waxy solid (1.34g, 48%>).
O
Spectroscopic analysis
i.r. vmax(KBr): 3338 (NH), 1741 (ester/acetate C =0), 1645 (amide C=0), 1379, 1270, 
1246, 1167, 1027cm'1.
1H-n.m.r.(400MHz)5(CDCl3): 2.05 (6H, s, PhCH(OCOCH3)CH2CO-), 2.75 (4H, m, 
PhCH(OCOCH3)CH2CO-), 3.73 (4H, s, -NHCH2C 0 2CH3), 3.98 (4H, d, J=7Hz, 
-NHCH2C 0 2CH3), 6.14 (2H, m, PhCH(OCOCH3)CH2CO-), 6.22 (2H, t, J=7Hz, NH), 
7.25-7.36 (10H, m, ArH)
13C-n.m.r.(100MHz)5(CDCl3): 173.41 (-NHCH2C 0 2CH3), 169.62, 168.33
(PhCH(OCOCH3)CH2CO- and PhCH(OCOCH3)CH2CO-), 139.45, 128.56, 128.23, 126.22
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(aromatic carbons), 72.74 (PhCH(OCOCH3)CH2CO-), 52.34 (-NHCH2C 0 2CH3), 43.40 
(PhCH(OCOCH3)CH2CO-), 40.67 (-NHCH2C 0 2CH3), 20 99 (PhCH(OCOCH3)CH2CO-)
Ar-((i?ASr)-3-H vdroxv-3-phenvlpropionvD  glycine (26a)
1M NaOH (25ml) was added to a solution of 7V-((i?AS,)-2-acetoxy-2-phenylpropionyl) 
glycine methyl ester (2.8g, O.Olmol) in methanol (20ml) and allowed to stir at room 
temperature for lhr. The solution was then cooled to 0°C and acidified with 10% 
hydrochloric acid. The solvent was evaporated and the solid extracted with acetone. The 
solvent was removed in vacuo. The resultant solid was filtered and recrystallized from 
acetone/«-hexane to yield the title compound as a white crystalline solid (1.83g, 82%) 
m.p. 140-142°C.
Spectroscopic analysis
i.r. vmax(KBr): 3283 (OH), 3108, 1706 (carboxylic acid O O ) , 1591, 1448, 1420, 1348, 
1264, 1196, 1106, 1044cm'1.
1H-n.m.r.(400MHz)8(DMSO): 2.40 (2H, dd, JA=14.76Hz, JB=4.5Hz, PhCH(OH)CH2CO-), 
3.75 (4H, d, J=5.7Hz, -NHCH2C 0 2H), 4.96 (2H, dd, JA=8.84Hz, JB=4.5Hz,
PhCH(OH)CH2CO-), 7.19-7.63 ( 10H, m, ArH), 8.20 (2H, t, J=5.7Hz, -NH).
N ote: The second PhCH(OH)CH2CO- signal is obscured by the DMSO signal.
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13C-n.m.r.(100MHz)5(DMSC>): 171.38, 170.57 (-NHCH2C 0 2H and PhCH(OH)CH2CO-),
145.36, 128.99, 128.05, 126.85, 125.70 (aromatic carbons), 69.51 (PhCH(OH)CH2CO-), 
45.46 (-NHCH2C 0 2H), 40.46 (PhCH(OH)CH2CO-).
Mass spectrum: [M+H]+ found 223.8581 C 11H 14NO4 requires 224.09215
/V-((/?Ay)-3-Acetoxv-3-pheiivlpropionyl)-L-aIanine m ethyl ester (25b)
Dicyclohexylcarbodiimide (2.1g, O.Olmol) was added to a solution of O-acetyl-D/L-P- 
phenyllactic acid (2.1g, O.Olmol), L-alanine methyl ester hydrochloride (1.4g, O.Olmol) and 
dry pyridine (1.6ml, 0.02mol) in dichloromethane (100ml) at 0°C. After 30min the reaction 
temperature was increased to room temperature and the reaction allowed to proceed for 6hr. 
The precipitate o f dicyclohexylurea was then removed by filtration. The filtrate was washed 
with 10% sodium hydrogen carbonate, 5%> hydrochloric acid, water and dried. The solvent 
was removed in vacuo and recrystallization from ethyl acetate/pet ether 40-60 yielded the 
title compound a a white crystalline solid (1.23g, 42%). 
m.p. 124-126°C (uncorrected).
O
Spectroscopic analysis
i.r. vmax(KBr): 3341 (NH), 1740, 1711 (ester/ acetate O O ) , 1683 (amide C=0), 1548, 
1460, 1380, 1263, 1243, 1209, 1152, 1029cm'1.
177
1H-n.ni.r.(400MHz)5(CDCl3): 1.30 (6H, d, J=6 .88Hz, -NHCH(CH3)C 0 2CH3), 2.09 (6H, s, 
PhCH(OCOCH3)CH2CO-), 2.64 (2H, dd, JA=14.5Hz, JB=4.92Hz, 
PhCH(OCOCH3)CH2CO-), 2.86 (2H, dd, JA=14.5Hz, JB=8.84Hz, 
PhCH(OCOCH3)CH2CO-), 3.74 (6H, s, -NHCH(CH3)C 0 2CH3), 4 55-4.59 (2H, m, 
-NHCH(CH3)C 0 2CH3), 6.12-6.16 (2H, m, PhCH(OCOCH3)CH2CO-), 6.22 (2H, d, 
J=6 .88Hz, -NH), 7.26-7.36 (10H, m, ArH).
13C-n.m.r.(100MHz)5(CDCl3): 173.36 (-NHCH(CH3)C 0 2CH3), 169.75, 168.33
(PhCH(OCOCH3)CH2CO- and PhCH(OCOCH3)CH2CO-), 139.44, 128.58, 128.24, 126.23 
(aromatic carbons), 72.63 (PhCH(OCOCH3)CH2CO-), 52.46 (-NHCH(CH3)C 02CH3), 
47.91 (-NHCH(CH3)C 0 2CH3), 43.70 (PhCH(OCOCH3)CH2CO-), 21.04
(PhCH(OCOCH3)CH2CO-), 18.33 (-NHCH(CH3)C 0 2CH3),
Mass spectrum: [M+H]+ found 294.0253 C 15H 18NO5 requires 294.13397
A ttem pted  synthesis of N-fCRASyS-hvdroxY-^-nheiiylDropionvD-L-alanine
1M NaOH (25ml), was added to a solution of 7V-((i?/5)-2-acetoxy-2-phenylpropionyl)-L- 
alanine methyl ester (2.93g, O.Olmol) in methanol (20ml) and allowed to stir at room 
temperature for Ihr. The solution was then cooled to 0°C and acidified with 10% 
hydrochloric acid. The solvent was evaporated, and the residue extracted with acetone. 
The solvent was removed in vacuo. Attempted purification o f the resultant yellow oil by 
flash chromatography [chloroform/methanol (95:5)] did not yield the desired product and 
the reaction was not investigated further.
A ttem pted  synthesis o f A^CR/iSVS-acetoxy-S-phenylpropionvP-L-leucine 
m ethyl ester (25c)
Dicyclohexylcarbodiimide (2.1g, O.Olmol) was added to a solution of 0-acetyl-D/L-(3- 
phenyllactic acid (2.1g, O.Olmol), L-leucine methyl ester hydrochloride (1.81 g, O.Olmol)
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and dry pyridine (1.6ml, 0.02mol) in dichloromethane (100ml) at 0°C. After 30min the 
reaction temperature was raised to room temperature and the reaction continued for 6hr. 
The precipitate o f dicyclohexylurea was removed by filtration. The filtrate was washed with 
10% sodium hydrogen carbonate, 5% hydrochloric acid, water and dried. The solvent was 
removed in vacuo. Attempted purification of the resultant oil by flash chromatography 
[petroleum ether 40-60/ethyl acetate (6:4)] did not yield the desired product and the reaction 
was not investigated further.
A ^CRA SyS-A cetoxy-S-phenvIpropionvD -L-phenylalanine m ethyl ester (25c)
Dicyclohexylcarbodiimide (2.1g, O.Olmol) was added to a solution o f 0-acetyl-D/L-P- 
phenyllactic acid (2.1g, O.Olmol), L-phenylalanine methyl ester hydrochloride (2.16g,
O.Olmol) and dry pyridine (1.6ml, 0.02mol) in dichloromethane (100ml) at 0°C. After 30min 
the reaction temperature was raised to room temperature and the reaction continued for 6hr. 
The precipitate o f  dicyclohexylurea was removed by filtration. The filtrate was washed with 
10% sodium hydrogen carbonate, 5% hydrochloric acid, water and dried. The solvent was 
removed in vacuo and the resultant oil recrystallized from ethyl acetate/pet ether to give the 
title compound as a white crystalline solid, 
m.p. 104-106°C (uncorrected).
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Spectroscopic analysis
i.r. vmax(KBr): 3333 (NH), 1742 (ester/acetate C=0), 1643 (amide C=0), 1543, 1494, 1454, 
1433, 1374, 1352, 1281, 1244, 1178, 1120cm-1.
1H-n.m.r.(400MHz)5(CDCl3): 2.00 (6H, s, PhCH(OCOCH3)CH2CO-), 2.65 (2H, dd, 
JA=14.8Hz, Jr=4.44Hz, PhCH(OCOCH3)CH2CO-), 2.82 (2H, dd, JA=14.8Hz, JB=8 .8Hz, 
PhCH(OCOCH3)CH2CO-), 3.05-3.18 (4H, m, -NHCH(CH2Ph)C 02CH3), 3.70 (6H, s, 
-NHCH(CH2Ph)C 02CH3), 4.82-4.88 (2H, m, -NHCH(CH2Ph)C02CH3), 6.09-6.15 (4H, m, 
PhCH(OCOCH3)CH2CO- and -NH), 7.07 (20H, m, ArH).
13C-n.m.r.(100MHz)5(CDCl3): 171.76 (-NHCH(CH2Ph)C 02CH3), 169.63, 168.42
(PhCH(OCOCH3)CH2CO- and PhCH(OCOCH3)CH2CO-), 139.39, 135.74, 129.15, 128.56, 
128.23, 127.11, 126.35, 126.20 (aromatic carbons), 72.57 (PhCH(OCOCH3)CH2CO-), 
53.17 (-NHCH(CH2Ph)C 02CH3), 52.31 (-NHCH(CH2Ph)C 02CH3), 43.34 
(-NHCH(CH2Ph)C 02CH3), 37.06 (PhCH(OCOCH3)CH2CO-), 21.02
(PhCH(OCOCH3)CH2CO-).
A^iiflASyS-Hvdroxv-S-nhenvlpropionvP-L-phenvlfllanine (26b)
1M NaOH (25ml) was added to a solution of Af-((i?AS)-3-acetoxy-3-phenylpropionyl)-L- 
phenylalanine methyl ester (3.69g, O.Olmol) in methanol (20ml) and allowed to stir at room 
temperature for lhr. The solution was then cooled to 0°C and acidified with 10% 
hydrochloric acid. The methanol was removed in vacuo and the solution allowed to cool. 
The resultant white precipitate was filtered and recrystallized from acetone/«-hexane 
yielding the title compound as a white crystalline solid 
m.p. 130-132°C (uncorrected).
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Spectroscopic analysis
i.r. vmax(KBr): 3384 (OH), 3334 (NH), 1736 (carboxylic acid C=0), 1707, 1638 (amide 
C=0), 1529, 1494, 1452, 1430, 1409, 1373, 1347, 1263, 1235cm'1.
1H-n.m.r.(400MHz)5(DMSO): 2.32-2.41 (2H, m, PhCH(OH)CH2CO-), 2.80-2.91 (2H, m, 
-NHCH(CH2P h)C 0 2H), 2.95-3.06 (2H, m, -NHCH(CH2Ph)C 02H), 4.40-4.48 (2H, m, 
-NHCH(CH2P h)C 0 2H), 4.90 (2H, dd, JA=8.36Hz, JB=5.4Hz, PhCH(OH)CH2CO-), 
7.12-7.30 (20H, m, ArH), 8.16-8.21 (2H, m, -NH).
Note: Second PhCH(OH)CH2CO- signal is obscured by the DMSO signal.
13C-n.m.r.(100MHz)5(DMSO): 172.92 170.04 (-NHCH(CH2Ph)C02H and
PhCH(OH)CH2CO-), 145.23, 145.20, 137.56, 129.19, 129.11, 128.22, 128.16, 127.99, 
126.82, 126.79, 126.44, 126.40, 125.75, 125.69 (aromatic carbons), 69.53, 69.47 
(PhCH(OH)CH2CO-), 53.51, 53.31 (-NHCH(CH2Ph)C 02H), 45.38, 45.28 
(-NHCH(CH2P h)C 0 2H), 36.95, 36.83 (PhCH(OH)CH2CO-).
Mass spectrum: [M+H]+ found: 314.0065 Ci8H2oN04 requires 314.13907, [M+Na]+ found 
335.98417 Ci8H i9N 0 4Na requires 336.12125, [M+H-H20 ] + found 296.0165 C]8Hi8N 0 3 
requires 296.12853
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iV-((/?/,y)-3-Acetoxv-3-phenvlpropionvO phenethvlamide (25d)
Dicyclohexylcarbodiimide (2.1g, O.Olmol) was added to a solution of O-acetyl-P-L- 
phenyllactic acid (2.1g, O.Olmol), phenethylamine (1.26ml, O.Olmol) and dry pyridine 
(1.6ml, 0.02mol) in dichloromethane (100ml) at 0°C. After 30min the reaction temperature 
was raised to room temperature and the reaction continued for 6 hr. The precipitate of 
dicyclohexylurea was removed by filtration. The filtrate was washed with 10% sodium 
hydrogen carbonate, 5% hydrochloric acid, water and dried. The solvent was removed in 
vacuo and the resultant oil purified by flash chromatography on silica gel [petroleum ether 
40-60/ethyl acetate (6:4)] to yield the title compound as a white waxy solid.
Spectroscopic analysis
i.r. vmax(CHCl3): 3388 (NH), 1740 (acetate O O ), 1651 (amide C=0), 1552, 1496, 1455, 
1372, 1233, 1166, 1024cm'1.
1H-n.m.r.(400MHz)8(CDCl3): 1.98 (6H, s, PhCH(OCOCH3)CH2CO-), 2.55 (2H, dd, 
JA=14.28Hz, Jb=5.4Hz, PhCH(OCOCH3)CH2CO-), 2.67-2.79 (6 H, m, -NHCH2CH2Ph and 
PhCH(OCOCH3)CH2CO-), 3.39-3.47 (4H, m, -NHCH2CH2Ph), 6.00 (2H, t, 5.66Hz, -NH), 
6.14, (2H, dd, JA= 8 .8 8 Hz, Jb=5.92Hz, PhCH(OCOCH3)CH2CO-), 7.05-7.31 (20H, m, 
ArH).
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13C-n.m.r.(100MHz)5(CDCl3): 169.60, 168.75 (PhCH(OCOCH3)CH2CO- and
PhCH(OCOCH3)CH2CO-), 139.48, 138.60, 128.48, 128.40, 128.36, 128.10, 126.27, 
126.16, (aromatic carbons), 72.71 (PhCH(OCOCH3)CH2CO-), 43.45 (-NHCH2CH2Ph), 
40.45 (-NHCH2CH2Ph), 35.30 (-PhCH(OCOCH3)CH2CO-), 20.89 
(PhCH(OCOCH3)CH2CO-)
iy-((i?Ay)-3-Hvdroxv-3-phenvlpropionvl) phenethylamide (26c)
1M NaOH (25ml) was added to a solution of 7V-((i?/.S)-3-acetoxy-3-phenylpropionyl) 
phenethylamide (3.1g, O.Olmol) in methanol (20ml) and stirred at room temperature for lhr. 
The solution was then cooled to 0°C and acidified with 10% hydrochloric acid. The 
methanol was removed in vacuo and the solution allowed to cool. The resultant white 
precipitate was filtered and reciystallized from acetone/rc-hexane to furnish the title 
compound as a white crystalline solid 
m.p. 144- 146°C (uncorrected).
Spectroscopic analysis
i.r. vmax(KBr): 3396 (OH), 3314 (NH), 1644 (amide O O ), 1551, 1496, 1460, 1452, 1409, 
1196, 1063 cm'1.
1H-n.m.r.(400MHz)5(DMSO): 2.33 (2H, dd, JA=14.24Hz, JB=4.92 Hz, 
PhCH(OH)CH2CO-), 2.43 (2 H, dd, JA=14.24Hz, JB=8.36Hz, PhCH(OH)CH2CO-), 2.65 
(4H, t, J=7.38Hz, -NHCH2CH2Ph), 3.16-3.29 (4H, m, -NHCH2CH2Ph), 4.92-4.97 (2H, m,
PhCH(OH)CH2CO-), 5.38 (2H, d, J=4.44Hz, PhCH(OH)CH2CO-), 7.15-7.32 (20H, m, 
ArH), 7.92 (2H, t, J=5.4Hz, -NH).
l3C-n.m.r.( 1 OOMHz)S(DMSO): 170.01 (PhCH(OH)CH2CO-), 145.37, 139.50, 128.60, 
128.29, 127.99, 126.79, 126.01, 125.69 (aromatic carbons), 69.66 (PhCH(OH)CH2CO-), 
45.70 (-NHCH2CH2Ph), 35.18 (PhCH(OH)CH2CO-).
Note: The -NHCH2CH2Ph signal is obscured by the DMSO signal.
Mass spectrum: [M+H] 4 found: 270.1200 CnH 20NO2 requires 270.14927, [M+H-H20] 
found 252.0268 C nH 18NO requires 252.13873
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Ar-((jRAST)-2-Hvdroxy-2-phenvIacetylVL-leucine methyl ester (27a)
Thionyl chloride (5.84ml, 0.08mol) was cautiously added to methanol (200ml) which was 
stirring at 0 °C. 7V-((i?/iS)-2-Hydroxy-2-phenylacetyl)-L-leucine (5.3g, 0.02mol) was then 
added to the reaction mixture in portions. The reaction was allowed to procced at room 
temperature overnight, the excess thionyl chloride and methanol distilled off and the residue 
dissolved in ethyl acetate. The organic phase was washed with 10% sodium hydrogen 
carbonate solution, water, 5% hydrochloric acid, water and dried. The solvent was removed 
in vacuo and the resultant oil purified by flash chromatography on silica gel [petroleum 
ether/ethyl acetate (6:4) ] to yield the title compound as a yellow oil (4.8g, 8 6 %).
Spectroscopic analysis
i.r. vmax(CHCl3): 3422 (OH), 1730 (ester C=0), 1635 (amide C=0), 1280, 1064, 1028cm'1.
1H-n.m.r.(400MHz)5(CDCl3): 0.81 (12H, m, -NHCH(CH2CH(CH3)2)C 0 2CH3), 1.48-1.61 
(6H, m, -NHCH(CH2CH(CH3)2)C 0 2CH3 and -NHCH(CH2CH(CH3)2)C 0 2CH3), 3.41 & 
3.66 (6H, 2 diastereomeric singlets, -NHCH(CH2CH(CH3)2)C 0 2CH3), 4.49-4.56 (2H, m, 
-NHCH(CH2CH(CH3)2)C 0 2CH3), 4.94-4.97 (2H, m, PhCH(OH)CO-), 7.13 (2H, d, 
J=8.36Hz, -NH), 7.22-7.36 (10H, m, ArH).
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13C-n.m.r.(100MHz)5(CDCl3): 173.27, 172.63, 172.37 (-M iCH(CH 2CH(CH3)2)C 0 2CH3 
and PhCH(OH)CO-), 139.35, 139.13, 128.38, 128.29, 128.17, 128.03, 126.76, 126.41 
(aromatic carbons), 73.83 (PhCH(OH)CO-), 52.16, 52.10,
(-NHCH(CH2CH(CH3)2)C 0 2CH3), 50.38, 50.31 (-NHCH(CH2CH(CH3)2)C 0 2CH3), 40.91, 
40.85 (-NHCH(CH2CH(CH3)2)C 0 2CH3), 24.60 (-NHCH(CH2CH(CH3)2)C 0 2CH3), 22.56, 
21.51 (-NHCH(CH2CH(CH3)2)C 0 2CH3),
Af-((/?Ay)-2-HYdi oxv-2-nhenvlacetvl)-L-phenvlaIaninc methyl ester (27b)
Thionyl chloride (5.84ml, 0.08mol), was cautiously added to methanol (200ml) which was 
stirring at 0°C. -/V-((7?AS)-2-Hydroxy-2-phenylacetyl)-L-phenylalanine (5.98g, 0.02mol) was 
then added to the reaction mixture in portions. The reaction was allowed to proceed at 
room temperature overnight, the excess thionyl chloride and methanol distilled off and the 
resultant dissolved in ethyl acetate. The organic phase was washed with 10% sodium 
hydrogen carbonate solution, water, 5% hydrochloric acid, water and dried. The solvent 
was removed in vacuo and recrystallization of the resultant crude product from ethyl 
acetate/petroleum ether 40-60 furnished the title compound as a white crystalline solid 
(5.13g, 82%).
in.p. 98-100°C (uncorrected).
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Spectroscopic analysis
i.r. vmax(KBr): 3474 (OH), 3358 (NH), 1730 (ester C=0), 1657 (amide O O ), 1506, 1452, 
1435, 1382, 1289, 1213, 1176, 1119, 1083cm'1.
1H-n.m.r.(400MHz)5(CDCl3): 2.95-3.11 (4H, m, -NHCH(CH2Ph)C 02CH3), 3.64 & 3.66 
(6H, 2 diastereomeric singlets, -NHCH(CH2Ph)C 02CH3), 4.76-4.81 (2H, m, 
-NHCH(CH2P h)C 02CH3), 4.94 (2H, s, PhCH(OH)CO-), 6.95-6.97 (2H, m, -NH), 7.14- 
7.30 (20H, m, ArH).
13C-n.m.r.(100MHz)5(CDCl3): 172.23, 172.03, 171.77 (-NHCH(CH2Ph)C02CH3 and 
PhCH(OH)CO-), 139.10, 138.95, 135.46, 135.27, 129.10, 128.97, 128.64, 128.38, 128.17, 
126.92, 126.76, 126.49 (aromatic carbons), 73.98, 73.77 (PhCH(OH)CO-), 52.90, 52.69 
(-NHCH(CH2Ph)C 02CH3), 52.31, 52.26 (NHCH(CH2Ph)C 02CH3), 37.58, 37.46 
(-NHCH(CH2P h)C 02CH3).
/V-((.RAy)-0-Methanesulphonvl-2-hvdroxv-2-phcnvlacetvl)-L-leucine methyl ester (28a)
Methanesulphonyl chloride (2.32ml, 0.03mol) was added to a solution of N-((R/S)-2- 
hydroxy-2-phenylacetyl)-L-leucine methyl ester (2.79g, mol) and triethylamine (3.62ml,
0.026mol) in dichloromethane (150ml) at 0°C. The reaction was stirred at this temperature 
for 2hr, the dichloromethane evaporated and the residue taken up in ethyl acetate. The 
organic layer was washed with ice water, cold 1M hydrochloric acid, saturated sodium 
bicarbonate and dried. The solvent was removed in vacuo and precipitation from ethyl 
acetate/petroleum ether 40-60 yielded the title compound as a white crystalline solid (2.82g, 
79%).
m.p. 50-52°C.
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Spectroscopic analysis
i.r vmax(CHCl3): 3372 (NH), 1732 (ester C=0), 1523, 1455, 1412, 1208cm'1.
1H-n.m.r.(400MHz)5(CDCl3): 0.89-0.97 (12H, m, -NHCH(CH2CH(CH3)2)C 0 2CH3), 1.59- 
1.73 (6H, m, -NHCH(CH2CH(CH3)2)C 0 2CH3 , and -NHCH(CH2CH(CH3)2)C 0 2CH3), 2.84 
& 2.95 (6H, 2 diastereomeric singlets, PhC H (0S 0 2CH3)C 0-), 3.73 (6H, 2 diastereomeric 
singlets, -NHCH(CH2CH(CH3)2)C 0 2CH3), 4.62-4.68 (2H, m,
-NHCH(CH2CH(CH3)2)C 0 2CH3), 5.92 (2H, s, PhC H (0S 0 2CH3)C0-), 6.90 (2H, d, 
J=8.36Hz, -NH), 7.40-7.50 (10H, m, ArH).
13C-n.m.r.(100MHz)5(CDCl3): 172.68, 172.56 (-NHCH(CH2Ph)C 02CH3), 166.72, 166.67 
(PhCH(0 S 0 2CH3)C 0-), 133.73, 129.96, 129.84, 129.06, 129.03, 128.99, 128.06, 127.67, 
127.56 (aromatic carbons), 81.20 PhC H (0S03CH3), 52.39, 52.34
(-NHCH(CH2CH(CH3)2C 0 2CH3), 50.75, 50.71, (-NHCH(CH2CH(CH3)2)C 0 2CH3), 41.07, 
40.98 (-NHCH(CH2CH(CH3)2)C 0 2CH3), 39.31, 39.16, (PhC H (0S0 2CH3), 24.75 
(-NHCH(CH2CH(CH3)2)C 0 2CH3), 22.69, 21.60 (-NHCH(CH2CH(CH3)2)C 0 2CH3).
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Ar-((j?Ay)-0-Methanesulphonvl-2-hvdroxv-2-phenvlacetvl)-L-phenylalanine
methyl ester (28b)
Methanesulphonyl chloride (2.32ml, 0.03mol) was added to a solution of N-((R/S)-2- 
hydroxy-2-phenylacetyl)-L-phenylalanine methyl ester (3.13g, 0.01 mol) and triethylamine 
(3.62ml, 0.026mol) in dichloromethane (150ml) at 0°C. The reaction was stirred at this 
temperature for 2 hr, the dichloromethane evaporated and the residue taken up in ethyl 
acetate. The organic layer was washed with ice water, cold 1M hydrochloric acid, saturated 
sodium bicarbonate and dried. The solvent was removed in vacuo and precipitation from 
ethyl acetate/petroleum ether yielded the title compound as a white crystalline solid (2.97g, 
76%).
m.p. 114-116°C (uncorrected).
O
OCH
Spectroscopic analysis
i.r vmax(KBr): 3290 (NH), 1746 (ester C=0), 1665 (amide O O ), 1542, 1496, 1452, 1439, 
1355, 1280, 1225, 1196, 1178, 1123cm'1
1H-n.m.r.(400MHz)5(CDCl3): 2.87 (6H, s, PhC H (0S02CH3)C0-), 3.06 (2H, dd,
JA=14.28Hz, Jb=7.4Hz, -NHCH(CH2Ph)C 02CH3), 3.24 (2H, dd, JA=14.28Hz, JB=5.44Hz, 
-NHCH(CH2Ph)C 02CH3), 3.77 (6H, s, -NHCH(CH2P h)C 02CH3), 4.89-4.95 (2H, m, 
-NHCH(CH2Ph)C 02CH3), 5.85 (2H, s, PhC H (0S0 2CH3)C 0-), 6.84 (2H, d, J=7.88Hz, 
-NH), 7.23-7.40 (20H, m, ArH).
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13C-n.m.r.(100MHz)ô(CDCl3): 171.25 (-NHCH(CH2Ph)Ç 02CH3), 166.45
(PhC H (0S 02CH3)C0-), 135.34, 133.54, 129.82, 129.21, 129.01, 128.67, 127.55, 127.23 
(aromatic carbons), 81.09 (PhÇH (0S02CH3)C0-), 52.98 (-NHCH(CH2Ph)C02ÇH3), 52.60 
(-NHCH(CH2Ph)C 02CH3), 39.19 (PhC H (0S02ÇH3)C0-), 37.52 
(-NHCH(CH2Ph)C 02CH3).
A/-((/?/.y)-0--iyietlianesulphonvI-2-hvdroxv-2-nhciivlacetvl) phenethylamide (28c)
Methanesulphonyl chloride (2.32ml, 0.03mol) was added to a solution of N-((R/S)-2- 
hydroxy-2-phenylacetyl) phenethylamide (2.55g, O.Olmol) and triethylamine (3.62ml,
0.026mol) in dichloromethane (150ml) at 0°C. The reaction was stirred at this temperature 
for 2hr, the dichloromethane evaporated and the residue taken up in ethyl acetate. The 
organic layer was washed with ice water, cold 1M hydrochloric acid, saturated sodium 
bicarbonate and dried. The solvent was removed in vacuo and recrystallization of the crude 
product from ethyl acetate/petroleum ether yielded the title compound as a white crystalline 
solid.
m.p. 92-94°C (uncorrected)
S
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Spectroscopic analysis
i.r. vmax(KBr): 3343 (NH), 1658 (amide C=0), 1534, 1496, 1456, 1348, 1279, 1199, 1172, 
1086, 1075, 1039cm'1.
^ -n .m .r .(400MHz)0(CDC13) : 2.78 (6H, s, PhCH(OSOCH3)CO-), 2.79-2.86 (4H, m, 
-NHCH2CH2Ph), 3.54-3.60 (4H, m, -NHCH2CH2Ph), 5.83 (2H, s, PhC H (0S02CH3)C0-), 
6.53 (2H, s, -NH), 7.14-7.39 (20H, m, ArH).
13C-n.m.r.(100MHz)5(CDCl3): 166.66 (PhC H (0S02CH3)C 0-), 138.22, 133.89, 129.84, 
129.05, 128.73, 127.67, 126.59 (aromatic carbons), 81.40 (PhC H (0S02CH3)C0-), 40.60 
(-NHCH2CH2Ph), 39.18 (PhCH (0S02CH3)C0-), 35.28 (-NHCH2CH2Ph).
iV-dRASyi-Acethio-l-phenvlacetvQ-L-leucine methyl ester (29a)
Potassium thioacetate (2.86g, 0.025mol) was added to a solution of N-((R/S)-0- 
methanesulphonyl-2-hydroxy-2-phenylacetyl)-L-leucine methyl ester (1.79g, 0.005mol) in 
dry dimethylformamide (50ml). The reaction mixture was stirred at room temperature for 5 
days under a positive N2 pressure. The reaction mixture was extracted with ethyl acetate, 
washed with brine, dried and the solvent evaporated. The residue was taken up in 
dichloromethane and treated with activated charcoal to remove much of the brown colour. 
Purification by flash chromatography on silica gel [chloroform] furnished the title compound 
as a yellow waxy solid (0.92g, 55%).
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Spectroscopic analysis
i.r. vmax(CHCl3): 3324 (NH), 1744 (ester C=0), 1694 (amide C=0), 1536, 1496, 1469, 
1453, 1437, 1354, 1275, 1205, 1135cm'1.
1H-n.m.r.(400MHz)5(CDCl3): 0.83-0.91 (12H, m, -NHCH(CH2CH(CH3)2)C 0 2CH3), 1.45- 
1.65 (6H, m, -NHCH(CH2CH(CH3)2)C0 2CH3 and -NHCH(CH2CH(CH3)2)C 0 2CH3), 2.36 
(6H, s, PhCH(SCOCH3)CO-), 3.66 & 3.70 (6H, 2 diastereomeric singlets, 
-NHCH(CH2CH(CH3)2)C 0 2CH3), 4.54-4.61 (2H, m, -NHCH(CH2CH(CH3)2)C 0 2CH3), 
5.25 & 5.26 (2H, 2  diastereomeric singlets, PhCH(SCOCH3)CO-), 6.55 (2H, m, -NH ), 
7.26-7.40 (10H, m, ArH).
13C-n.m.r.(100MHz)5(CDCl3): 194.53 (PhCH(SCOCH3)CO-), 172.91, 172.84 (- 
NHCH(CH2CH(CH3)2)C 0 2CH3), 168.68 (PhCH(SCOCH3)CO-), 135.29, 122.76, 128.53, 
128.49, 128.28, 128.24 (aromatic carbons), 52.22, 52.17 (-
NHCH(CH2CH(CH3)2)C 0 2CH3), 51.63, (-PhCH(SCOCH3)CO-), 51.15, 51.11 (- 
NHCH(CH2CH(CH3)2)C 0 2CH3), 41.33, 41.16 (-NHCH(CH2CH(CH3)2)C 0 2CH3), 30.00 
(PhCH(SCOCH3)CO-), 24.70
(-NHCH(CH2CH(CH3)2)C 0 2CH3), 22.70, 21.72 (-NHCH(CH2CH(CH3)2)C 0 2CH3).
Mass spectrum: [M+H]" found: 338,0021 CnH 24N 0 4 S requires 338.14242, [M+H- 
CH2CO]+ found 296.0193 Ci5H22N 0 3S requires 296.13188
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A^ÆAS>2-Accthio-2-r)henvlacetyl)-L-phenvlalanine methyl ester (29b)
Potassium thioacetate (2.86g, 0.025mol) was added to a solution of N-((R/S)-0- 
methanesulphonyl-2-hydroxy-2-phenylacetyl)-L-phenylalanine methyl ester (l-95g,
0.005mol) in dry dimethylformamide (50ml). The reaction mixture was stirred at room 
temperature for 5 days under a positive N2 pressure. The reaction mixture was extracted 
with ethyl acetate, washed with brine, dried and the solvent evaporated. The residue was 
taken up in dichloromethane and treated with activated charcoal to remove much of the 
brown colour. Purification by flash chromatography on silica gel [chloroform] gave the title 
compound as a white solid (1.05g, 57%). 
m.p. 98-100°C (uncorrected).
H 3 C
H
N
O
OCH
Spectroscopic analysis
i.r. vmax(KBr): 3309 (NH), 1740 (ester O O ), 1655 (amide C=0), 1530, 1495, 1452, 1432, 
1351, 1315, 1278, 1230, 1174, 1132, 1102cm'1.
1H-n.m.r.(400MHz)5(CDCl3): 2.33 & 2.34 (6H, 2 diastereomeric singlets,
PhCH(SCOCH3)CO-), 3.00-3.20 (4H, m, -NHCH(CH2Ph)C02CH3), 3.70 & 3.73 (6H, 2 
diastereomeric singlets, -NHCH(CH2Ph)C02CH3), 4.81-4.88 (2H, m, 
-NHCH(CH2P h)C 0 2CH3), 5.18 (2H, 2 diastereomeric singlets, PhCH(SOCH3)CO-), 6.41 & 
6.49 (2H, 2 distereomeric doublets, J=7.64Hz, -NH), 6.81-7.34 (20H, m, ArH).
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13C-n.m.r.(100MHz)ô(CDCl3): 194.54 (PhCH(SÇOCH3)CO-), 172.87, 172.80, 
(-NHCH(CH2Ph)Ç0 2CH3), 168.71 (PhCH(SCOCH3)ÇO-), 135.65, 135.33, 129.28, 129.20, 
128.96, 128.85, 128.60, 128.56, 128.53, 128.47, 128.41, 128.38, 127.03 (aromatic 
carbons), 53.54, 53.45 (-NHCH(CH2Ph)C 02ÇH3), 52.42, 52.37 (PhÇH(SCOCH3)CO-), 
51.58 (-NHÇH(CH2Ph)C 02CH3), 37.60, 37.46 (-NHCH(CH2Ph)C 02CH3), 30.08
(PhCH(SCOCH3)CO-).
Mass spectrum: [M+H]+found: 372.0507 C2oH22N 0 4 S requires 372.12678, [M+Na]+, found 
394.10187 C20H2iNO4SNa requires 394.10896, [M+H-CH2C O f found 329.9734 
C18H20NO3S requires 330.11624
A^-((/?/^)-2-Acethio-2-phenylacetv0 phenethylamide (29c)
Potassium acetate (2 .8 6 g, 0.025mol) was added to a solution of N-((R/S)-0- 
methanesulphonyl-2-hydroxy-2-phenylacetyl) phenethylamide (1.76g, 0.005mol) in dry 
dimethylformamide (50ml). The reaction mixture was stirred at room temperature for 5 
days under a positive N2 pressure. The reaction mixture was extracted with ethyl acetate, 
washed with brine, dried and the solvent evaporated. The residue was taken up in 
dichloromethane and treated with activated charcoal to remove much of the brown colour. 
Purification by flash chromatography on silica gel [chloroform] yielded the title compound 
as a white solid (0.84g, 54%) 
m.p. 82-84°C.
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Spectroscopic analysis
i r. vmax(KBr): 3346 (NH), 1690, 1658 (amide O O ), 1530, 1497, 1454, 1356, 1313, 1288, 
1221, 1198, 1138, 1108, 1075, 1029cm'1.
1H-n.m.r.(400MHz)5(CDCl3): 2.32 (6H, s, PhCH(SCOCH3)CO-), 2.74-2.80 (4H, m, 
-NHCH2CH2Ph), 3.42-3.56 (4H, m, -NHCH2CH2Ph), 5.13 (2H, s, PhCH(SCOCH3)CO-), 
6.02 (2H, s, -NH), 7.06-7.35 (20H, m, ArH)
13C-n.m.r.(100MHz)5(CDCl3): 194.53 (PhCH(SCOCH3)CO-), 168.81
(PhCH(SCOCH3)CO-), 138.52, 135.84, 128.84, 128.73, 128.53, 128.50, 128.26, 126.42 
(aromatic carbons), 52.07 (PhCH(SCOCH3)CO-), 41.15 (-NHCH2CH2Ph), 35.29 
(-NHCH2CH2Ph), 30.08 (PhCH(SCOCH3)CO-).
Attempted preparation of A^ifflAVV-l-thio-l-phenylacetyl-L-leucine
1M NaOH (10ml) was added to a stirred solution of 7v/’-((i?/1S}-2-acethio-2-phenylacetyl)-L- 
phenylalanine methyl ester (1.74g, 0.005mol) in methanol (12ml). After lhr the reaction 
was cooled on an ice bath and acidified with dilute hydrochloric acid. The methanol was 
evaporated and the solution allowed to cool. The resultant precipitate was filtered and 
dried. Attempted purification of the precipitate by recrystallization from ethanol/water did 
not yield the desired product and the reaction was not investigated further.
Attempted preparation of 7V-(f/?AST)-2-thio-2-phenYlacetyi-l/-phenvlalanine
1M NaOH (10ml) was added to a stirred solution o f 7V-((/?/5 )-2 -acethio-2 -phenylacetyl)-L- 
phenylalanine methyl ester ( 1.9lg, 0.005mol) in methanol (12ml). After lhr the reaction 
was cooled on an ice bath and acidified with dilute hydrochloric acid. The methanol was 
evaporated and the solution allowed to cool. The resultant precipitate was filtered and
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dried. Attempted purification of the precipitate by recrystallization from ethanol/water did 
not yield the desired product and the reaction was not investigated further.
Af-((/?Ay)-2-Thio-2-phenvlacetvQ phenethylamide (30)
1M NaOH (10ml) was added to a stirred solution o f JV’-((/?AS)-2-acethio-2-phenylacetyl) 
phenethylamide (1.56g, 0.005mol) in methanol (12ml). After lhr the reaction was cooled on 
an ice bath and acidified with dilute hydrochloric acid. The methanol was removed in 
vacuo, and the solution allowed to cool. The resultant precipitate was filtered and dried. 
Recrystallization from acetone/«-hexane yielded the title compound as a white crystalline 
solid (0.69g, 51%). 
m.p. 202-204°C.
Spectroscopic analysis
i.r. vmax(KBr): 3293 (NH), 1652 (amide C=0), 1534, 1495, 1452, 1313, 1227, 1197cm'1.
1H-n.m.r.(400MHz)5(DMSO): 2.64-2.68 (4H, m, -NHCH2CH2Ph), 3.25-3.30 (4H, m, 
-NHCH2CH2Ph), 4.74 (2H, s, PhCH(SH)CO-), 7.08-7.40 (20H, m, ArH), 8.39 (2H, t, 
J=5.66Hz, -NH).
196
l3C-n.m.r.(100MHz)S(DMSC)): 168.57 (PhCH(SH)CO-), 139.18, 136.80, 128.64, 128.52, 
128.40, 128.25, 128.02, 126.03 (aromatic carbons), 58.44 (PhCH(SH)CO-), 40.73 
-NHCH2CH2Ph), 34.90 (-NHCH2CH2Ph).
Mass spectrum: [M+H]" found: 272.1298 CjsHigNOS requires 272.1108
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N-BOC-D-leucine methyl ester Ola)
Di-feri-butyldicarbonate (2.18g, O.Olmol) in dichloromethane (20ml) was added slowly to a 
solution o f L-leucine methyl ester (1.82g, O.Olmol) and triethylamine (1.4ml, O.Olmol) in 
dichloromethane (50ml) at 0°C. After 30min the temperature was raised to room 
temperature and the reaction continued for 4hr. The reaction mixture was washed with 
cold 2.5% hydrochloric acid (2x10ml), 10% sodium hydrogen carbonate (2x25ml), water 
and dried. Purification of the product by passing through a pad of silica gel [diethyl ether] 
yielded the title product as a clear oil (2.26g, 92%).
<H 3 C ) 3 C
o
Spectroscopic analysis
i.r. vmax(CHCl3): 3376 (NH), 1760 (ester C=0), 1501, 1368cm'1.
1H-n.m.r.(400MHz)8(CDCl3): 0.94 (6H, m, -NHCH(CH2CH(CH3)2)C 0 2CH3), 1.45 (9H, s, 
((H3C)3COCO-), 1.56-1.74 (3H, m, -NHCH(CH2CH(CH3)2)C 0 2CH3 and 
-NHCHCH(CH2CH(CH3)2)C 0 2CH3), 3.73 (3H, s, -NHCH2CH(CH3)2)C 0 2CH3), 4.32 (1H, 
m, -NHCH(CH2CH(CH3)2)C 0 2CH3), 5.11 (1H, d, J=7.4Hz, NH).
13 C-n. m . r . (1 00MHz)5(CDC13) : 173.84 (-NHCH(CH2CH(CH3)2)C 0 2CH3), 155.28
((H3C)3COCO-), 79.48 ((H3C)3COCO-) 51.82 (-NHCH(CH2CH(CH3)2)C 0 2CH3), 45.98 (- 
NHCH(CH2CH(CH3)2)C 0 2CH3), 41.50 (-NHCH(CH2CH(CH3)2)C 0 2CH3) 28 09, 
((H3C)3COCO-), 24.54 (-NHCH(CH2CH(CH3)2)C 0 2CH3), 22.62, 21.64 
(-NHCH(CH2CH(CH3)2)C 0 2CH3).
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iV-BOC-D-phenvIalanine methyl ester (31b)
Di-fert-butyldicarbonate (2.18g, O.Olmol) in dichloromethane (20ml) was added slowly to a 
solution o f L-phenylalanine methyl ester hydrochloride (2 .16g, O.Olmol) and triethylamine 
(1.4ml, O.Olmol) in dichloromethane (50ml) at 0°C. After 30min the temperature was raised 
to room temperature and the reaction continued for 4hr. The reaction mixture was washed 
with cold 2.5% hydrochloric acid (2x10ml), 10% sodium hydrogen carbonate (2x25ml), 
water and dried. Purification of the product by passing through a pad of silica gel [diethyl 
ether] yielded the title product as a waxy solid (2.63g, 94%).
Spectroscopic analysis
i.r. vmax(CHCl3): 3370 (NH), 1740 (ester C=0), 1682, 1605, 1504, 1169, 1055cm'1.
1H-n.m.r.(400MHz)5(CDCl3): 1.41 (9H, s, ((H3C)3COCO-), 3.00-3.13 (2H, m, 
-NHCH(CH2P h)C 02CH3), 3.68 (3H, s, -NHCH(CH2P h)C 0 2CH3), 4.58 (1H, m 
-NHCH(CH2P h)C 02CH3), 5.10 (1H, d, J=7.88Hz, -NHCH(CH2Ph)C02CH3), 7.08-7.30 
(5H, m, ArH).
13C-n.m.r.(400MHz)5(CDCl3): 172.18 (-NHCH(CH2P h)C 02CH3), 154.91 
((H3C)3COCO-), 135.88, 129.13, 128.25, 126.78 (aromatic carbons), 79.61 
((H3C)3COCO-) 51.97 (-NHCH(CH2Ph)C 02CH3), 46.02 (-NHCH(CH2Ph)C02CH3), 38.09 
(-NHCH(CH2P h)C 0 2CH3), 28.09 ((H3C)3COCO-).
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7V-B0C-D-leucinal (32a)
A solution of 1M diisobutylaluminium hydride in hexane (25ml, 0.025mol) was added 
dropwise to a solution of A'-BOC-L-leucine methyl ester (2.45g, O.Olmol) in dry toluene 
(100ml) at -70°C under an atmosphere o f N2. After 20min the reaction was quenched by the 
addition o f methanol (4ml) and Rochelle salt solution was added. After the reaction was 
allowed to warm to room temperature the mixture was extracted with ether (3x50ml). The 
ether layers were dried and concentrated under vacuum. The crude product was passed 
through a short pad o f silica gel [petroleum ether 40-60/ethyl acetate (9:1)] to yield the title 
product112 as a colourless oil (1.03g, 48%).
. 0
<H 3 C >3C
0
Spectroscopic analysis
i.r. vmax(CHCl3): 3344 (NH), 1697 (C=0), 1513, 1367, 1252, 1169cm'1.
1H-n.m.r.(400MHz)5(CDCl3): 0.96 (6H, d, J=6.4Hz, -NHCH(CH2CH(CH3)2)CHO), 1.45 
(9H, s, ((H3C)3COCO-), 1.60-1.83 (3H, m, -NHCH(CH2CH(CH3)2)CHO and 
-NHCH(CH2CH(CH3)2)CHO), 4.24 (1H, m, -NHCH(CH2CH(CH3)2)CHO), 5.09 (1H, m, - 
NH), 9.59 (1H, s, -NHCH(CH2CH(CH3)2)CHO).
13C-n.m.r.(100MHz)S(CDCl3): 200.46 (-NHCH(CH2CH(CH3)2)CHO), 155.12
((H3C)3COCO-) 79.91 ((H3C)3COCO-) 58.29 (-NHCH(CH2CH(CH3)2)CHO), 37.92 
(-NHCH(CH2CH(CH3)2)CHO), 28.17 ((H3C)3COCO-), 22.99 
(-NHCH(CH2CH(CH3)2)CHO), 22.38, 21.80 (-NHCH(CH2CH(CH3)2)CHO).
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A'-BOC-D-phenylalaninal (32b)
A solution o f 1M diisobutylaluminium hydride in hexane (25ml, 0.025mol) was added 
dropwise to a solution of A^-BOC-L-phenylalanine methyl ester (2.79g, O.Olmol) in dry 
toluene (100ml) at -70°C under an atmosphere of N2. After 2 0 min the reaction was 
quenched by the addition of methanol (4ml) and Rochelle salt solution was added. After the 
reaction was allowed to warm to room temperature the mixture was extracted with ether 
(3x50ml). The ether layers were dried and concentrated under vacuum. The crude product 
was passed through a short pad of silica gel [petroleum ether/ethyl acetate (9:1)] to yield the 
title product158 as a white solid. (1.32g, 53%).
(H C) C
V 3 3
O
H
N
0
i.r. vmax(KBr): 3423 (NH), 1688 (O O ), 1519, 1369, 1168, 1074cm'1.
1H-n.m.r.(400MHz)5(CDCl3): 1.43 (9H, s, ((H3C)3COCO-), 3.11 (2H, d, J=6 .88Hz, 
-NHCH(CH2Ph)CHO), 4.42 (1H, m, -NHCH(CH2Ph)CHO), 5.07 (1H, d, J=5.4Hz, -NH), 
7.16-7.33 (5H, m, ArH), 9.63 (1H, s, -NHCH(CH2Ph)CHO).
13C-n.m.r.(100MHz)5(CDCl3): 199.39 (-NHCH(CH2Ph)CHO), 154.96 ((H3C)3COCO-), 
135.74, 129.29, 128.41, 127.02 (aromatic carbons), 60.72, (-NHCH(CH2Ph)CHO), 35.40 
(-NHCH(CH2Ph)CHO), 28.29 ((H3C)3COCO-).
Note: The (H3C)3COCO- signal is obscured by the CDC13 signal.
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Attempted preparation of (3(iS7/?)-4/0-Ar-BOC-4-ainino-3-hvdroxY-6-methv[heptene
A 1M solution of vinylmagnesium bromide in THF (20ml, 0.02mol) was added dropwise to 
a solution o f freshly prepared BOC-D-leucinal (2.15g, O.Olmol) in THF (25ml) which was 
stirring at -78°C under an atmosphere of N 2. After the additon was complete the reaction 
mixture was allowed to warm to room temperature and poured into a saturated solution of 
ammonium chloride. The resulting slurry was extracted with ether (3x50ml) and the 
combined ether extracts dried and the solvent evaporated. Attempted purification by flash 
chromatography on silica gel [toluene / ethyl acetate (8 :2 )] did not yield the desired product 
and the reaction was not investigated further.
Attempted preparation of (3(iS//?)-47?)-./V-BOC-4-amino-3-hvdroxv-5-Pheiivlpentene
A 1M solution o f vinylmagnesium bromide in THF (20ml, 0.02mol) was added dropwise to 
a solution o f freshly prepared BOC-D-phenylalaninal (2.49g, O.Olmol) in THF (25ml) which 
was stirring at -78°C under an atmosphere of N2. After the additon was complete the 
reaction mixture was allowed to warm to room temperature and poured into a saturated 
solution of ammonium chloride. The resulting slurry was extracted with ether (3x50ml) and 
the combined ether extracts dried and the solvent evaporated. Attempted purification by 
flash chromatography on silica gel [toluene / ethyl acetate (8 :2 )] did not yield the desired 
product and the reaction was not investigated further.
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CHAPTER FIVE 
BIOLOGICAL RESULTS
Introduction
A standard assay has been developed using a synthetic fluorogenic substrate to test 
the activity o f the compounds that were prepared during the course of this study. Many 
assays for metalloprotease substrates have been based on synthetic oligopeptides in which 
the scissile bond is an amide bond with a fluorogenic species. 162’163 In this assay activity was 
determined by measuring the release of 7-amino-4-methyl-coumarin (a fluorescent species), 
from the substrate L-leucine-7-amido-4-methyl-coumarin (L-leu-AMC) (fig. 5.1) which does 
not fluoresce upon ezymatic hydrolysis by the aminopeptidase isolated from the rodent 
malarial parasite P. chabaudi. This aminopeptidase is identical to that found in the human 
malarial parasite P. falciparum  and thus results obtained in this study can be extrapolated 
directly to the human malaria parasite. The use of rodent malarial parasites rather than 
human malarial parasites also greatly facilitates research. The malarial aminopeptidase 
shows a high degree of activity for L-leu-AMC .20 Cleavage o f the amide bond by the 
enzyme results in the release of free AMC (fig. 5.2). In the presence of a compound which 
competes for binding sites on the enzyme there is a reduction in the amount of L-leu-AMC 
cleaved, less free AMC is released and thus less fluorescence is observed.
O
0
H N
2
CH
CH
CH
Fig. 5.1 L-Ieucine-7-amido-4-methyl-coumarin.
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Fig. 5.2 Hydrolysis of L-leu-AMC by aminopeptidase with liberation of fluorescent
7-amino-4-methylcouniarin.
In this assay a crude extract o f the plasmodium  aminopeptidase was added to 
solutions which had a concentration o f 10|iM of the compounds to be tested and a 
concentration of 10|aM of L-leu-AMC in a final volume of 1ml of phosphate buffered saline 
(PBS) at pH 7.2. The resulting solutions were incubated at 37°C for 30 minutes. The 
enzyme activity was then quenched by the addition of 200^L o f 10% acetic acid solution. 
The amount o f liberated AMC was determined using a fluorimeter (excitation 370nm, 
emission 440nm). The results tabulated below are expressed as fluorescent intensity at a 
concentration of 10pM (IF @ lOpM), as the percentage inhibition o f enzyme activity at this 
concentration, and as the concentration o f inhibitor required to cause a decrease in enzyme 
activity of 50%> (IC50) relative to a positive control (IF @ 10|jM=195) which contained only 
the parasite extract and the L-leu-AMC. All assays were performed in duplicate and the 
mean result taken. Results for bestatin at a concentration o f lpM  were also recorded
Note: Some of the compounds tested were activators rather than inhibitors of enzyme 
activity and these are labelled with an asterisk (*) in the tables. For these compounds the
(IF = 0).
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results are expressed as the percentage activation o f enzyme activity. The IC50 value was 
not appplicable to these compounds and thus was not calculated.
5.1 ./V-fraws-Cinnamovl and related derivatives
Table 5.1 Results of biological assay for jV-fra/is-cinnamoyl and related derivatives.
Compound IF @ IO^ iM % Inhibition / 
Activation @ 10pM
IC50 (M-M)
la 123 36.9 13.5
lb 117 40 12.5
lc 70.2 64 7.8
Id 120 38.5 13
le 104 46.7 10.7
If 119 40 12.5
lg 66.3 66 7.6
lh 60.5 69 7.2
li 50.7 74 6.8
lj 56.6 71 7
2 105 46.2 10.8
3a 67 65.6 7.6
3b 52.7 73 6.8
3c 47.2 75.8 6 .6
5 93.6 52 9.6
6a* 292 49.7 N/A
6b 55 71.8 7
* Activator
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The results of the biological assay for the 7V-/ra«s-cinnamoyl derivatives show that 
these compounds generally behave as moderate inhibitors with the highest inhibition being 
observed for N-trans-3-nitrocinnamoyl-glycine ethyl ester (3c) (IC5o=6 .6 [iM). Their activity 
is probably due to their structural similarity to bestatin which allows them to “fit in” to the 
active site. It is assumed that the amide carbonyl could form a monodentate ligand with the 
active site metal by analogy with the model proposed for bestatin. The electrophilic active 
site metal may be capable of interacting positively with the electron density around the - 
C=C- bond. The phenyl and carboxylic acid groups may also be able to interact favourably 
with the active site as described for bestatin.
The level o f inhibition recorded for the jV-fra«s,-3-nitrocinnamoyl glycine derivatives 
(3a-c) (IC50=7.7-6.6[iM) is significantly higher than their A/-/ran.v-cinnamoyl glycine 
derivative counterparts (la-c) (1C5o=13.5-7.8[jM). It is known that bestatin analogues with 
an electron-withdrawing group in the para  position have higher activities than bestatin and 
that ¿»-nitrobestatin has at least five times the activity o f bestatin. Although in our case the 
nitro group is in the met a position it still seems to exert an effect by increasing inhibition.
Little difference is observed between the A^ram-cinnamoyl derivatives of the 
different amino acids (la, ld-lf) with only the L-valine (le) derivative showing a slight 
improvement in inhibition (IC 5 o= 1 0 .7 |jM ) .  This is unexpected since the aminopeptidase has 
a preference for alkyl side chains such as those found in alanine and leucine. This may 
indicate that the 7V-/ram-cinnamoyl derivatives are not binding to the active site in a manner 
analogous to bestatin in which the leucine, alanine and isoleucine side chains show the 
greatest activity. The dipeptide N-trans-cinnamoyl glycylglycine (2) has similar activity to 
TV-iram'-cinnamoyl glycine. This would suggest that the enzyme does not have an extended 
binding site but has an affinity for dipeptide-sized molecular chains.
Modifications of the C-terminus have a pronounced effect on the activity of the N- 
trans-cinnamoyl derivatives. In general it is observed that the ester derivatives have a 
greater activity than the corresponding carboxylic acid derivatives. It is plausible that the 
ester groups facillitate binding to a hydrophobic subsite in the active site. The amide (li) 
and alcohol (lj) also show increased activity over the corresponding free carboxylic acid 
derivative (If). These results are contradictory to results for bestatin in which a free
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carboxylic acid is necessary for full activity. This again may indicate a different mode of 
binding for the A^-irara-cinnamoyl derivatives.
An interesting anomaly is observed for the Ar-2,3-dibromopropionyl derivatives (6a, 
6b) in which the L-leucine derivative (6b) acts as an inhibitor (IC5o-7 |iM) but the glycine 
derivative (6a) acts as an activator of enzyme activity (% activity @ 10[iM=49.7). Little is 
known about the phenomenon o f enzyme activation but it has been observed in some 
bestatin analogues. 164 Perhaps these compounds have the ability to bind to allosteric sites on 
the enzyme thus causing a conformational change in the active site which enhances enzyme 
activity. This is plausible since aminopeptidases tend to be large proteases, for example 
leucine aminopeptidase has a molecular weight of ~250,000.5° Most proteases are small 
monomeric enzymes of molecular weight 15,000 to 35,000. It may be that the smaller 
glycine derivative can bind to another site on the enzyme and that in binding to this site it 
enhances enzyme activity. The L-leucine derivative may be too large to fit into this 
proposed site, but still is able to fit into the active site and thus act as an inhibitor.
iV-/ra«s-4-Phenylbut-2-enoyl-L-leucine methyl ester (5) which has a greater 
structural similarity to bestatin than AL/ra/7.y-cinnamoyl-L-leucine methyl ester (lg) has 
unexpectedly a lesser activity. It is possible that the rigid -C=C- bond of the N-trans- 
cinnamoyl derivative holds the phenyl group in a fixed position to interact with a 
hydrophobic subsite in the active site. In the Ai-/mm-4-phenylbut-2-enoyl derivative there is 
free rotation around the benzylic methylene and the phenyl group is not so rigidly held in 
position.
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5.2 Ar-3,5-Dinitrobenzoyl derivatives
Table 5.2 Results of biological assay for 7V-3,5-dmitrobenzoyl derivatives.
Compound IF @ IO^ iM % Inhibition / 
Activation @ 10|iM
IC50
7a 70 64.1 7.8
7b 109 44.1 11.3
7c 72 63.1 7.9
7d 111.5 42.8 11.7
8 144 26.2 19.1
The results o f the biological assay again show the A^S-dinitrobenzoyl derivatives to 
be acting as moderate inhibitors of the malarial aminopeptidase. The highest inhibition is 
observed for A'-3,5-dinitrobenzoyl glycine (7a) (IC5o=7.8|jM) and 7V-3,5-dinitrobenzoyl-L- 
leucine (7c) (IC5o=7.9|aM). 7V-3,5-dinitrobenzoyl-L-alanine (7b) and 7V-3,5-dinitrobenzoyl- 
D-leucine (7d) had lesser activity. It is interesting to note that although the enzyme is 
specific for L-amino acids, the D-leucine derivative (7d) had a similar activity to the L- 
alanine derivative. The poorest activity was observed for the dipeptide derivative (8) and 
this again would point to the fact that the enzyme does not have an extended binding site but 
prefers to bind to dipeptide-sized molecular chains.
2 0 8
5.3 iV-Toluene-p-sulphonyl derivatives
Table 5.3 Results of biological assay for iV-toluene-p-sulphonyl derivatives.
Compound IF @ 10p.M % Inhibition / 
Activation @ IOjiM
ICso (p.M)
9a 74 62 8.1
9b 76 61 8.2
9c 94 51.8 9.7
9d 78 60 8.3
9e 72 63.1 7.9
9f 79 59.5 8.4
9g 142 27.2 18.4
9h 107 45.1 11.1
The results o f the biological assay for the iV-toluene-/?-sulphonyl derivatives again 
show that these compounds behave as moderate inhibitors o f the malarial aminopeptidase. 
Interestingly vV-toluene-/>sulphonyl-L-isoleucine methyl ester (9f) (1C5o= 8.4|J.M) and N- 
toluene-p-sulphonyl-L-isoleucine ethyl ester (9g) (IC50=18.4|j,M) show less activity than N- 
toluene-p-sulphonyl-L-isoleucine (9e) (IC5o=7.9|aM). This is a reversal of the trend 
observed for the previous two sets of compounds in which the esters appear to act as better 
inhibitors than the free carboxylic acid compounds. The differences observed may be due to 
a different mode o f binding to the enzyme, since unlike the previous two sets of compounds 
which have an amide linkage, compounds (9a-h) contain a sulphonamide bond.
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5.4 jV-3-NitrophthaloYl derivatives
Table 5.4 Results of biological assay for 7V-3-nitrophthaloyl derivatives.
Compound IF @ 10(aM % Inhibition / 
Activation @ IOjjM
IC50 (nM)
10a 104 46.7 10.7
10b 82 57.9 8.6
10c* 454 132.8 N/A
lOd* 441 126.2 N/A
lOe 78 60 8.3
lOf* 341 74.9 N/A
10g* 355 82.1 N/A
* Activator
The /V-3 -nitrophthaloyl derivatives exhibit very different results than the previously 
described compounds as one would expect from their very different structure. The free 
carboxylic acid derivatives (10a), (10b) and (10e) behave as weak inhibitors with the best 
inhibition is seen for the derivatives of L-leucine (10b) (IC 5o=8.6 |jM ) and L-isoleucine (lOe) 
(IC So=8.3mM).
The esters o f these compounds (10c, lOd, lOf, lOg) actually increase enzyme activity 
by 132.8%, 126.2%, 74.9% and 82.1% respectively at a concentration of lO^iM. These 
results are intriguing and these compounds may merit further study since there may be 
situations in which the enhancement o f aminopeptidase activity may be useful as a 
chemotherapeutic tool.
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5.5 Ai-Phenylureido derivatives
Table 5.5 Results of biological assay for 7V-phenylureido derivatives.
Compound IF @ lO^M % Inhibition / 
Activation @ 10pM
IC50 (jiM)
11a 80 59 8.5
l ib 82 57.9 8.6
11c 123 36.9 13.6
The biological results o f the TV-phenylureido derivatives show them to be weak 
inhibitors of the malarial aminopeptidase. The presence of a urea linkage does not seem to 
make a significant difference to the activity. The greatest activity is observed for N- 
phenylureido-L-alanine (11a) (IC5o=8.5|j.M) and /V-phenylureido-L-leucine (lib)
(IC50=8.6jiM).
5.6 iV-Chloroacetvl derivatives
Table 5.6 Results of biological assay for iV-Chloroacetyl derivatives.
Compound IF @ lOpM % Inhibition / 
Activation @ lOfiM
IC50
12a 140 28.2 17.7
12b 129 33.8 14.8
12c 115 41 12.2
12d 99.5 49 10.2
12e 154 21 23.8
13 103 47.2 10.6
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The W-chloroacetyl derivatives are weak inhibitors o f the malarial aminopeptidase. 
The highest activity was observed for 7V-chloroacetyl-L-leucine ethyl ester (12d) 
(IC5o=10.2|iM). The esters TV-chloroacetyl-L-leucine methyl ester (12c) (1C5o= 12.2jj.M) and 
./V-chloroacetyl-L-leucine ethyl ester (12d) (IC5o=10.2|iM) show higher activity than the 
corresponding free carboxylic acid derivative iV-chloroacetyl-L-leucine (12b) 
(IC5o=14.8|j.M). The lowest activity is observed for iV-chloroacetyl-D-leucine (12e) 
(IC5o=23.8|oM) which is consistent with the fact that the enzyme is specific for L-amino 
acids. The trimethylammonium salt (13) (IC50= 10.6jliM) shows an increase in inhibitory 
activity over its parent compound (12b) (ICso= 14.8nM)).
5.7 /V-2-Hvdroxv-2-phenylacetvl derivatives
Table 5.7 Results of biological assay for iV-2-hydroxy-2-phenylacetyl derivatives
Compound IF @ lOjxM % Inhibition / 
Activation @ 10|aM
IC5o (/¿M)
16a 89.8 53.9 9.3
16b 112.2 42.5 11.8
16c 63.6 67.4 7.4
16d 99.1 49.2 10.2
16e 82.3 57.8 8.7
17a 188.9 3.1 161
17b 145.9 25.2 19.8
17c 117.8 39.6 12.6
17d 74.8 61.6 8.1
The ^V-2-hydroxy-2-phenylacetyl derivatives tested do not show much greater 
activity than the previously tested compounds even though these compounds contain an 
extra functional group which could possibly enable them to act as bidentate chelators of the
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active site metal. Unexpectedly the derivatives in which the hydroxyl functionality is 
protected as the acetate tend to be better inhibitors than the derivatives which have a free 
hydroxyl. For example Ar-2-acetoxy-2-phenylacetyl-L-leucine methyl ester (16c) has an IC5o 
value o f 7.4(j,M, while A^-2-hydroxy-2-phenylacetyl-L-leucine (17b) has an IC50 value of 
19.8|xM. This would seem to indicate that the 2-hydroxy is not involved in binding to the 
active site metal as described by Nishino and Powers for bestatin.117 However these 
compounds may not be binding to the active site in a similar manner to bestatin since they do 
not contain a free amino group and thus a direct correlation cannot be assumed. It also must 
be remembered that the carboxylic acid group of these compounds is protected as the methyl 
ester and this has been shown to generally increase inhibitor activity in the previous results 
If we compare the results observed for compounds (27a) (IC5o=^M) and (27b) (IC5o=M.M) 
which have a free 2 -hydroxy group but a protected carboxylic acid group we see that they 
exhibit higher activity than the corresponding compounds with a free hydroxy group and a 
free carboxylic acid group (17b, 17c) but slightly lesser activity than the compounds where 
both functional groups are protected (16c, 16d).
It is interesting to note that the two phenethylamide derivatives (16e) (IC5o=8 .7 nM) 
and (17d) (IC5o= 8 .1 (iM) exhibit relatively good activity even though they are not amino acid 
derivatives. This again suggests that these compounds are binding in a different manner to 
bestatin, which requires a free carboxylic acid group for full activity. It is observed as a 
general trend for the amino acid derivatives that the derivatives of L-leucine (16c, 17b) and 
L-phenylalanine (16d, 17c) tend to be better inhibitors than those of glycine (16a, 17a) or L- 
alanine (16b). This observation combined with the activity recorded for the phenethylamide 
derivatives (16e, 17d) suggests that compounds with a bulky alkyl or aryl group can interact 
more favourably with a hydrophobic pocket in the active site.
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5.8 7V-2-Hvdroxv-3-phenylpropionyl derivatives
Table 5.8 Results of biological assay for ./V-2-hydroxy-3-phenylpropionyl derivatives.
Compound IF @ lOpM % Inhibition / 
Activation @ IOjaM
IC50 (nM)
20a 101 48.2 10.4
20b 138.4 29 17.2
20c 130.9 32.9 15.2
20d 82.3 57.8 8.7
20 e 61.7 68.4 7.3
21a 97.2 50.2 10
21b 117.8 39.6 12.6
21c 87.9 54.9 9.1
21d 71 63.6 7.9
21e 118 39.5 12.7
The biological results of the iV-2-hydroxy-3-phenylpropionyl derivatives display a 
very different trend to that observed for the JV-2-hydroxy-2-phenylacetyl derivatives even 
though they have a similar structure. This would seem to indicate that the length of the side 
chain of the a-hydroxy acid moiety is important in determining the best fit of the inhibitors in 
the active site. Unlike the trend observed for the JV-2-hydroxy-2-phenylacetyl derivatives, 
the AL2-hydroxy-3-phenylpropionyl derivatives with a free hydroxy functionality (21a-d) 
are better inhibitors than the corresponding compounds in which the 2-hydroxy is protected 
as the acetate (20a-d). However this trend is only true for the amino acid derivatives, for 
example 7V-2-acetoxy-3-phenylpropionyl phenethylamide (20e) (ICso=7.3|jM) is a better 
inhibitor than 7V-2-hydroxy-3-phenylpropionyl phenethylamide (21e) (ICso= 12.7|jM). It may 
be that even a slight modification of the side chain may position the inhibitor in the active 
side in such a way as to allow a greater interaction between the 2-hydroxy group and the
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active site metal and also between the free carboxylic acid functionality and some other 
group in the active site capable of interacting favourably with it.
5.9 iY-3-Hvdroxv-3-phenvlpropionvl derivatives
Table 5.9 Results of biological assay for 7V-3-hydroxy-3-phenylpropionyl derivatives.
Compound IF @ lOfiM % Inhibition / 
Activation @ 10|iM
1C50(hM)
25a 114 41.5 12
25b 108.5 44.4 11.3
25c 117.9 39.5 12.7
25d 100.9 48.3 10.4
26a 145.9 25.2 19.8
26b 130.9 32.9 15.2
26c 118.1 39.4 12.7
The results of the biological assay for the A^-3-hydroxy-3-phenylpropionyl derivatives 
show them to be poorer inhibitors than either their iV-2-hydroxy-2-phenylacetyl or N-3- 
hydroxy-3-phenylpropionyl counterparts. This is to be expected since it is probable that the 
distance between the carbonyl and 3-hydroxy functionalities is too great for both of them to 
interact with the active site metal. For bestatin a 2-hydroxy group is essential for full 
activity. The trend observed for the Ar-2-hydroxy-2-phenylacetyl derivatives in which 
greater activity is observed for compounds in which the hydroxy group is protected as the 
acetate is repeated here, for example Ar-3-acetoxy-3-phenylpropionyl glycine methyl ester 
(25a) has an IC50 value of 12|iM, while N-3-hydroxy-3-phenylpropionyl glycine (26a) has an 
IC5o value of 19.8nM.
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5.10 jV-2-Thio-2-phenvlacetyl derivatives
Table 5.10 Results of biological assay for jV-2-thio-2-phenylacetyl derivatives
Compound IF @ lOfiM % Inhibition /
Activation @ 10|iM
ICS„ (|xM)
27a 97.2 50.2 10
27b 102.9 47.2 10.6
28a 93.5 52.1 9.6
28b 112.1 42.5 11.8
28c 76.7 60.7 8.2
29a 1 2 1 .6 37.6 13.3
29b 89.8 53.9 9.3
29c 67.3 65.5 7.6
30 7.5 96.2 5.2
The results for the 2-thio-2-phenylacetyl-derivatives show these compounds to be 
promising starting point for developing potent inhibitors o f the malarial aminopeptidase. 
Unfortunately we were unable to isolate the free thiol derivatives o f L-leucine or L -  
phenylalanine however Ar-2-thio-2-phenylacetyl-phenethylamide (30) ( I C 5 o = 5 . 2 | j . M )  the 
greatest activity o f all the compounds prepared in this study. The high activity of this 
compound is most likely due to a strong interaction between the thiol group and the active 
site metal. Unlike the structurally related JV-2-hydroxy-2-phenylacetyl derivatives in which 
the protected derivative has a greater activity the corresponding thioacetate derivative (29c) 
has a lesser inhibitory activity ( I C 5 o ~ 7 . 6 | j M )  and the coresponding mesylate derivative (28c) 
is an even poorer inhibitor (IC5o=8 .2 |jM) perhaps due to the bulkiness of the 
methanesulphonyl group. Unfortunately we were unable to isolate the iV-2-thio-2- 
phenylacetyl derivatives of leucine and phenylalanine but this type of compound may have
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promise as inhibitors of the malarial aminopeptidase. Similar compounds with an a-thioacyl 
group are known to be potent orally active inhibitors o f zinc metalloproteases.165' 168
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5.11 Experimental 
Experimental note
The cell-free extract of P. chabaudi was kindly provided by Dr. John Dalton in the School 
of Biological Sciences D.C.U. It was obtained from the blood of mice containing early 
trophozoites, when the parasetemia had reached 15-20%. The blood was chromatographed 
on a CF11 column to remove white blood cells and platelets, which bind to the column. The 
collected red blood cells were then washed with phosphate buffered saline (PBS), pH 7.4. 
The cells were lysed with 0.1% saponin on ice to obtain free parasites. Haemoglobin was 
removed by centrifugation (15000g for 20min). Cell-free extracts were prepared by three 
cycles of freeze-thaw lysis followed by centrifugation (15000g for 20min at 4°C) The cell- 
free extracts were stored at -4°C. In order to simplify the assay procedure we took the 
average molecular weight of the inhibitors to be 300g mol"1.
Determination of inhibitor activity by Fluorescence assay
A 3.33 x 10"3 stock solution of each of the test compounds was prepared by dissolving lmg 
of each of the compounds into 1ml of DMF. The cell-free extract of enzyme in PBS 
(100|J.L) was added to a solution containing 0.01M L-leucine-AMC in PBS (100|xL), 3p.l of 
the stock solution o f test compounds (for a final concentration of lO^M), and 800(j.L PBS, 
giving a final volume of approximately 1ml. All test solutions were prepared in duplicate. 
Positive controls containing no inhibitor, as well as negative controls containing l(j.M 
(IOOjxL) bestatin were also prepared. The test solutions were incubated at 37°C for 30min, 
and the enzyme activity stopped by the addition of 10%> acetic acid (200|j.L). The liberated 
AMC was determined using a Perkin-Elmer fluorimeter (excitation 370nm, emission 
440nm).
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CONCLUSION
Many o f the compounds that were prepared in this study possessed modest 
aminopeptidase inhibitory potency in the micromolar range. Some of the compounds 
were also found to be activators o f the enzyme, with the esters o f the iV-3-nitrophihaloyl 
amino acid derivatives being particularly potent activators o f the aminopeptidase. These 
compounds require further study, since there may be situations in which the activation of 
aminopeptidases may be a powerful chemotherapeutic tool. Interestingly the N-a- 
hydroxyphenylacyl amino acid derivatives did not show much greater activity than the 
simpler iV-cinnamoyl amino acid derivatives even though it was assumed that the 
presence o f the hydroxyl group would allow these compounds to chelate the active site 
metal in a bidentate ligand with both the hydroxyl and carbonyl functionalities. 
Unexpectedly for the 7V-2-hydroxy-2-phenylacetyl amino acid derivatives, the 
compounds in which the hydroxyl group is protected as the acetate are more potent 
inhibitors than the compounds with a free hydroxyl group. The reverse trend is observed 
for the 7V-2-hydroxy-3-phenylpropionyl amino acid derivatives. Thus changing the length 
o f the side chain of the a-hydroxyalkoyl moiety may greatly affect the activity of the 
compound, probably by affecting its binding to the active site. The a-thiophenylacyl 
derivatives would appear to be the most effective inhibitors prepared in this study, 
possibly due to a strong complexation between the sulphydryl group and the active site 
metal. More work needs to be carried out to fully explain the mode of action of these 
types o f compounds.
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APPENDIX I 
LIST OF ABBREVIATIONS USED
AHBA a-Hydroxy-ß-amino acid
AHPB 2-Hydroxy-3-amino-4-phenylbutanoic acid
AMC 7-Amino-4-methyl~coumarin
APN Aminopeptidase N
BOC /-Butyloxycarbonyi
m-CPBA wt?/a-Chloroperoxybenoic acid
DCM Dichloromethane
DCCD 1, 3-Dicyclohexylcarbodiimide
DIBAL Diisobutylaluminium hydride
DMF N, Ai-Diinethylformamide
Et3N Triethylamine
EtOH Ethanol
MeOH Methanol
MsCl Methanesulphonyl chloride
THF Tetrahydrofuran
Z Benzyloxycarbonyl
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N -H  O  intramolecular and O -H  "' 0 , C -H  "' 0  and sp3 C -H  "' % (arene) 
intermolecular interactions in (25)-2-{[(2JR)-2-hydroxy-2-phenylethanoyl]amino}-4- 
methylpentanoic acid.
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N o t e :  T h i s  m a n u s c r i p t  h a s  b e e n  g e n e r a t e d  a u t o m a t i c a l l y  f r o m  a  C r y s t a l l o g r a p h i c  I n f o r m a t i o n  F i le  b y  th e  I U C r  
c i f t e x  p r o g r a m .  T h i s  p r o g r a m  is s t i l l  u n d e r  d e v e lo p m e n t ,  a n d  a u t h o r s ,  C o e d i t o r s  a n d  r e v ie w e r s  are a d v is e d  
t h a t  s o m e  a s p e c t s  o f  f o r m a t t i n g  a n d  d a t a  p r e s e n ta t io n  a re  s t i l l  n o t  h a n d le d  in a n  o p t i m a l  m a n n e r .  F e a tu r e s  
w h ic h  r e q u ir e  f u r t h e r  w o r k  i n c l u d e  su p p re s s io n  o f  r e d u n d a n t  c e l l  p a r a m e t e r s  (e . g .  ot: 7  in  m o n o c l in ic  sp a c e  
g r o u p s ) ,  fu l l  f o r m a t t i n g  o f  r e f e r e n c e  l i s t ,  a n d  th e  p l a c e m e n t  o f  th e  e x p e r i m e n t a l  t e x t .  N o t e  a lso  t h a t  c o m p o u n d  
n a m e  id e n t i f ie r s  a re  d e r iv e d  f r o m  th e  a r b i t r a r y  d a t a  b lo c k  n a m e s  w i t h i n  th e  C I F ;  th e s e  a re  l ia b le  to  b e  c h a n g e d .  
P l e a s e  i n d i c a t e  a n y  n e c e s s a r y  c h a n g e s  for  i m p l e m e n t a t i o n  b y  A c t a  e d i t o r i a l  sta f f .
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Abstract
The title  com pound, C 1 3 H 1 5 N 3 O 7 ,  crystallises as two independent molecules 
which differ in conform ation. Interm olecular hydrogen bonding arises between 
the am ide and carboxylic acid groups as N — H- ■ - 0 = C  forming one-dimensional 
chains, (N- • O 2.966 (7) A, 3.019 (7) A) and C = 0 - • - H — 0  interactions forming
o
a two-dim ensional netw ork by linking neighbouring chains, (O- • O 2.675(8) A, 
2.778(7) A).
C o m m e n t
The study  of biologically im portan t molecules continues to  be of prim ary im­
portance in m edicinal chemistry. Processes such as blood coagulation, hormone 
processing, viral replication and cancer cell invasion are critically dependent on 
protease enzymes which are attractive  target molecules in the design of specific
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and  selective d rugs, (T esta , K yburz, Führer & G iger, 1993). Im p o rtan t p ro ­
tease  inh ib ito rs  are  usually  based  on m odified am ino  acids in co rpo ra ting  s tru c ­
tu ra l fea tu res w hich de term ine  no rm al en zy m e-su b stra te  recognition  processes. 
S tru c tu re -b ased  d ru g  design strateg ies to identify  in te rac tio n s  betw een a  p o ten ­
tia l in h ib ito r an d  ta rg e t recep to r require accu ra te  in h ib ito r  s tru c tu res. We are 
cu rren tly  s tu d y in g  s tru c tu re  ac tiv ity  rela tionsh ips an d  m olecu lar recognition p ro ­
cesses in biologically  im p o rta n t molecules such as N -3 ,5-dinitrobenzoyl-L -leucine, 
C 1 3 H 1 5 N 3 O 7 , (I), for app lica tions in d rug  design.
In  th e  cry sta l s tru c tu re  of (I), two independen t m olecules in  the  asym m etric  
u n it differ in  conform ation  in  th e  ch iral space g roup  P I .  S im ilar views of th e  two 
independen t m olecules A an d  B w ith  our num bering  schem e are given in Figs. 
l a  an d  16. T h e  b o n d  leng ths (Table 2) are in  accord  w ith  an tic ip a ted  values 
(O rpen  et ah, 1994). T he  m olecules differ in co n fo rm ation  ab o u t the  N1— C2 
bond  w ith  th e  la rg est angle difference is N l— C2— C4, 115.9 (5)°, 110.0 (5)° and  
th e  to rsion  angle C l— N l— C2— C-3 is 56.1 (7)°, —81 .5 (7 )°  in  A, B respectively.
T he aro m atic  C l— C l l — C12 and  C l— C l l — C16 angles are {123.2(6)°, 
116 .7(6)°, A ) an d  {125 .6(5)°, 116 .6 (5)°, B} re su ltin g  from  th e  in tram olecu­
la r in te rac tions H16A- • -05A  2.45 A, H 1 A -• -H12A 2.08 A in  A, H 16B -■-05B  
2.42 A and  H 1 B - • -H12B 2.14 A in  B, ( 0 5 B - ■-H2B 2.48 A). T h e  arom atic  ring 
p lanes are o rien ted  a t angles of 19 .1 (4 )°, 12 .8 (6 )° to  th e ir  respective am ide 
groups (0 5 ,C 1 ,N 1 ,C 2 ) w ith  all n itro  groups alm ost co -p lanar (<  10° from  
th e  ring  p lanes); th e  carboxy la te  (C 2 ,C 3 ,0 6 ,0 7 )  g roups are  alm ost no rm al to  
(C 11,C 1,C 5,N 1,C 2) 8 5 .9 (2 )° , 79 .1 (2)° in A an d  B respectively.
T he m olecules align in  one dim ensional chains as [A..]n and  [B..]„ due to  
th e  p a rtia l tt-tt stack ing  of th e  3 ,5-d in itrobenzoyl g roups. In term olecu lar hydro ­
gen bonding  along th e  [A..]ri an d  [B..]n chains re su lts  from  am ide [a /b ]N — 
H- • • 0 = C [ /i / b ] carboxy la te  in te rac tions w ith  N- • -O d istances of 2.966 (7) A {for
o
[A..]„} and  3.019 (7) A {for [B ..]„). In te rac tions betw een  th e  neighbouring A 
an d  B chains arises as carboxy la te  [ a / b ] 0 — H -  • - 0 = C [ b / a \ am ide bonding  w ith  
0 -  • -O d istances of 2.675 (8 ) A (A —>-B) and  2.778 (7) A (B —>A).
T his com bin a tio n  of hydrogen bond ing  resu lts  in  th e  fo rm ation  of two 20- 
m em bered  hyd ro g en  b o n d ed  ring  system s each consisting  of two A and  two B
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m olecules, {J , K  in  F ig. 2}, differing by [B..]n —>[A..]n (.J) and  [A ..]„—>[B..]n (K ) 
(w here —+ ind icates  th e  carboxylic acid to  am ide 0 = C  hydrogen  bonds). E ach 
cyclical a rran g em en t consists of four hydrogen bonds listed  as, (clockwise in Fig. 
2 from  th e  centre): J , 0 6 B — H2- ■ 0 5 A , N 1 A— H 1 A- • - 0 7 A \  ’0 6 B — H2- • -OSA*, 
*N1B— H1B- • -07B  a n d  K , 0 6 A — HI- • -C^B11, iUN l B - H 1 B - • -0 7 B H, ’0 6 A —  
H 1 ---0 5 B 111, N1A— H 1 A ---0 7 A 1, {i, 1+  x,y,z\ ii, x , l +y,z] iii, 1+  x ,l+ y ,z} .  
T he rings have th e  g ra p h  set R 4 4 (2 0 ) J , R ,4 4 (2 0 ) Iv, w hich rep ea ts  as a  two- 
d im ensional netw ork in  th e  la ttice . E xam ination  of th e  s tru c tu re  w ith  P L A T O N  
(Spek, 1996a) showed th a t  th e re  w ere no solvent accessible voids.
T h e  s tru c tu re  of (L) -Leucine (L-Leu) has been  re p o rte d  previously, (H ard ing  
& H owieson, 1976; Collect, Solans, F o n t-A lta b a  & S u b irana , 1986; G orbitz & 
D alhus, 1996) an d  con tains tw o crystallographically  indep en d en t zw itterion  m ol­
ecules hav ing  sim ilar conform ations in the asym m etric  u n it , unlike (I) above, 
w here th e  tw o m olecules differ significantly in  conform ation .
E x p e r i m e n t a l
N -3 , 5 -d in itrobenzoyl"L -leucine was synthesised by  th e  reac tio n  of 3 ,5 -d i- 
n itro b en zo y l chloride w ith  th e  paren t (L)-leucine. R ecrysta llisa tion  from  
e th a n o l/w a te r  afforded colourless plate-like crystals su itab le  for X -ray analysis.
m .p . 178-180°C  (u n co rrec ted ), 187° (Vogel, 1989). i.r. z/max(K B r): 3400, 1725, 
1650, 1550, 1350cm “ 1. ‘H N M R  d a ta  (400 M Hz) (5, D M SO ): 0 .87-0.94 (6 H, d, 
. / =  6.4Hz, C (C H 3)2), 1 .59-1.82 (3H, m , CH 2 CH ), 4 .47-4 .53  ( 1 H, m , N C H C 0 2), 
8.38 (1 H, d, J  =  7.9Hz, N H ), 8.96 (1H, t, J  =  2Hz, A rH  para-), 9.10 (2H, d, J  =  
2Hz, x4rH ortho-).
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Crystal data 
C1 3 H1 5 N3 O7  
M r =  325.2S 
Ti'iclinic 
P I
a =  5.8046(3) Â
6 =  10.640 (2) Â
c =  12.9556(14) Â 
a  =  109.428(11)°
P =  102.416(7)°
7  =  90.250 (8 )°
V  =  734.44(15) A3 
Z = 2
D x =  1.471 Mg m - 3  
D m not m easured 
Mo Ko rad iation  
A =  0.7107 À
Data collection
Enraf-Nonius CAD-4 diffractometer 
uj -20 scans
Absorption correction: none 
2621 measured reflections 
2621 independent reflections 
1326 reflections with 
/  >  2a{I)
0max =  25.1°
Cell param eters from 25 reflections 
9 =  9 .3-22.0° 
pi =  0 .1 2 1  m m -1  
T = 294(1) K 
P late
0.30 x 0.20 x 0.05 m m  
Colorless
C rystal source: synthesized by the 
au thors, see tex t
h =  0 -> 6 
k =  -1 2  —  12 
/ =  - 1 5  -»  14 
3 standard reflections 
frequency: 60 min 
intensity decay: no decay, variation 
1.0%
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Refinem ent 
Refinem ent on F2 
R [ ^  > 2<j(i^)] =  0.0449 
w R (F 2) =  0.0798 
5  =  0.934 
2621 reflections 
417 param eters
riding (C— H 0.93 to 0.98, N— H 0.86,
O— H 0.82 Â) 
w = l/[a 2(F 02) +  (0.0248P)2 +
0.0000P]
where P  =  (P 02 4- 2 P c2)/3
0 /c r ) max < 0.001 
¿Vmax =  0.188 e A -3 
A /W n =  -0 .1 8 2  e Â - 3 
Extinction correction: SHELXL93  
Extinction coefficient: 0.0112(18) 
Scattering factors from  International
Tables fo r  Crystallography (Vol. C) 
Absolute configuration: Flack, H. D.
(1983), Acta Cryst. A39, 876-881 
Flack param eter =  0.25 (159)
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Table 1. Fractional atomic coordinates and equivalent isotropic displacement
o
parameters (A'2)
Ueq =  (l/3)EiSi I/y aJ,aiai.ai .
x  y z U e q
O lA 0.4818 (9) 0.7249 (5) 0.0375 (7) 0.072 (2)
02A 0.6293 (8) 0.6808 (5) 0.1891 (6) 0.0659 (15)
03A 0.1297 (10) 0.4481 (6) 0.3281 (6) 0.074 (2)
04A -0 .2254(11 ) 0.3699 (5) 0.2305 (6) 0.077 (2)
05A -0 .5 1 9 9 (7 ) 0.4204 (4) -0 .1 3 0 4 (5 ) 0.0490 (12)
06A -0 .5 2 1 6 (7 ) 0.7293 (5) -0 .1 9 5 4 (6 ) 0.0576 (15)
OTA -0 .8 4 1 6 (8 ) 0.5861 (5) -0 .2 6 5 2 (6 ) 0.0562 (14)
N1A -0 .2 7 8 6 (8 ) 0.4975 (4) -0 .2 1 6 1 (6 ) 0.0333 (12)
N13A 0.4699 (10) 0.6702 (6) 0.1060 (7) 0.048 (2)
N15A -0 .0 309(13 ) 0.4234 (6) 0.2424 (7) 0.060 (2)
C IA -0 .3211  (12) 0.4608 (6) -0 .1 3 1 9 (7 ) 0.037 (2)
C2A -0 .4 6 7 6 (1 0 ) 0.5118 (6) -0 .3 0 7 2 (7 ) 0.038 (2)
C3A -0 .6 340(12 ) 0.6104 (7) -0 .2 5 4 0 (6 ) 0.037 (2)
C4A -0 .6006(10 ) 0.3821 (6) -0 .3 9 1 7 (7 ) 0.044 (2)
C5A -0 .4 4 9 4 (1 3 ) 0.2787 (7) -0 .4 4 8 6 (7 ) 0.059 (2)
C6A -0 .2926(13 ) 0.3304 (7) -0 .5 0 7 0  (8) 0.071 (2)
C7A -0 .6 1 5 6 (1 5 ) 0.1592 (7) -0 .5321  (8) 0.078 (3)
C llA -0 .1 1 8 0 (1 1 ) 0.4819 (6) -0 .0 3 2 0 (7 ) 0.0296 (15)
C12A 0.0896 (11) 0.5607 (6) -0 .0 1 2 8 (7 ) 0.043 (2)
C13A 0.2543 (12) 0.5850 (6) 0.0868 (7) 0.037 (2)
C14A 0.2275 (11) 0.5394 (6) 0.1706 (7) 0.042 (2)
C15A 0.0152 (12) 0.4649 (6) 0.1501 (7) 0.040 (2)
C16A -0 .1 5 8 3 (1 1 ) 0.4360 (6) 0.0511 (6) 0.040 (2)
O lB -1 .6661  (8) 0.2242 (5) 0.0248 (6) 0.0557 (14)
02B -1 .6 9 2 5 (8 ) 0.1932 (5) 0.1787 (6) 0.0589 (14)
0 3 B -1 .1 0 8 5 (9 ) -0 .0 4 9 1 (5 ) 0.3425 (6) 0.061 (2)
04 B -0 .8 5 1 0 (9 ) -0 .1 4 8 0 (5 ) 0.2506 (6) 0.063 (2)
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05B -0 .7999 8) -0 .0 9 5 7 (4 ) -0 .0 9 2 4 (5 ) 0.0496 (13)
06B -0 .8681 7) 0.2087 (4) -0 .2 2 0 7 (6 ) 0.0542 (13)
07B -0 .5 6 8 8 8) 0.0807 (5) -0 .2 5 1 5 (6 ) 0.0569 (14)
NIB -1 .0817 8) -0 .0 1 1 3 (5 ) -0 .1938  (6) 0.0357 (13)
N13B -1 .6006 10) 0.1758 (6) 0.0983 (6) 0.048 (2)
N15B -1 .0 1 9 7 11) -0 .0801 (6) 0.2613 (7) 0.048 (2)
C lB -0 .9 8 9 4 11) -0 .0440  (6) -0 .1 0 3 3 (7 ) 0.033 (2)
C2B -0 .9 5 6 2 10) -0 .0 2 6 1 (6 ) -0 .2 8 2 8 (7 ) 0.038 (2)
C3B -0 .7752 11) 0.0901 (7) -0 .2 5 2 6 (7 ) 0.040 (2)
C4B -1 .1330 11) -0 .0490  (7) -0 .3 9 4 6 (7 ) 0.040 (2)
C5B -1 .2653 12) -0 .1 8 8 7 (7 ) -0 .4399  (7) 0.052 (2)
C6B -1 .1159 14) -0 .2 9 6 4 (7 ) -0 .4 9 4 6 (8 ) 0.083 (3)
C7B -1 .4961 13) -0 .1 9 3 0 (9 ) -0 .5 2 4 4 (9 ) 0.093 (3)
C11B -1 .1189 11) -0 .0 1 6 3 (6 ) -0 .0 1 1 9 (6 ) 0.032 (2)
C12B -1 .3045 11) 0.0650 (6) 0.0003 (7) 0.037 (2)
C13B -1 .3 9 6 6 10) 0.0937 (6) 0.0917 (7) 0.0308 (15)
C14B -1 .3120 11) 0.0488 (6) 0.1787 (7) 0.038 (2)
C15B -1 .1245 12) -0 .0 3 0 4 (6 ) 0.1683 (6) 0.035 (2)
C16B -1 .0270 10) -0 .0 6 4 5 (5 ) 0.0764 0.032 (2)
Table 2. Selected geometric parameters (A , ° )
0 5 A — C IA 1.236 (7) 0 5 B — C lB 1.234 (7)
0 6 A -  C3A 1.321 (7) 0 6 B — C3B 1.345 (7)
07 A — C3A 1.199 (7) 0 7 B — C3B 1.200 (7)
N1A— C IA 1.343 (7) N IB — C lB 1.337 (7)
N1A— C2A 1.478 (6) N IB — C2B 1.458 (7)
C IA — C11A 1.505 (8) C lB — C U B 1.486 (8)
C2A— C3A 1.524 (8) C2B— C3B 1.509 (8)
C2A— C4A 1.523 (7) C2B— C4B 1.528 (7)
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C IA —N1A— C2A 123.4 (5) C lB — N IB — C2B 121.8 (5)
N1A— C2A— C3A 108.3 (5) N IB — C2B— C3B 111.6 (5)
N1A— C2A— C4A 115.9 (5) N IB — C2B— C4B 110.0 (5)
C3A— C2A— C4A 112.1 (5) C3B— C2B— C4B 113.0 (5)
06 A — C3A— 07A 123.5 (6) 0 6 B — C3B— 07B 122.7 (6)
06A — C3A— C2A 111.2 (5) 0 6 B — C3B— C2B 112.3 (5)
0 7 A — C3A— C2A 125.2 (6) 0 7 B — C3B— C2B 125.0 (6)
C2A— C4A— C5A 115.7 (5) C2B— C4B— C5B 111.5 (5)
C IA — C11A— C12A 123.2 (6) C1B— C U B —C12B 125.6 (5)
C IA — C11A— C16A 116.7 (6) C lB — C l IB — C16B 116.6 (5)
C2A— N1A— C IA — 05A 8.9 (9) C2B— N IB — C1B— 05B -4 .3 (9)
C2A—N1A— C IA — C11A -1 6 5 .9  (5) C2B— N IB — C lB — C U B 175.2 (5)
C IA —N1A— C2A— C3A 56.1 (7) C lB — N IB — C2B— C3B -81 .5 (7)
C IA — N1A— C2A— C4A -7 0 .8  (7) C lB — N IB — C2B— C4B 152.2 (5)
N1A— C2A- -C3A— 07A -1 2 0 .7  (6) N IB — C2B— C3B— 07B 124.8 (7)
C4A— C2A— C3A— 07A 8.4 (9) C4B— C2B— C3B— 07B -110.5 (7)
N1A— C2A— C3A— 06A 61.2 (6) N IB — C2B— C3B— 06B -5 2 .0 (7)
C4A— C2A— C3A— 06A -1 6 9 .7  (5) C4B— C 2B - C3B— 06B 72.7 (7)
N1A— C2A— C4A— C5A -5 5 .1  (7) N IB — C2B— C4B— C5B -71 .3 (7)
C3A— C2A— C4A— C5A 179.9 (5) C3B— C2B— C4B— C5B 163.2 (6)
C2A— C4A -C 5A — C6A -5 5 .5  (8) C2B— C4B— C5B— C6B -7 8 .4 (7)
C2A— C4A -C5A— C7A -1 7 8 .2  (6) C2B— C4B— C5B— C7B 159.2 (6)
Table 3. Hydrogen-bonding geometry (A , °)
D—H- • -A D— H H- • -A D ---A  D— H- • -A
N1A—H 1A ---07A 5 0.86 2.15 2.966 (7) 158
0 6 A — HI- ■ 05B " 0.82 1.86 2.675 (8) 173
N IB — H lB ---0 7 B iii 0.86 2.17 3.019 (7) 168
0 6 B —H 2---05A  0.82 1.97 2.778 (7) 166
Sym m etry codes: (i) 1 +  x, y, z\ (ii) x, 1 + y , z ;  (iii) x  -  1, y, z.
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Molecule (I) crystallised in the triclinic system; space group P I  or P -l; the mol­
ecule is chiral, space group P I  chosen and confirmed by the analysis. The absolute 
configuration is based on L-leucine. The plate  diffracted weakly b u t sufficient 
da ta  were collected to  establish the  structu re  and  elucidate the hydrogen bonding 
interactions in  the crystal structure.
D a ta  collection: CAD-4 (E nraf-N onius, 1992). Cell refinement: SET4  & 
C E L D IM (E nraf— Nonius, 1992). D ata  reduction: DATB.D'2 in N RC VAX94  (Gabe, 
Le Page, C harland , Lee & W hite, 1989). P rogram (s) used to  solve structure: 
SH ELXS86  (Sheldrick, 1986). Program (s) used to refine structure: NRCVAX94  
and SH ELXL93  (Sheldrick, 1993). M olecular graphics: NR,CVAX94. ORTEP  
(Johnson, 1976), PL A T O N  (Spek, 1996a), P L U T O N  (Spek 1996 b). Software used 
to prepare  m ateria l for publication: N R C V A X 94 , SH ELXL93  and WordPerfect 
m acro P R E P C IF  (Ferguson, 1997).
G. F. thanks NSERC (C anada) for Research G rants and J. F. G. thanks the 
Research and  P ostg raduate  Com m ittee of Dublin City University for partial 
funding (Research G rant No. RC96-SR A F-06JG ) of a research visit to the 
U niversity of Guelph (Ju ly  -A ugust, 1996).
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Supplem entary d a ta  for th is paper are available from  the IUCr electronic archives 
(Reference: P R IN T C IF). Services for accessing these d a ta  are described at the 
back of the journal.
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Fig. la . A view of A w ith our num bering scheme. Displacement ellipsoids are 
draw n a t the 30% probability  level.
Fig. lb. A  view of B w ith  our num bering scheme. Displacem ent ellipsoids are drawn 
at the  30% probability  level.
Fig. 2. A view of the hydrogen-bonding interactions in com pound (I). The nitro  
groups and para-H atom s have been removed from molecules A and B in the 
asym m etric unit (labelled as *). All H atoms except for the am ide NH in the four 
sym m etry re la ted  molecules were removed for clarity. Displacement ellipsoids 
for the  non-H atom s were draw n at the  30% probability level and the  O and N 
atom s of A are draw n w ith  cross-hatched therm al ellipsoids.
Table 1. Fractional atom ic coordinates and equivalent isotropic displacement 
param eters ( A2) for com pound (I)
Table 2. Selected geom etric param eters ( A, °) for com pound (I)
Table 3. Hydrogen bond param eters ( A, °) for com pound (I)
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N—H • • 'O in tra m o lecu la r  and  O-H- ■ •O, C-H-  • ’O an d  sp^ C—
H • ■ -7T(arene) in term o lecu la r  in tera ctio n s in  (2 5 ')-2 -{[(2 i? )-2 -h yd ro-  
x y -2 -p h e n y le th a n o y l]a m in o }-4 -m eth y lp e n ta n o ic  acid
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A b stra c t
The title  com pound C 1 4 H 1 9NO 4 forms a hydrogen-boncled network in the
o
solid sta te  consisting of an  intram oleeular N— H - '-G  {N ---0 , 2.5&9(S)A} 
and interm olecular 0 — H -• - 0 = C  { 0 - - -0  , 2.704(2), 2.801 (2) A} hydrogen 
bonds; C—H- • -O {C- • -O, 3.344 (3) A} and sp3C— H- • -7r(arene) {shortest C- • -C, 
3.873 (4) A} in teractions.
C om m en t
The study of biologically active molecules is of p rim ary  im portance in medicinal 
chemistry. Processes such as horm one processing, viral replication and cancer 
cell invasion are critically dependent on  protease enzymes w hich have recently 
become a ttractive  target molecules in drug design. M any inhibitors are based on 
modified amino acids which incorporate the basic s tru c tu ra l features determ ining 
norm al enzym e-substrate interactions. The title  com pound (I), is p a rt of an 
ongoing study of hydrogen-bonding interactions in am ino acid derivatives which 
m ay be of relevance tow ards the design of an tim alarial drugs.
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A view of molecule (I) (R S  configuration) w ith our num bering scheme is given 
in Fig. 1 and selected dimensions are in  Table 2. The b o n d  lengths and  angles are 
in agreem ent w ith expected values (O rpen et al., 1994). The phenyl ring is almost 
perpendicular to the  {N 1,C 2,C 3,03,C 4,04} plane, 86.60(6)° and the m axim um
o
deviation from p lanarity  for an atom  in  either p lane  is 0.172(1) A for C4; the 
phenyl ring is at an angle of 76.45(9)° to the carboxylic acid { 0 1 ,0 2 ,C l,C2} 
plane. Exam ination of the  structu re  w ith P L A T O N  (Spek, 1997a) indicated tha t 
there were no solvent accessible voids in the crystal lattice.
Extensive hydrogen bonding is present in  the  c ry sta l s truc tu re  consisting of 
an intram olecular N— H- ■ -0  and interm olecular O— H- • - 0 = C  hydrogen bonds, 
C— H- • 0  and sp3C— H -• -7r(arene) interactions; a view is given in Fig. 2 and 
details are in Table 3. The N- • 0  distance in the in tram olecular N— H- • -0  hydro­
gen bond is 2.569 (3) A w ith  N— H ---0 , 116(2)°. T he G ---0  interm olecular 
distances for 01- ■ -0 3 ' and 0 4 - • -0311 are 2.704(2) and  2.801 (2) A w ith 0 — 
H- ■ -0  angles of 170 (3)° and 168 (2)° respectively, (i =  1 -x ,y - l /2 , -z]  ii =  1 — x,y- 
1 / 2 , 1  -z). A weak C— H- ■ 0  in teraction C 2 —H 2~ •G2 iii w ith  C- • -0 iU, 3.344(3) A 
and C— H- • -0 U1 159° is also present, (iii =  1-x, -  +  y,-z). A sp3C—H- • -7r(arene) 
in teraction w ith the  C 8 ...C g llv distance, 3.873 (4) A and C 8 — H8 A ...C g(l)lv, 
145° (C g l is the  ring centroid of the phenyl ring, iv =  1 +  x,y,z) completes 
the  interm olecular interactions.
The s tru c tu re  of (L)-Leucine has been reported  previously, (H arding et al. , 
1976; Collect et al., 1986; Gorbitz & Dalhus, 1996) and contains two crystal- 
lographically independent zwitterion molecules having sim ilar conformations in 
the asym m etric unit.
T he presence of C— H- • -0  and C— H- • -7r(arene) interactions w ith stronger 
hydrogen bonds e.g. 0 — H- ■ -O has been com m ented on previously (Steiner, 
1997). We have recently reported  the  struc tu re  of 2-(lfT-Imidazol-2-yl)-3,4- 
dim ethyl- 5-phenyl-1 ,3-oxazolidine (Gallagher et al., 1998) where dom inant 
N— H' • -N hydrogen bonds are present in the  c ry sta l structure  w ith  weaker 
C— H -• -7r(arene), C— H -•-0  and C— H -• -7r (C = C )  in teractions completing the 
hydrogen bonding network. The subtle interplay of these interm olecular forces 
results in the  presence of four molecule in the asym m etric unit. In (2R /2S)-2-(l-
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oxo-1,3-dihydro-2.ff-isoindol-2-yl)-3-phenylpropanoic acid, the O—H- ■ 0  hydro­
gen bonds are present w ith  C—H- • O and C— H- • -7i(arene) interm olecular 
interactions such th a t all hydrogen bond donor and acceptors take p a rt in  hydro­
gen bonding (B rady et al., 1998). It is obvious th a t system atic studies of series 
of re lated  molecules are necessary for even an elem entary understand ing  of the 
factors which govern the  observed interactions in crystal structures. Further 
studies are in  progress on re lated  amino acid derivatives.
E x p er im en ta l
25ml of 1M NaOH was added to a solution of N -((R/S)-2-acetoxy-2-phenyl- 
acetyl)-L-leucine m ethyl ester (3.2g, O.Olmol) in CH 3 OH (20ml) and allowed to 
s tir at room  tem p eratu re  for lh r. The solution was cooled to  0° and  acidified with 
10% HC1; the  CH 3 OH was removed in vacuo. Recrystallisation of the resulting 
precip itate  from  acetone/n-hexane yielded colourless blocks (2.3g, 87%) suitable 
for X-ray analysis, m .p. 116-118°C (uncorrected), i.r. z/max(KBr): 3459 (OH), 
3389(NH), 3296, 1725 (carboxylic acid C = 0 ) ,  1639 (am ide C = 0 ) ,  1556, 1267, 
1160cm -1. *H NM R d a ta  (400 MHz) (6, DMSO): 0.75 -0.85 (12-ff, m , C(CH3)2), 
1.46-1.66 (6 H, m , CH 2 CH), 4.22-4.28 (2 if, m, N C H C 0 2), 4.93 (2 H, s, OH), 6.25 
(2H, s, NCOCH ), 7.22-7.40 ( 1 OH, m, ArH), 7.98-8.00 (2S ,  d, J  =  8 .8 8 Hz, NH). 
13C NM R d a ta  (100 MHz) (6 , DMSO): 173.79, 171.94 ( - C 0 2H and - C = 0 ) ,  
141.25, 127.89, 127.38, 126.62 (arom atic C atom s), 73.28 (-C H O H ), 49.75 ( -  
NHCH), 24.32 (-C H 2), 22.83, 21.36 (CH (CH 3)2. Note: T he signals at 173.79 
and 171.94 m ay be interchangeable. M ass spectrum  M—H20  found: 247.1322, 
C i4 H i9 N 0 3 requires 247.1207 m / z  (%): 247 (0.5) (M — H 2 0 ) ,  107(100), 8 6 (2 2 ), 
77(19).
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Crystal data
c 14h 19n o 4
M r  =  265.30 
Monoclinic
P2i
a =  8.5S87 (10) A 
b =  8.6404(6) Â 
c =  9.6169(6) A 
0  =  98.398(7)°
V =  706.0(1) A3 
Z =  2
D x = 1.248 Mg m “ 3 
D m not m easured 
Mo Ka  rad ia tion  
A =  0.7107 Â
Data collection
Enraf-N onius CAD-4 diffractom eter 
ui-20 scans
A bsorption correction: none 
3225 m easured reflections 
3133 independent reflections 
2540 reflections w ith 
>2a(T)
R inl =  0.008
Cell param eters from 25 reflections 
9 =  10.4-19.7°
¡.i =  0.091 m m - 1  
T  = 294(1) Iv 
Block
0.3S x 0.32 x 0.14 m m  
Colourless
C rystal source: synthesized by the 
au thors, see text
h =  - 1 1  1 1
k =  —11  — *■ 11 
I =  0 -» 12
3 s tan d a rd  reflections 
frequency: 1 2 0  m in 
intensity decay: no decay, variation 
1.0%
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Refinement  
Refinem ent on F*2 
R[F° > 2a(Fa)] =  0.0399 
w R ( F 2) =  0.1192 
S  =  1.013 
3133 reflections 
184 param eters 
mixed
w = l / [ a  2{ F 2) + (0.0786P)2] 
where P  = ( F 2 +  2 F 2) jZ
(4 / ^  = 0.000 
Apm ax =  0.16 e A - 3  
Apm\Ti — 0.15 e A
Extinction  correction: SHELXL97  
Extinction coefficient: 0.037 ( 8 ) 
Scattering factors from  International  
Tables for  Crystallography (Vol. C) 
Absolute struc ture : Flack (1983) 
Flack param eter =  —1 (1)
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Table i . Fractional atomic coordinates and equivalent isotropic displacement
o
parameters (A*)
Ueq = (1 /3 )2  i Z j U ” a 1 aJ a j . a j .
X V z ueq
0 1 0.59948 (19) 0.5082 -0 .1 1 7 9 9 (1 6 ) 0.0428 (4)
0 2 0.6090 (3) 0.3478 (3) 0.06460 (18) 0.0603 (5)
0 3 0.47750 (17) 0.7702 (2) 0.29740 (14) 0.0357 (3)
0 4 0.62859 (17) 0.4387 (3) 0.48594 (16) 0.0405 (4)
N1 0.64033 (19) 0.5759 (3) 0.25073 (16) 0.0302 (4)
C l 0.6194 (2) 0.4751 (3) 0.0168 (2 ) 0.0332 (4)
C2 0.6649 (2) 0.6160 (3) 0.10900 (18) 0.0285 (4)
C3 0.5450 (2) 0.6452 (3) 0.32722 (18) 0.0277 (4)
C4 0.5127 (2) 0.5566 (3) 0.4572 (2) 0.0310 (4)
C5 0.8373 (2) 0.6567 (3) 0.1013 (2) 0.0369 (5)
C 6 0.8983 (3) 0.8023 (4) 0.1799 (3) 0.0468 (6 )
C7 0.8209 (4) 0.9465 (4) 0.1149 (4) 0.0743 (9)
C 8 1.0762 (3) 0.8109 (5) 0.1859 (4) 0.0754 (10)
C l l 0.3466 (2) 0.4924 (3) 0.4289 (2) 0.0339 (4)
C12 0.2312 (3) 0.5483 (4) 0.5024 (3) 0.0499 (6 )
C13 0.0789 (3) 0.4889 (4) 0.4754 (3) 0.0639 (8 )
C14 0.0437 (3) 0.3732 (4) 0.3802 (3) 0.0621 (8 )
C15 0.1573 (3) 0.3148 (4) 0.3067 (3) 0.0594 (7)
C16 0.3088 (3) 0.3757 (3) 0.3308 (2) 0.0440 (5)
o
Table 2. Selected geometric parameters (A, °)
0 1 - -Cl 1.314 (2) N l— C3 1.322
0 2 —-Cl 1.200 (3) C l— C 2 1.523
0 3 — C3 1.239 (2) C2— C5 1.534
0 4 - -C4 1.423 (2) C3— C4 1.525
m - -C2 1.451 (2) C4— C l l 1.518
P R IN T C IF  (F O ) 7
C2— N I— C3 126.97 (18) N l— C3— C4 115.49 (17)
0 1 — C l — 0 2 124.81 (19) 0 4 — C4— C3 108.22 (15)
0 1 — C l— C 2 112.69 (17) 0 4 — C4— C ll 1 1 2 . 6 8  (16)
0 2 — C l— C 2 122.44 (18) C3— C4— C l l 108.36 (15)
INI— C2— C l 107.21 (15) C2— C5— C 6 115.51 (17)
N l— C2— C5 111.94 (16) C5— C 6 — C7 112.3 (2)
C l— C2— C5 108.83 (15) C5— C 6 — C 8 109.3 (2)
0 3 — C3— N l 124.95 (17) C7— C 6 — C 8 1 1 0 . 8  (2 )
0 3 — C3— C4 119.48 (16)
C3— N I— C 2 — C l - 1 2 0 . 0  (2 ) 0 3 — C3— C4— 0 4 -166 .9  (2)
C3— N l— C2— C5 1 2 0 . 8  (2 ) N l— C3— C4— 0 4 16.1 (2 )
C2— N I— C3— 0 3 -1 1 .0  (3) 0 3 — C 3 - C 4 — C l l 70.7 (2)
C 2 — N l— C3— C4 165.9 (2) N l— C3— C4— C l l -106 .4  (2)
o
Table 3. Hydrogen-bonding geometry (A,  °)
D— H- ■ -A D— H H- • •A D-- -A D— H- ■ •A
N I— H 11---04 0.84 (3) 2.09 (2) 2.569 (3) 116 (2 )
0 1 — H l- - -0 3 ¡ 0.88 (4) 1.84 (4) 2.704 (2) 170 (3)
0 4 — H 41-• 0 3 u 0.87 (3) 1.95 (3) 2.801 (2) 168 (2 )
C2— H2- • -02 iU 0.98 2.41 3.344 (3) 159
C 8 — H 8 A- • -C gliv 0.96 3.01 3.939 (3) 164
C 8 — H 8 A- ■ - C l l iv 0.96 3.18 4.104 (4) 161
C 8 — H 8 A- ■ -C12iv 0.96 3.05 3.873 (4) 145
C8 — H 8 A- ■ -C13iv 0.96 3.16 3.934 (5) 139
C 8 — H 8 A- ■ -C l4 iv 0.96 3.43 4.246 (4) 144
C 8 — H 8 A- • -C l5iv 0.96 3.57 4.470 (5) 157
C 8 — H 8 A- • -C l6 iv 0.96 3.44 4.389 (4) 172
Sym m etry codes: (i) 1 -- x , y -  1 , - 2 ; (ii) 1 - x , y -  £ , 1  -  z; (iii) 1 -  X, \  + y : - z \
(iv) 1 + x, y, z .
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Molecule (I) which is chiral, crystallised as R S  and SS  diastereoiners in the 
solid state. A crystal w ith R S  configuration at the  ch iral centres was chosen 
for exam ination; space group P2\ from the system atic absences.
A full ’’Friedel” d a ta  set was collected for this s tru c tu re  although the anomalous 
dispersion term s for O, N and C are small. T he absolute s truc tu re  was not 
determ ined (Flack param eter, —1 (1)) by our X -ray analysis bu t can be inferred 
from  the known absolute configuration of the starting, m ateria l used in the 
synthesis.
T he H atom s a ttached  to  caxbon were tre a te d  as rid ing atom s w ith the  C—H 
bond lengths in the range 0.93 to 0.98 A; the  N— H and Q— H distances were 
refined to 0.837 (28) A, 0.876 (38) A and 0.867 (29) A respectively.
D ata  collection: CAD-4 (Enraf-N onius, 1992). Cell refinement: SETA & 
CELDIM  (Enraf-N onius, 1992). D ata  reduction: D ATRD 2  in N RCVAX96  (Gabe, 
Le Page, C harland, Lee & W hite, 1989). P rogram (s) used to  solve structure: 
SHELXS97  (Sheldrick, 1997). Program (s) used to refine structure: NRCVAX96  
and SHELXL91  (Sheldrick, 1997). M olecular graphics: NRCVAX9Q, ORTEP  
(Johnson, 1976), P L A T O N  (Spek, 1997 a), P L U T O N  (Spek, 19976). Software used 
to prepare m aterial for publication: N R C V A X 96, SHELXL97  and WordPerfect 
m acro P R P C IF 97  (Ferguson, 1997).
P. K. and  M. 0 . ‘D th an k  the School of Chem ical Sciences for financial support. 
J. F. G. thanks the  Research and P ostg raduate  C om m ittee of Dublin City 
University, the Royal Irish Academy and  F orbairt for generous funding of a 
research visit to  the  University of Guelph (June-A ugust, 1997) and especially 
Professor George Ferguson for use of his diffractom eter and  com puter system .
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Supplem entary d a ta  for th is paper are available from  the  IUCr electronic archives 
(Reference: PR IN T C IF ). Services for accessing these d a ta  are described at the 
back of the journal.
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Fig. 1. A view of (I) w ith our num bering scheme. D isplacem ent ellipsoids are drawn 
at the  30% probability  level.
Fig. 2. A view of the  hydrogen bonding in the  crystal structure.
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